MiR-150 for the treatment of blood disorders

ABSTRACT

The invention provides methods of treating certain blood related disorders, in particular, thrombocytopenia and anemia comprising increasing miR-150 expression or inhibiting miR-150 in progenitor cells respectively.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.13/652,672 filed on Oct. 16, 2012, now U.S. Pat. No. 8,530,443, which isa continuation application of U.S. patent application Ser. No.12/363,016 filed on Jan. 30, 2009, which claims benefit under 35 U.S.C.§119(e) of U.S. Provisional Application No. 61/062,931 filed on Jan. 30,2008, and U.S. Provisional Application No. 61/086,556 filed on Aug. 6,2008, the contents of each of which are incorporated herein by referencein their entireties.

GOVERNMENT SUPPORT

This invention was made with Government support under Grant No. HL081030awarded by the National Institute of Health. The Government has certainrights in this invention.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted in ASCII format via EFS-Web and is hereby incorporated byreference in its entirety. Said ASCII copy, created on Aug. 20, 2013, isnamed 030258-061193_SequenceListing and is 185,582 bytes in size.

BACKGROUND OF INVENTION

Blood disorders such as thrombocytopenia and anemia affect a significantpopulation, with anemia being the most common disorder of the two. Atleast 50% of new patients admitted to a hospital's intensive care unitwill develop thrombocytopenia during their stay. The development ofthrombocytopenia correlates with mortality, longer duration ofmechanical ventilation, and an increased need for blood producttransfusion.

Anemia occurs when the level of healthy red blood cells (RBCs) in thebody becomes too low. RBCs contain hemoglobin, which carries oxygen tothe body's tissues. Thus, low levels of healthy RBCs can cause a varietyof complications, including fatigue and stress on bodily organs. Morethan 3 million people in the United States have anemia. Women and peoplewith chronic diseases are at the greatest risk for anemia. A personpresents with anemia when the body loses too much blood (such as withheavy periods, certain diseases, and trauma); or the body has problemsmaking red blood cells; or red blood cells break down or die faster thanthe body can replace them with new ones; or more than one of theseproblems happen at the same time.

Aplastic anemia occurs when the bone marrow cannot make enough RBCs.This can be due to a viral infection, or exposure to certain toxicchemicals, radiation, or medications (such as antibiotics, antiseizuredrugs, or cancer treatments). Some childhood cancers can also causeaplastic anemia, as can certain chronic diseases that affect the abilityof the bone marrow to make blood cells. Vitamin B12 and irondeficiencies also contribute to anemia.

Thrombocytopenia is a deficiency of platelets (thrombocytes). The bloodusually contains about 140,000 to 440,000 platelets per microliter.Bleeding can occur with relatively minor trauma when the platelet countfalls below about 50,000 platelets per microliter of blood. The mostserious risk of bleeding, however, generally does not occur until theplatelet count falls below 10,000 to 20,000 platelets per microliter. Atthese very low levels, bleeding may occur without any injury.

Abnormal reductions in the number of platelets are caused whenabnormalities occur in any of the following three processes: decreasedplatelet production by the bone marrow; increased trapping of plateletsby the spleen; or a more rapid than normal destruction of platelets.Persons with this condition easily bruise and can have episodes ofexcess bleeding (a hemorrhage).

Many diseases can cause thrombocytopenia. Thrombocytopenia can occurwhen the bone marrow does not produce enough platelets, as happens inleukemia, lymphoma and some anemias—aplastic, megaloblastic, vitamin B12deficiency, and folic acid deficiency. Excessive alcohol consumption canalso imped platelet production. Infection with the humanimmunodeficiency virus (HIV), the virus that causes AIDS, often resultsin thrombocytopenia. Platelets can become entrapped in an enlargedspleen, as happens in myelofibrosis and Gaucher's disease, reducing thenumber of platelets in the bloodstream. Massive blood transfusions candilute the concentration of platelets in the blood. Finally, the bodymay use or destroy too many platelets, as occurs in many disorders,three of the most notable being idiopathic thrombocytopenic purpura,thrombotic thrombocytopenic purpura, and hemolytic-uremic syndrome.

Currently, the treatment options for anemia and thrombocytopenia aredirected at the immediate increase of circulating RBC and plateletrespectively, followed by identifying the underlying causes. Alternativetreatment methods aimed at boosting the innate production of RBCs andplatelets, for example, the use of erythropoietin and thrombopoietin tostimulate the bone marrow to produce more red blood cells, are stillneeded and will be useful in complementing existing treatments foranemia and thrombocytopenia.

SUMMARY OF THE INVENTION

Embodiments of the invention provide methods of treating certain bloodrelated disorders, in particular, thrombocytopenia and anemia.Thrombycytopenia is a condition where there is low platelet count in theblood. Anemia is a condition where there is a low number of red bloodcells (RBC) in the blood. Embodiments of the inventions are based on thediscovery that miR-150 is involved in the differentiation ofmegakaryocyte-erythrocyte progenitor cells (MEPs) from the bone marrow.Overexpression of miR-150 can shift more MEPs toward megakaryocytedifferentiation and also block erythrocyte maturation. In contrast, alower level of miR-150 expression shift more MEPs towards erythrocytedifferentiation. Accordingly, embodied in the invention is a method oftreating thrombocytopenia in a host in need thereof, the methodcomprising administering to a host an effective amount of an agent thatincreases miR-150 expression in a cell.

The cell being administered an effective amount of an agent thatincreases miR-150 expression is a progenitor cell, preferably, ahematopoietic progenitor cell. The increase in miR-150 expressionpromotes megakaryocyte differentiation from the hematopoietic progenitorcell and consequently more platelets are produced.

In one embodiment, the agent that increases miR-150 expression in a cellcomprises a vector comprising a nucleic acid sequence that is at least90% identical to SEQ. ID. No. 1. In other embodiments, the nucleic acidis at least 92%, at least 93% at least 94%, at least 95%, at least 96%,at least 97%, at least 98%, at least 99%, and all the intermediatepercentages between 90% and 100%, identical to SEQ. ID. No. 1. Thedifferences from SEQ. ID. No. 1 should be such that the overall hairpinstructure of the pri-miR-150 is maintained. The agent serves to increasethe basal level of miR-150 in hematopoietic progenitor cells. The vectorcan be a virus or a non-virus.

In another embodiment, the agent that increases miR-150 expression in acell comprises a nucleic acid sequence that is at least 90% identical toSEQ. ID. No. 1. In other embodiments, the nucleic acid is at least 92%,at least 94%, at least 95%, at least 97%, at least 99%, and all theintermediate percentages between 90% and 100%, identical to SEQ. ID.No. 1. The differences from SEQ. ID. No. 1 should be such that theoverall hairpin structure of the pri-miR-150 is maintained.

Embodied herein is a method of treating thrombocytopenia in a host inneed thereof, the method comprising: (a) obtaining a sample ofhematopoietic progenitor cells from the host; (b) contacting thehematopoietic progenitor cells with a vector comprising a nucleic acidsequence that is at least 90% identical to SEQ. ID. No. 1; and (c)introducing the cell from step b into the host.

Also embodied herein is a method of treating anemia in a host in needthereof, the method comprising administering to a host an effectiveamount of an agent that inhibits miR-150 in a cell.

The cell being administered an effective amount of an agent thatinhibits miR-150 expression is a progenitor cell, preferably, ahematopoietic progenitor cell. By inhibiting miR-150 expression in thecells, the repression associated with the miR-150 is relieved anderythrocyte differentiation from the progenitor cells is promoted.

In one embodiment, the agent comprises a vector comprising a nucleicacid sequence that is at least 90% identical to SEQ. ID. No. 3. Inanother embodiment, the agent is an antagomir of miR-150, ananti-miR-150 oligonucleotide, an antisense oligonucleotide to miR-150, alocked nucleic acid that anneals to miR-150, or a double strand RNA.Nucleic acid sequences similar to SEQ. ID. No. 3, antagomir of miR-150,an anti-miR-150 oligonucleotide, an antisense oligonucleotide tomiR-150, a locked nucleic acid that anneals to miR-150, or a doublestrand RNA all complementary base-pair with miR-150, although notnecessarily perfectly, and can thus inhibit miR-150 from complexing withthe miRISC. The vector comprising a nucleic acid sequence can be virusor a non-virus.

Embodied herein is a method of treating anemia in a host in needthereof, the method comprising: (a) obtaining a sample of hematopoieticprogenitor cells from said host; (b) contacting the hematopoieticprogenitor cells with a vector comprising a nucleic acid sequence thatis at least 90% identical to SEQ. ID. No. 3; and (c) introducing thecell from step b into the same host.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A shows the schematic of a novel, sensitive and high-throughputmiRNA labeling methodology for expression profiling. RT: reversetranscription; Bi: biotin; arrows: primers.

FIG. 1B shows a heatmap on log 2-transformed data, with black colorindicating higher expression and light grey for lower expression. Datareflect the median expression of miRNAs within correspondingpopulations. Arrows point to miRNAs mentioned in text. Multiple harvestsof MEP (n=8), MEGA1 (n=4), MEGA2 (n=6), ERY1 (n=4), ERY2 (n=3), and ERY3(n=2) populations were purified from human umbilical cord blood cells(23) and profiled for miRNA expression.

FIG. 1C shows the median expression of miR-150 was plotted for eachpopulation, with the oval area proportional to the expression level.

FIG. 1D shows miR-150 expression measured using quantitative RT-PCR onmultiple harvests of MEP (n=3), MEGA1 (n=4), MEGA2 (n=3), ERY1 (n=3),ERY2 (n=3) and ERY3 (n=3) populations. The ΔCt values (Ct (thresholdcycle) of 18S minus Ct of miR-150) are shown for all samples. Note thatΔCt reflects log scale of expression. Samples indicated with black dotswere also used in miRNA profiling in FIGS. 1B and 1C, whereas those withopen circles were additional samples.

FIG. 2A shows representative flow cytometry plots of the differentiationlineage of CD34+ hematopoietic progenitors cells transduced withconstructs expressing a control hairpin (shLuc), miR-150, a mutantmiR-150 or miR-15b-16-2. Plots represents lineage markers CD41(megakaryocytic) and GlyA (erythroid).

FIG. 2B shows the histograms of the data obtained for FIG. 2A. Errorbars reflect standard deviation. n=3

FIG. 2C shows the percentage of bone marrow GFP+ or GFP− megakaryocytes(CD41+Ter119−)-J) in mice transduced with either miR-150 and a GFPmarker or with control retroviral vector and analyzed 5 to 8 weekspost-transplantation. Each dot represents data from one recipient mouse.n=7.

FIG. 2D shows the percentage of bone marrow GFP+ or GFP− erythrocyte(CD41−Ter119+) in mice transduced with either miR-150 and a GFP markeror with control retroviral vector and analyzed 5 to 8 weekspost-transplantation. Each dot represents data from one recipient mouse.n=7.

FIG. 2E shows representative flow cytometry plots on bone marrow cellswith megakaryocytic (CD41) and erythroid (Ter119) markers from data ofFIGS. 2C and 2D.

FIG. 2F shows the PF4 expression of recipient bone marrow cells that areGFP+ and GFP−. Each pair of bars represents data from one recipientmouse.

FIG. 2G shows the ratio of GFP+ platelet percentage to the percentage ofGFP+ bone marrow cells in the peripheral blood of recipient animals7-week post-transplantation. T was plotted to reflect thethrombocytogenic potential of bone marrow cells. n=5.

FIG. 2H show the representative flow cytometry plots of bone marrowcells assayed with CD71 and Ter119. The gates R1 to R4 representimmature to mature erythrocytes.

FIG. 2I shows a ratio between GFP+ and GFP− population within the samerecipient mouse based upon the percentage of R1 population among allerythrocytes (sum of R1 to R4), n=7. P<0.002.

FIG. 2J shows a ratio between GFP+ and GFP− population within the samerecipient mouse based on data for R4 population. P<2×10-4.

FIG. 3A shows the megakaryocyte colony forming units (CFU-Mks) formedfrom GFP+ and GFP− populations of bone marrow cells isolated from micetransduced with miR-150 retroviral vector or vector control. CFU-Mkswere quantitated from 100,000 sorted cells. n=4.

FIG. 3B shows the effects of solvent (PBS), antagomir against miR-150(anti-150) or a scrambled antagomir on the differentiation of CFU-Mkfrom MEP cells sorted from wild-type C57BL/6J mice. 4000 cells wereanalyzed per assay. n=4.

FIG. 3C shows the effects of solvent (PBS), antagomir against miR-150(anti-150) or a scrambled antagomir on the differentiation of CFU-Mkfrom Lin-Kit+Sca+ (LKS) stem cells. 1000 cells were analyzed per assay.n=4.

FIG. 3D shows the miR-150 expression in mice were treated withphenylhydrazine to induce anemia, or in mice were treated with PBS(mock). miR-150 expression was assayed by qRT-PCR in lineage negativecells purified from bone marrow. n=3. Error bars represent standarddeviation.

FIG. 4A shows the Western blot analysis for MYB and beta-Tubulinexpressed in K562 cells transduced with constructs expressing GFP,mutant miR-150 or miR-150.

FIG. 4B shows the design of luciferase reporters for human MYB 3′ UTR,with grey vertical bar indicating wild-type (wt) sites and blackindicating mutant (mut) sites. The mutant miRNA site and mutant 3′UTRsites are complementary.

FIG. 4C shows a normalized plot of luciferase activities in 293T cellstransduced with constructs expressing GFP, mutant miR-150 or miR-150.Error bars represent standard deviation. n=8.

FIG. 4D shows the histograms of the differentiation lineages of cellstransduced with miR-150 and MYB expression constructs and theircorresponding vector controls (shLuc, Vector). The lineage markers areCD41 (megakaryocytic) and GlyA (erythroid). n=3. Error bars reflectstandard deviation. * P=0.04.

FIG. 4E shows the representative flow cytometry plots of thedifferentiation lineages in FIG. 4D. Plots represents lineage markersCD41 (megakaryocytic) and GlyA (erythroid).

FIG. 5A shows the reproducibility performance of the plate capturemethod of miRNA labeling.

FIG. 5B shows the comparison of methods. miRNA expression profiling wasperformed on the same MCF-7 and 293T total RNA using either the platecapture method, or the previously reported method involving multipledenaturing acrylamide gel purification of small RNAs (“gel purificationmethod”).

FIG. 6A shows the expression of miR-150 in FACS-sorted umbilical cordblood populations. Expression is measured by quantitative RT-PCRanalysis as in FIG. 1D were plotted in an oval plot with the oval areaproportional to the median value of 2^(ΔCt) for each of the populations.

FIG. 6B shows the histogram of miR-150 expression in CD41+CD61+ andCD71+GlyA+ cells FACS-sorted from the bone marrow of a healthy adulthuman donor. miR-150 expression was measured using quantitative RT-PCR.2^(ΔCt) values are shown. Error bars represent standard deviation ofmeasurement.

FIG. 7 shows the evolutionary conservation of mature miR-150 sequencesof across multiple species (SEQ ID NOS: 786-791, respectively, in orderof appearance). Sequence data were from miRBASE. Big and bold lettersindicate non-conserved bases.

FIG. 8 shows the miR-150 expression in cultured human CD34+ bone marrowcells transduced with a control vector (shLuc, n=3) or a m-iR150construct (n=3), and in multiple harvests of MEP, ERY1, ERY2, ERY3,MEGA1 and MEGA2 populations (as described in FIG. 1D). Threshold cyclevalues were normalized against 18S ribosomal RNA levels. ΔCt values areplotted

FIG. 9 shows a schematic model for murine bone marrow transplantation.

FIG. 10A shows the gated forward and side scattering flow cytometryanalysis of bone marrow cells from wild-type mouse and recipient mice5-8 weeks after transplantation with vector control or miR-150 vector.GFP gating was determined on cells from wild-type animal.

FIG. 10B shows the GFP gated flow cytometry analysis of bone marrowcells from recipient mice 5-8 weeks after transplantation with vectorcontrol.

FIG. 10C shows the GFP gated flow cytometry analysis of bone marrowcells from recipient mice 5-8 weeks after transplantation with miR-150vector.

FIG. 10D shows the GFP gated flow cytometry analysis of bone marrowcells from wild-type mouse.

FIG. 11A shows the gated sensitized forward and side scattering flowcytometry analysis of platelets in peripheral blood of wild-type mouseand from recipients 7 weeks after transplantation with vector control ormiR-150 vector. Peripheral blood cells were stained with CD41 antibody.

FIG. 11B shows the GFP and CD41 flow cytometry analysis of platelets inperipheral blood from recipients 7 weeks after transplantation withvector control.

FIG. 11C shows the GFP and CD41 flow cytometry analysis of platelets inperipheral blood from recipients 7 weeks after transplantation withmiR-150 vector.

FIG. 11D shows the GFP and CD41 flow cytometry analysis of platelets inperipheral blood from wild-type mouse.

FIG. 12A shows the absolute cell numbers of GFP+ erythrocytes in thebone marrow of vector control or miR-150 recipient mice. Data reflectcell numbers from two legs of each mouse. Cell number was calculatedbased on total bone marrow cell yield, GFP status and megakaryocyte anderythrocyte percentage as determined by CD41 and Ter119 staining.

FIG. 12B shows the absolute cell numbers of GFP+ megakaryocytes in thebone marrow of vector control or miR-150 recipient mice.

FIG. 12C shows the absolute cell numbers of GFP− erythrocytes in thebone marrow of vector control or miR-150 recipient mice.

FIG. 12D shows the absolute cell numbers of GFP− megakaryocytes in thebone marrow of vector control or miR-150 recipient mice.

FIG. 13 shows that miR-150 decreases erythroid colony formation.

FIG. 14 shows that antagomir-150 knocks down miR-150 expression.

FIG. 15 shows the formation of megakaryocyte colony in the presence ofantagomir-150. Brown color reflects megakaryocyte-specific acetylcholinesterase activity.

FIG. 16A shows the MYB expression as measured using quantitative RT-PCRon multiple harvests of MEP (n=3), MEGA1 (n=4), MEGA2 (n=3), ERY1 (n=3),ERY2 (n=3) and ERY3 (n=3) populations. The ΔCt values (Ct of 18S minusCt of MYB) are shown for all samples. Samples with black dots were usedin miRNA profiling in FIGS. 1B and 1C, whereas those with open circlesare additional samples.

FIG. 16B shows the data plotted in an oval plot with the oval areaproportional to the median value of 2^(ΔCt) for each of the MEP, MEGA1,MEGA2, ERY1, ERY2 and ERY3 populations.

FIG. 17A shows the human MYB 3′UTR sequence (SEQ ID NO: 785) with fourputative miR-150 binding sites in boxes.

FIG. 17B shows the conservation of the four putative miR-150 targetingsites across several shown species (SEQ ID NOS: 792-798, respectively,in order of appearance). Conservation data were obtained from UCSCgenome browser.

FIG. 18A shows the knockdown efficiency of two independent shRNAsagainst MYB expression in MYB-expressing K562 cells. MYB expression wasmeasured by quantitative RT-PCR. The values of 2^(ΔCt) are shown.

FIG. 18B shows the percentage of differentiated megakaryocytes(CD41+GlyA−) from CD34+ human adult bone marrow cells transduced withcontrol vector (shLuc), miR-150 or shRNAs against MYB in an in vitroculture. n=3. Error bars represent standard deviation.

DETAILED DESCRIPTION OF THE INVENTION Definitions of Terms

As used herein, the term “comprising” means that other elements can alsobe present in addition to the defined elements presented. The use of“comprising” indicates inclusion rather than limitation.

The term “consisting of” refers to compositions, methods, and respectivecomponents thereof as described herein, which are exclusive of anyelement not recited in that description of the embodiment.

As used herein the term “consisting essentially of” refers to thoseelements required for a given embodiment. The term permits the presenceof elements that do not materially affect the basic and novel orfunctional characteristic(s) of that embodiment of the invention.

As used herein, the term “therapeutically effective amount” refers to anamount of an agent that is sufficient to effect a therapeuticallysignificant increase in the circulating platelet count in a hostdiagnosed with thrombocytopenia to at least above 1.6×10⁵ platelets/mm³or an amount of an agent that is sufficient to effect a therapeuticallysignificant increase in the circulating RBC count in a host diagnosedwith anemia to at least above 4.0×10¹² red cells/L in adults and4.6×10¹² red cells/L in children.

As used herein, the term “treating thrombocytopenia” refers to a meansof increasing the number of circulating platelets in a host who has lowplatelet count, less than about 1.6×10⁵ platelets/mm³.

As used herein, the term “agent” refers to a nucleic acid sequence or avector. The nucleic acid sequence can have modifications such as2′O-methylation and 3′ end cholesterol found in antagomirs and lockednucleic acid oligonucleotides.

As used herein, the term “complementary base pair” refers to A:T and G:Cin DNA and A:U in RNA. Most DNA consists of sequences of nucleotide onlyfour nitrogenous bases: base or base adenine (A), thymine (T), guanine(G), and cytosine (C). Together these bases form the genetic alphabet,and long ordered sequences of them contain, in coded form, much of theinformation present in genes. Most RNA also consists of sequences ofonly four bases. However, in RNA, thymine is replaced by uracil (U).

As used herein, the term “nucleic acid sequence” refers to any molecule,preferably a polymeric molecule, incorporating units of ribonucleicacid, deoxyribonucleic acid or an analog thereof. The nucleic acid canbe either single-stranded or double-stranded. A single-stranded nucleicacid can be one strand nucleic acid of a denatured double-stranded DNA.Alternatively, it can be a single-stranded nucleic acid not derived fromany double-stranded DNA. In one aspect, the template nucleic acid isDNA. In another aspect, the template is RNA. Suitable nucleic acidmolecules are DNA, including genomic DNA, ribosomal DNA and cDNA. Othersuitable nucleic acid molecules are RNA, including mRNA, rRNA and tRNA.The nucleic acid molecule can be naturally occurring, as in genomic DNA,or it may be synthetic, ie., prepared based up human action, or may be acombination of the two. The nucleic acid molecule can also have certainmodification such as 2′-deoxy, 2′-deoxy-2′-fluoro, 2′-O-methyl,2′-O-methoxyethyl (2′-O-MOE), 2′-O-aminopropyl (2′-O-AP),2′-O-dimethylaminoethyl (2′-O-DMAOE), 2′-O-dimethylaminopropyl(2′-O-DMAP), 2′-O-dimethylaminoethyloxyethyl (2′-O-DMAEOE), or2′-O—N-methylacetamido (2′-O-NMA), cholesterol addition, andphosphorothioate backbone as described in US Patent Application20070213292; and certain ribonucleoside that are is linked between the2′-oxygen and the 4′-carbon atoms with a methylene unit as described inU.S. Pat. No. 6,268,490, wherein both patent and patent application areincorporated hereby reference in their entirety.

The term “vector”, as used herein, refers to a nucleic acid constructdesigned for delivery to a host cell or transfer between different hostcells. As used herein, a vector can be viral or non-viral.

As used herein, the term “expression vector” refers to a vector that hasthe ability to incorporate and express heterologous nucleic acidfragments in a cell. An expression vector may comprise additionalelements, for example, the expression vector may have two replicationsystems, thus allowing it to be maintained in two organisms, for examplein human cells for expression and in a prokaryotic host for cloning andamplification.

As used herein, the term “heterologous nucleic acid fragments” refers tonucleic acid sequences that are not naturally occurring in that cell.For example, when a miR-150 gene is inserted into the genome of abacteria or virus, that miR-150 gene is heterologous to that recipientbacteria or virus because the bacteria and viral genome do not naturallyhave the miR-150 gene.

As used herein, the term “viral vector” refers to a nucleic acid vectorconstruct that includes at least one element of viral origin and has thecapacity to be packaged into a viral vector particle. The viral vectorcan contain the miR-150 gene in place of non-essential viral genes. Thevector and/or particle may be utilized for the purpose of transferringany nucleic acids into cells either in vitro or in vivo. Numerous formsof viral vectors are known in the art.

The term “replication incompetent” as used herein means the viral vectorcannot further replicate and package its genomes. For example, when thecells of a subject are infected with replication incompetent recombinantadeno-associated virus (rAAV) virions, the heterologous (also known astransgene) gene is expressed in the patient's cells, but, the rAAV isreplication defective (e.g., lacks accessory genes that encode essentialproteins from packaging the virus) and viral particles cannot be formedin the patient's cells.

The term “gene” means the nucleic acid sequence which is transcribed(DNA) to RNA in vitro or in vivo when operably linked to appropriateregulatory sequences. The gene may or may not include regions precedingand following the coding region, e.g. 5′ untranslated (5′UTR) or“leader” sequences and 3′ UTR or “trailer” sequences, as well asintervening sequences (introns) between individual coding segments(exons).

As used herein, “identity”, in the context of two or more nucleic acidssequences, refers to two or more sequences or subsequences that are thesame or have a specified percentage of nucleotides that are the same(i.e., about 60% identity, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%,92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over aspecified region, when compared and aligned for maximum correspondenceover a comparison window or designated region) when the sequences arealigned to maximize sequence matching, i.e., taking into account gapsand insertions, such as when using a BLAST or BLAST 2.0 sequencecomparison algorithms with default parameters described below, or bymanual alignment and visual inspection. Such sequences are then said tobe “substantially identical.”This term also refers to, or can be appliedto, the complement of a test sequence. The term also includes sequencesthat have deletions and/or additions, as well as those that havesubstitutions. As described below, the preferred algorithms can accountfor gaps and the like. Preferably, identity exists over a region that isat least about 25 nucleotides in length, or more preferably over aregion that is 50-100 nucleotides in length. For sequence comparison,typically one sequence acts as a reference sequence, to which testsequences are compared. When using a sequence comparison algorithm, testand reference sequences are input into a computer, subsequencecoordinates are designated, if necessary, and sequence algorithm programparameters are designated. The sequence comparison algorithm thencalculates the percent sequence identity for the test sequence(s)relative to the reference sequence, based on the designated programparameters.

For sequence comparison, typically one sequence acts as a referencesequence, to which test sequences are compared. When using a sequencecomparison algorithm, test and reference sequences are entered into acomputer, subsequence coordinates are designated, if necessary, andsequence algorithm program parameters are designated. Preferably,default program parameters can be used, or alternative parameters can bedesignated. The sequence comparison algorithm then calculates thepercent sequence identities for the test sequences relative to thereference sequence, based on the program parameters.

A “comparison window”, as used herein, includes reference to a segmentof any one of the number of contiguous positions selected from the groupconsisting of from 20 to 600, usually about 50 to about 200, moreusually about 100 to about 150 in which a sequence can be compared to areference sequence of the same number of contiguous positions after thetwo sequences are optimally aligned. Methods of alignment of sequencesfor comparison are well-known in the art. Optimal alignment of sequencesfor comparison can be conducted, e.g., by the local homology algorithmof Smith & Waterman, Adv. Appl. Math. 2: 482, 1981, by the homologyalignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48: 443, 1970,by the search for similarity method of Pearson & Lipman, Proc. Nat'l.Acad. Sci. USA 85: 2444, 1988, by computerized implementations of thesealgorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin GeneticsSoftware Package, Genetics Computer Group, 575 Science Dr., Madison,Wis.), or by manual alignment and visual inspection (see, e.g., CurrentProtocols in Molecular Biology, Ausubel et al., eds. 1995 supplement)).

Identity can be readily calculated by known methods, including but notlimited to those described in (Computational Molecular Biology, Lesk, A.M., ea., Oxford University Press, New York, 1988; Biocomputing:Informatics and—14 Genome Projects, Smith, D. W., ea., Academic Press,New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A.M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; SequenceAnalysis in Molecular Biology, von Heinje, G., Academic Press, 1987; andSequence Analysis Primer, Gribskov, M. and Devereux, J., eds., MStockton Press, New York, 1991; and Carillo, H., and Lipman, D., SIAM J.Applied Math., 48: 1073 (1988)). Methods to determine identity aredesigned to give the largest match between the sequences tested.Moreover, methods to determine identity are codified in publiclyavailable computer programs such as BLASTP.

Where necessary or desired, optimal alignment of sequences forcomparison can be conducted, for example, by the local homologyalgorithm of Smith and Waterman (Adv. Appl. Math. 2:482 (1981), which isincorporated by reference herein), by the homology alignment algorithmof Needleman and Wunsch (J. Mol. Biol. 48:443-53 (1970), which isincorporated by reference herein), by the search for similarity methodof Pearson and Lipman (Proc. Natl. Acad. Sci. USA 85:2444-48 (1988),which is incorporated by reference herein), by computerizedimplementations of these algorithms (e.g., GAP, BESTFIT, FASTA, andTFASTA in the Wisconsin Genetics Software Package, Genetics ComputerGroup, 575 Science Dr., Madison, Wis.), or by visual inspection. (Seegenerally Ausubel et al. (eds.), Current Protocols in Molecular Biology,4th ed., John Wiley and Sons, New York (1999)).

One example of a useful algorithm is PILEUP. PILEUP creates a multiplesequence alignment from a group of related sequences using progressive,pairwise alignments to show the percent sequence identity. It also plotsa tree or dendogram showing the clustering relationships used to createthe alignment. PILEUP uses a simplification of the progressive alignmentmethod of Feng and Doolittle (J. Mol. Evol. 25:351-60 (1987), which isincorporated by reference herein). The method used is similar to themethod described by Higgins and Sharp (Comput. Appl. Biosci. 5:151-53(1989), which is incorporated by reference herein). The program canalign up to 300 sequences, each of a maximum length of 5,000 nucleotidesor amino acids. The multiple alignment procedure begins with thepairwise alignment of the two most similar sequences, producing acluster of two aligned sequences. This cluster is then aligned to thenext most related sequence or cluster of aligned sequences. Two clustersof sequences are aligned by a simple extension of the pairwise alignmentof two individual sequences. The final alignment is achieved by a seriesof progressive, pairwise alignments. The program is run by designatingspecific sequences and their amino acid or nucleotide coordinates forregions of sequence comparison and by designating the programparameters. For example, a reference sequence can be compared to othertest sequences to determine the percent sequence identity relationshipusing the following parameters: default gap weight (3.00), default gaplength weight (0.10), and weighted end gaps.

Another example of an algorithm that is suitable for determining percentsequence identity and sequence similarity is the BLAST algorithm, whichis described by Altschul et al. (J. Mol. Biol. 215:403-410 (1990), whichis incorporated by reference herein). (See also Zhang et al., NucleicAcid Res. 26:3986-90 (1998); Altschul et al., Nucleic Acid Res.25:3389-402 (1997), which are incorporated by reference herein).Software for performing BLAST analyses is publicly available through theNational Center for Biotechnology Information internet web site. Thisalgorithm involves first identifying high scoring sequence pairs (HSPs)by identifying short words of length W in the query sequence, whicheither match or satisfy some positive-valued threshold score T whenaligned with a word of the same length in a database sequence. T isreferred to as the neighborhood word score threshold (Altschul et al.(1990), supra). These initial neighborhood word hits act as seeds forinitiating searches to find longer HSPs containing them. The word hitsare then extended in both directions along each sequence for as far asthe cumulative alignment score can be increased. Extension of the wordhits in each direction is halted when: the cumulative alignment scorefalls off by the quantity X from its maximum achieved value; thecumulative score goes to zero or below, due to the accumulation of oneor more negative-scoring residue alignments; or the end of eithersequence is reached. The BLAST algorithm parameters W, T, and Xdetermine the sensitivity and speed of the alignment. The BLAST programuses as defaults a word length (W) of 11, the BLOSUM62 scoring matrix(see Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915-9(1992), which is incorporated by reference herein) alignments (B) of 50,expectation (E) of 10, M=5, N=−4, and a comparison of both strands.

In addition to calculating percent sequence identity, the BLASTalgorithm also performs a statistical analysis of the similarity betweentwo sequences (see, e.g., Karlin and Altschul, Proc. Natl. Acad. Sci.USA 90:5873-77 (1993), which is incorporated by reference herein). Onemeasure of similarity provided by the BLAST algorithm is the smallestsum probability (P(N)), which provides an indication of the probabilityby which a match between two nucleotide or amino acid sequences wouldoccur by chance. For example, an amino acid sequence is consideredsimilar to a reference amino acid sequence if the smallest sumprobability in a comparison of the test amino acid to the referenceamino acid is less than about 0.1, more typically less than about 0.01,and most typically less than about 0.001.

As used herein, the term “a progenitor cell” refers to refer to animmature or undifferentiated cell that has the potential later on tomature (differentiate) into a specific cell type, for example, a bloodcell, a skin cell, a bone cell, or a hair cells. A progenitor cell alsocan proliferate to make more progenitor cells that are similarlyimmature or undifferentiated.

As used herein, the term “hematopoietic progenitor cell” refers toprogenitor cells that can differentiate into the hematopoietic lineageand give rise to all blood cell types such as white blood cells and redblood cells.

As used herein, the term “microRNA or miRNA” refers to a microRNAmolecule found in eukaryotes that is involved in RNA-based generegulation. See, e.g., Carrington and Ambros, 2003, Science,301(5631):336-8 which is hereby incorporated by reference in itsentirety. miRNA are single-stranded RNA molecules of about 21-23nucleotides in length, which regulate gene expression. miRNAs areencoded by genes that are transcribed from DNA but not translated intoprotein (non-coding RNA); instead they are processed from primarytranscripts known as pri-miRNA to short stem-loop structures calledpre-miRNA and finally to functional miRNA. Mature miRNA molecules arepartially complementary to one or more messenger RNA (mRNA) molecules,and their main function is to downregulate gene expression. The termwill be used to refer to the RNA molecule processed from a precursorpre-miRNA.

Unless otherwise explained, all technical and scientific terms usedherein have the same meaning as commonly understood by one of ordinaryskill in the art to which this disclosure belongs. Definitions of commonterms in hematology and molecular biology can be found in The MerckManual of Diagnosis and Therapy, 18th Edition, published by MerckResearch Laboratories, 2006 (ISBN 0-911910-18-2); Robert S. Porter etal. (eds.), The Encyclopedia of Molecular Biology, published byBlackwell Science Ltd., 1994 (ISBN 0-632-02182-9); and Robert A. Meyers(ed.), Molecular Biology and Biotechnology: a Comprehensive DeskReference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8).Definitions of common terms in molecular biology may be found inBenjamin Lewin, Genes V, published by Oxford University Press, 1994(ISBN 0-19-854287-9); Kendrew et al. (eds.), The Encyclopedia ofMolecular Biology, published by Blackwell Science Ltd., 1994 (ISBN0-632-02182-9); and Robert A. Meyers (ed.), Molecular Biology andBiotechnology: a Comprehensive Desk Reference, published by VCHPublishers, Inc., 1995 (ISBN 1-56081-569-8).

Unless otherwise stated, the present invention was performed usingstandard procedures, as described, for example in Maniatis et al.,Molecular Cloning: A Laboratory Manual, Cold Spring Harbor LaboratoryPress, Cold Spring Harbor, N.Y., USA (1982); Sambrook et al., MolecularCloning: A Laboratory Manual (2 ed.), Cold Spring Harbor LaboratoryPress, Cold Spring Harbor, N.Y., USA (1989); Davis et al., Basic Methodsin Molecular Biology, Elsevier Science Publishing, Inc., New York, USA(1986); Methods in Enzymology: Guide to Molecular Cloning TechniquesVol. 152, S. L. Berger and A. R Kimmerl Eds., Academic Press Inc., SanDiego, USA (1987)); Current Protocols in Molecular Biology (CPMB) (FredM. Ausubel, et al. ed., John Wiley and Sons, Inc.); Current Protocols inProtein Science (CPPS) (John E. Coligan, et. al., ed., John Wiley andSons, Inc.); Current Protocols in Immunology (CPI) (John E. Coligan, et.al., ed. John Wiley and Sons, Inc.); Current Protocols in Cell Biology(CPCB) (Juan S. Bonifacino et. al. ed., John Wiley and Sons, Inc.);Culture of Animal Cells: A Manual of Basic Technique by R. Ian Freshney,Publisher: Wiley-Liss; 5th edition (2005); Animal Cell Culture Methods(Methods in Cell Biology, Vol 57, Jennie P. Mather and David Barneseditors, Academic Press, 1st edition, 1998) which are all incorporatedby reference herein in their entireties.

It should be understood that this invention is not limited to theparticular methodology, protocols, and reagents, etc., described hereinand, as such, may vary. The terminology used herein is for the purposeof describing particular embodiments only, and is not intended to limitthe scope of the present invention, which is defined solely by theclaims.

Other than in the operating examples, or where otherwise indicated, allnumbers expressing quantities of ingredients or reaction conditions usedherein should be understood as modified in all instances by the term“about.” The term “about” when used in connection with percentages maymean±1%.

The singular terms “a,” “an,” and “the” include plural referents unlesscontext clearly indicates otherwise. Similarly, the word “or” isintended to include “and” unless the context clearly indicatesotherwise. It is further to be understood that all base sizes or aminoacid sizes, and all molecular weight or molecular mass values, given fornucleic acids or polypeptides are approximate, and are provided fordescription. Although methods and materials similar or equivalent tothose described herein can be used in the practice or testing of thisdisclosure, suitable methods and materials are described below. The term“comprises” means “includes.” The abbreviation, “e.g.” is derived fromthe Latin exempli gratia, and is used herein to indicate a non-limitingexample. Thus, the abbreviation “e.g.” is synonymous with the term “forexample.”

All patents and other publications identified are expressly incorporatedherein by reference for the purpose of describing and disclosing, forexample, the methodologies described in such publications that might beused in connection with the present invention. These publications areprovided solely for their disclosure prior to the filing date of thepresent application. Nothing in this regard should be construed as anadmission that the inventors are not entitled to antedate suchdisclosure by virtue of prior invention or for any other reason. Allstatements as to the date or representation as to the contents of thesedocuments is based on the information available to the applicants anddoes not constitute any admission as to the correctness of the dates orcontents of these documents.

Embodiments of the Inventions

Embodiments of the methods disclosed herein are based on the discoverythat a microRNA (miRNAs), miR-150, regulates the differentiation ofmegakaryocyte-erythrocyte progenitor cells (MEPs) from the bone marrow.The regulation of the developmental fate of multi-potential cells is notwell known and the process by which bipotential hematopoietic progenitorcells are driven to become either red blood cells or platelets is notunderstood. The inventors discovered that miRNAs control mammalian cellfate of the multi-potential MEPs, in particular, miR-150 modulateslineage fate in MEPs. The inventors found that miR-150 is preferentiallyexpressed in the megakaryocytic lineage and that miR-150 expression inMEPs drives MEP differentiation toward megakaryocytes at the expense oferythroid cells in vitro and in vivo.

In experiments using human bone marrow hematopoietic progenitor cells,overexpression of the miR-150 gene resulted in a significant increase inmegakaryocyte colony forming units (CFU-Mk) differentiating from MEPswith a concomitant decrease in erythroid colony forming units. Whensimilar miR-150 overexpression experiments were conducted with murinebone marrow hematopoietic progenitor cells and the resultant miR-150overexpressing progenitor cells were transplanted back into the animal,the mice exhibited a larger population of megakaryocytes and a greaternumber of platelets compared to control mice miR-150 expression led to abona fide increase in bone marrow megakaryocytes that were competent toproduce mature platelets in circulation. MiR-150 expression induces ablockage in the earliest definable stage of erythropoiesis, in additionto causing a significant reduction in the total erythroid population.Accordingly, an increase amount of miR-150 regulates the differentiationof MEPs and the post-commitment megakaryocyte expansion.

While overexpression of miR-150 leads to pro-megakaryocytedifferentiation and an increase in platelet count, the inhibition ofmiR-150 expression results in more erythroid colony forming units, moreerythrocytes production and a corresponding decrease in CFU-Mk. In anartificial model of induced anemia, an inhibition of miR-150 with aspecific antagomir elevated the erythrocyte count in the model animal.Clearly, one of the roles of miR-150 is in vivo is to regulate thedifferentiation of bi-potential MEPs and the production of RBCs andplatelets.

MicroRNAs (miRNAs) are a class of 18-24 nt non-coding RNAs (ncRNAs) thatexist in a variety of organisms, including mammals, and are conserved inevolution. miRNAs are transcribed as 5′-capped large polyadenylatedtranscripts (pri-miRNA), primarily in a Pol II-dependent mannerApproximately 40% of human miRNAs are co-transcribed as clustersencoding up to eight distinct miRNA sequences in a single pri-microRNAtranscript. Many miRNAs can be encoded in intergenic regions, hostedwithin introns of pre-mRNAs or within ncRNA genes. Many miRNAs also tendto be clustered and transcribed as polycistrons and often have similarspatial temporal expression patterns. MiRNAs have been found to haveroles in a variety of biological processes including developmentaltiming, differentiation, apoptosis, cell proliferation, organdevelopment, and metabolism (Kloosterman, et al., 2006 Dev Cell11:441-50, and Krutzfeldt, et al., 2006 Cell Metab 4:9-12). Furthermore,miRNAs have been implicated in diseases such as cancer(Esquela-Kerscher, et al., 2006 Nat Rev Cancer 6:259-69) and hepatitis C(Jopling, et al., 2005 Science 309:1577-81), which make them attractivenew drug targets. In contrast to the widely used RNAi technology usingsmall interfering RNA (siRNA) duplexes, strategies to inhibit miRNAshave been less well investigated. Reverse-complement 2′-O-methyl sugarmodified RNA is frequently being used to block miRNA function incell-based systems (Krutzfeldt, et al., 2006 Nat Genet. 38:S14-9).

Pri-miRNAs are cleaved within the nucleus by the microprocessor complexconsisting of Drosha, an RNaseIII-type nuclease and a protein co-factor,DGCR8 (DiGeorge syndrome critical region 8 gene) in humans, Pasha inDrosophila. The resulting 60-70 nucleotide hairpin structure (pre-miRNA)encodes for a single miRNA sequence that is exported from the nucleus tothe cytoplasm by Exportin5 in a Ran-GTP dependent manner Cytoplasmicpre-miRNAs are further cleaved, by another RNaseIII-nuclease, Dicer inconcert with cofactors (TRBP and PACT in humans), to remove the loopsequence forming a short-lived asymmetric duplex intermediate (miRNA:miRNA *). The microRNA: microRNA * duplex is in turn loaded into themiRISC complex in which Argonaut (Ago) proteins appear to be the keyeffector molecules. The strand that becomes the active mature microRNAappears to be dependent upon which has the lowest free energy 5′ end andthe other strand is degraded by an unknown nuclease.

Accordingly, in one embodiment, disclosed herein is a method of treatingthrombocytopenia in a host in need thereof, the method comprisingadministering to a host an effective amount of an agent that increasesmiR-150 expression in a cell.

Thrombocytopenia is a deficiency of platelets (thrombocytes). Plateletscome from megakaryocytes, which are produced in the bone marrow fromhematopoietic progenitor cells. When abnormalities develop in themarrow, the marrow cells can lose their ability to produce platelets incorrect amounts. The result is a lower than normal level of platelets inthe blood. Drugs used in cancer chemotherapy can cause the marrow tomalfunction in this way, as can the presence of tumor cells in themarrow itself.

Normally, the spleen holds about one-third of the body's platelets aspart of this organ's function to recycle aging or damaged RBCs. Whenliver disease or cancer of the spleen is present, the spleen canenlarge, resulting in a greater number of platelets staying in theorgan. This condition then results in abnormally low numbers ofplatelets in the blood.

Platelets can break down in unusually high amounts in persons withabnormalities in their blood vessel walls; with blood clots; or withman-made replacement heart valves. Devices placed inside blood vesselsto keep them from closing (stents) due to weakened walls or fat build-upcan also cause platelets to break down. In addition, infections andother changes in the immune system can speed up the removal of plateletsfrom the circulation.

Thrombocytopenia generally means a circulating platelet count of lessthan the normal circulating range, e.g., less than about 1.6×10⁵/mm³,less than about 1.5×10⁵/mm³, less than about 1.3×10⁵/mm³ or less thanabout 1.0×10⁵/mm³. Under the common terminology criteria for adverseevents, version 3.0, grade 1 thrombocytopenia is the lower normal limitto 75,000 platelets/mm³, grade 2 thrombocytopenia is <75,000-50,000platelets/mm³, grade 3 thrombocytopenia is <50,000-25,000 platelets/mm³and grade 4 is <25,000 platelets/mm³.

The host needing treatment for thrombocytopenia can be any animal thathas platelets, the platelets are produced from megakaryocytes, and themegakaryocytes are differentiated from hematopoietic progenitor cells.In one embodiment, the host is a mammal, such as a dog, cat, horse, andmonkey, preferably a human.

A platelet count is performed to determine the number of platelets incirculation and on the basis of the platelet counts, the physician candetermine whether the host has thrombocytopenia. A platelet count ispart of the complete blood count test (CBC) routinely ordered byphysicians. A platelet count is a test to measure platelets that arepresent in the peripheral circulating blood of a host. This test can beperformed by skilled medical personnel such as physicians, nurses andtrained laboratory technicians by methods known in the art. For example,a sample of peripheral blood is drawn into anticoagulant to prevent theblood from clotting. The larger and heavier cells: white blood cells andRBCs are sedimented by low speed centrifugation (1000×G, 10 min) and theplatelet-rich liquid fraction of the blood is collected and counted.Other manual methods of determining platelet counts include visualevaluation of blood smears on microscope slides and methods usingRBCs-lysing agents followed by visual platelet counting. In oneembodiment, platelets are determined using automated blood countingmachines that include but are not limited to the Sysmex XE-2100, theAbbott Cell-Dyn range (e.g. Cell-Dyn 3500), Boule Nordic AB Ca530 Vetand Melet Schloesing MS4. In one embodiment, the platelet count isperformed according to the European Patent EP1123510 and U.S. Pat. No.6,872,572, both of which are hereby incorporated by reference in theirentirety.

In one embodiment, the cell from a host needing treatment forthrombocytopenia wherein the miR-150 expression is increased is aprogenitor cell. In another embodiment, the progenitor cell is ahematopoietic progenitor cell.

In one aspect, an agent that increases the miR-150 expression in a cellof a host comprises a vector comprising a nucleic acid sequence that isat least 90% identical to SEQ. ID. No. 1. In other aspects, the nucleicacid is at least 92%, at least 94%, at least 95%, at least 97%, at least99%, and all the intermediate percentages between 90% and 100%,identical to SEQ. ID. No. 1. The differences from SEQ. ID. No. 1 shouldbe such that the overall hairpin structure of the pri-miR-150 ismaintain.

In another aspect, the vector is a virus. In yet another aspect, thevector is a non-viral vector.

In one embodiment, an agent that increases miR-150 expression in a cellof a host comprises a nucleic acid sequence that is at least 90%identical to SEQ. ID. No. 1. In another embodiment, the nucleic acid isat least 92%, at least 94%, at least 95%, at least 97%, at least 99%,and all the intermediate percentages between 90% and 100%, identical toSEQ. ID. No. 1.

The SEQ. ID. No. 1 provides the Homo sapiens miR-150 stem-loop pri-miRNAwhich is also known as has-mir-150, MI0000479, NT_(—)011109, ormiRBase:MI0000479 at the miRBase at the Sanger Institute (world wide web“period” microRNA “period” Sanger “period” ac “period” uk).

While not wishing to be bound by theory, expression of the miR-150 geneor a nucleic acid that is at least 90% identical to SEQ. ID. No. 1 bygene transcription produces a primary transcript, pre-miR-150, that canfold into a stem-loop structure. The pre-miR-150 can be exported out ofthe nucleus and be processed in the cytoplasm into a duplex miR-150 fromwhich a mature miR-150 (SEQ. ID. 2) (miRBase:MIMAT0000451) becomesavailable for upload into the miRISC (the miRNA gene inhibitioncomplex). A vector comprising a nucleic acid that is at least 90%identical to SEQ. ID. No. 1, when transfected into a host cell,introduces the miR-150 gene as a transgene into the host cell. In thistransfected host cell harboring the miR1-50 transgene, overexpression ofthe miR-150 transgene increases the amount of miR-150 in the cell.Excess amounts of miR-150 can lead to enhanced repression of genesnaturally regulated by miR-150.

In one embodiment, a vector comprising a nucleic acid that is at least90% identical to SEQ. ID. No. 1 is an expression vector. The expressionvector can have a strong promoter sequence driving the robust mammaliantranscription of the miR-150 transgene in the host cell. Strong promotersequences include but are not limited to the Moloney murine leukemiavirus promoter, cytomegalovirus promoter, the simian virus 40 earlyregion promoter, the lymphotropic papovavirus, and the human beta-globingene promoter sequences. In one embodiment, the promoter can be chimericsequences from several promoter types as described in U.S. Pat. No.6,136,536 which is incorporated hereby reference in its entirety. Inanother embodiment, the promoter can be the human osteocalcin (hOC)promoter (McCarthy H. O., et. al., 2007, J. Gene Medicine, 9: 511-20).

In one embodiment, the expression vector can be a virus such as anadenovirus, an adeno-associated virus, or lentivirus, for example,MDH.xdna murine retroviral vector. Viral vectors provide an additionaladvantage of ease of transfecting the host cell by viral infection. Inanother embodiment, the expression in a non-viral vector. Such vectorscan be transfected into host cells using known transfection methodsknown in the art, such as cationic lipid transfection.

By increasing the miR-150 expression in the hematopoietic progenitorcells of a host, the differentiation of the hematopoietic progenitorcells can be shifted to producing more megakaryocytes, from whichplatelets are derived, eventually increasing the platelet count.

In one embodiment, disclosed herein is a method of treatingthrombocytopenia in a host in need thereof, comprises: (a) contactingthe hematopoietic progenitor cells with a vector comprising a nucleicacid sequence that is at least 90% identical to SEQ. ID. No. 1; and (b)introducing the cell carrying the transgene into the host.

The method comprises obtaining a sample of hematopoietic progenitorcells from a host.

In one embodiment, the hematopoietic progenitor cells are isolated fromhost, transfected, cultured, and transplanted back into the same host,i.e. an autologous cell transplant. In another embodiment, thehematopoietic progenitor cells are isolated from a donor who is anHLA-type match with a host (recipient) who is diagnosed withthrombocytopenia. Donor-recipient antigen type-matching is well known inthe art. The HLA-types include HLA-A, HLA-B, HLA-C, and HLA-D. Theserepresent the minimum number of cell surface antigen matching requiredfor transplantation. The donor's hematopoietic progenitor cells can betransfected with a vector or nucleic acid comprising the nucleic acidthat is at least 90% identical to SEQ. ID. No. 1 (the miR-150transgene), culture expanded, and then transplanted into the host.

In one embodiment, the method disclosed herein includes monitoring theplatelet count of a host before and after the administration of theagent for treatment of thrombocytopenia. The platelet count performedbefore treatment provides the data for a physician to make a diagnosisof thrombocytopenia and the platelet count also serves a referencenumber from which after the treatment platelet counts can be compared.Routine platelet count of samples of peripheral blood should beperformed at 1, 2, 3 months or every bi-monthly after treatment oraccording to physician's decision in order to monitor the efficacy ofthe treatment.

In one embodiment, disclosed herein is a method of treating anemia in ahost in need thereof, the method comprising administering an effectiveamount of an agent that inhibits miR-150 expression in a cell to a host.

Anemia generally means a red cell mass corresponding to less than about4.0×10¹² red cells/L in adult females and less than about 4.5×10¹² redcells/L in adult males (a hemoglobin level of less than about 12.0 g/dLin adult females and less than about 13.5 g/dL in adult males). Anemiamay occur as a result of bleeding (including internal), hemolysis,kidney disease, leukemia, multiple myeloma, bone marrow failure,erythropoietin deficiency, or deficiencies in iron, folate, vitamin B12,or vitamin B6.

The RBCs count is also a part of the complete blood count test (CBC)routinely ordered by physicians. A sample of peripheral blood can becollected and mixed with anticoagulant. For RBC counting by the manualvisual method, a small, fixed volume of blood is diluted, applied to ahemacytometer and counted under a microscope. Alternatively, RBCs arecounted with automated cell counters described herein.

In one embodiment, a host needing treatment for anemia can be any animalthat has RBCs (erythrocytes), and the RBCs are differentiated fromhematopoietic progenitor cells. In one embodiment, the host is a mammal,such as a dog, cat, horse, and monkey, preferably a human.

In one embodiment, the cell in a host wherein the miR-150 activity isinhibited, is a progenitor cell. In another embodiment, a progenitorcell wherein the miR-150 activity is inhibited is a hematopoieticprogenitor cell.

In one embodiment, an agent that inhibits miR-150 activity in a cellcomprises a nucleic acid sequence that can form complementarybase-pairing with SEQ. ID. No. 2, the mature miR-150, for at least 90%of the bases of SEQ. ID. No. 2. In one aspect, the nucleic acid can formcomplementary base-pairing with at least 92%, at least 94%, at least95%, at least 97%, at least 99%, and all the intermediate percentagesbetween 90% and 100%, to SEQ. ID. No. 2. In another embodiment, an agentis a vector comprising a nucleic acid sequence that is at least 90%identical to SEQ. ID. No. 3 (miRBase:MIMAT0004610). The nucleic acid isat least 92%, at least 94%, at least 95%, at least 97%, at least 99%,and all the intermediate percentages between 90% and 100%, identical toSEQ. ID. No. 3. In yet another embodiment, an agent is a nucleic acidsequence that is at least 90% identical to SEQ. ID. No. 3.

In some aspects, an agent that inhibits miR-150 activity in a cell canbe referred to as a miR-150 inhibitor, the miR-150 inhibitor functionsby blocking, preventing, and/or antagonizing the normal cellularactivity of the mature miR-150 which is to down regulate the expressionsof certain genes. A miR-150 inhibitor can be an antagomir of miR-150, anantisense oligonucleotide to miR-150, a locked nucleic acid that annealsto miR-150, and double-stranded RNA corresponding to miR-150 (dsRNA).

In one embodiment, a miR-150 inhibitor is between 17 and 25 nucleotidesin length and that comprises a 5′ to 3′ sequence that is at least 90%complementary to the 5′ to 3′ sequence of SEQ. ID. No. 2. In anotherembodiment, a miR-150 inhibitor is a synthetic RNA molecule of between17 and 125 residues in length comprising i) an miRNA region whosesequence from 5′ to 3′ is identical to a mature miR-150 sequence, andii) a complementary region whose sequence from 5′ to 3′ is between 60%and 100% complementary to the mature miR-150 sequence.

Antagomirs are a novel class of chemically engineered oligonucleotidesthat block the activity of miRNAs and essentially “silence” the miRNA(Krützfeldt J, et. al., 2005, Nature 438: 685-9). Antagomirs aresingle-stranded RNA that are perfectly complementary to their miRNAexcept that they are 2′-O-methyl (2′-OMe) oligoribonucleotides and arealso linked to cholesterol at the 3′ end. Both these modifications,2′-OMe and cholesterol, aid in the antagomir stability in vivo and easeof entry into the cells. Methods of designing and synthesizingantagomirs and the various modifications (e.g. 2′-O-Methoxyethyl) aredescribed in US Pat. Application 20070213292 and is hereby incorporatedby reference in its entirety. An example of a miR-150 antagomir is5′mC(*)mA(*)mCmUmGmGmUmAmCmAmAmGmGmGmUmUmGmGmG(*)mA(*) mG (*)mA(*)(3′-Chl) 3′ (SEQ. ID. No. 23). The mN: 2′OMe base; *:phosphorothioate linkage; Chl: cholesterol.

In one embodiment, the miR-150 inhibitor is a miR-150 antagomir. In oneembodiment, the miR-150 inhibitor is SEQ. ID. No. 23. In anotherembodiment, the miR-150 inhibitor consist essentially of SEQ. ID. No.23. In another embodiment, the miR-150 inhibitor consist of SEQ. ID. No.23. In another embodiment, the miR-150 inhibitor comprises SEQ. ID. No.23.

Locked nucleic acid (LNA)-modified oligonucleotides are distinctive2′-O-modified RNA in which the 2′-O-oxygen is bridged to the 4′-positionvia a methylene linker to form a rigid bicycle, locked into a C3′-endo(RNA) sugar conformation (Venter B., et. al., Biochemistry 2004; 43:13233-13241). The LNA modification leads to the thermodynamicallystrongest duplex formation with complementary RNA known. Consequently, abiological activity is often attained with very short LNAoligonucleotides. For example, an 8 nt fully-modified LNA oligomercomplementary to a structural loop inhibited 50% of self-splicing ofgroup I introns from rRNA genes in pathogenic organisms whereas DNA andRNA oligonucleotides were ineffective. Short fully-modified LNAoligonucleotides designed against telomerase were active in cellularassays, compared to mismatched negative controls. Furthermore, LNAsdisplay excellent mismatch discrimination. Mouritzen et al. (Expert RevMol Diagn 2003; 3: 27-38) showed single-nucleotide specificity againstcomplementary DNA using fully modified 12 nucleotide LNA probes coupledto glass slides during the development of a microarray used to probesamples for single-nucleotide polymorphisms (SNPs) associated with humandysmetabolic syndrome. The synthesis and incorporation of LNA bases canbe achieved by using standard DNA synthesis chemistry and described inU.S. Pat. No. 6,268,490 and is hereby incorporated by reference in itsentirety.

An anti-sense oligonucleotide of miR-150 has a sequence that perfectlycomplementary to SEQ. ID. No. 2, the mature miR-150. Complementarypairing between an anti-sense oligonucleotide of miR-150 and miR-150produces a duplex RNA that is highly susceptible to RNase degradation.An anti-sense oligonucleotide of miR-150 comprises the sequence5′-CACUGGUACAAGGGUUGGGAGA-3′ (SEQ. ID. No. 4).

One skilled in the art can also readily determine an appropriate dosageregimen for administering a compound that inhibits miRNA expression to agiven subject, as described herein. Suitable compounds for inhibitingmiRNA gene expression include double-stranded RNA (such as short- orsmall-interfering RNA or “siRNA”), antisense nucleic acids, andenzymatic RNA molecules, such as ribozymes. Each of these compounds canbe targeted to a given miRNA gene product and interfere with theexpression (e.g., by inhibiting translation, by inducing cleavage and/ordegradation) of the target miRNA gene product. For example, expressionof a given miRNA gene can be inhibited by inducing RNA interference ofthe miRNA gene with an isolated double-stranded RNA (“dsRNA”) moleculewhich has at least 90%, for example at least 95%, at least 98%, at least99%, or 100%, sequence homology with at least a portion of the miRNAgene product. In a particular embodiment, the dsRNA molecule is a “shortor small interfering RNA” or “siRNA.” siRNA useful in the presentmethods comprise short double-stranded RNA from about 17 nucleotides toabout 29 nucleotides in length, preferably from about 19 to about 25nucleotides in length. The siRNA comprise a sense RNA strand and acomplementary antisense RNA strand annealed together by standardWatson-Crick base-pairing interactions (hereinafter “base-paired”)—Thesense strand comprises a nucleic acid sequence that is substantiallyidentical to a nucleic acid sequence contained within the target miRNAgene product.

In one embodiment, an agent that inhibits miR-150 activity is a vectorthat comprises an anti-sense oligonucleotide to miR-150 (SEQ. ID. No.4). The anti-sense oligonucleotide sequence can be cloned into a vectorfor the expression in a host cell by any means known to one skilled inthe art. In one embodiment, the vector is a virus. In anotherembodiment, the vector is a non-virus. Designing, cloning, transfection,and expression of anti-sense oligonucleotides against miRNAs aredescribed in Scherr M. et. al., 2007, Nucleic Acid Research 35(22):e149and is incorporated hereby reference in its entirety.

In one embodiment, the agent can be various combinations of an antagomirof miR-150, an antisense oligonucleotide to miR-150, dsRNA to miR-150,or a locked nucleic acid that anneals to miR-150.

In one embodiment, disclosed herein is a method of treating anemia in ahost in need thereof, the method comprising: (a) contacting thehematopoietic progenitor cells with a vector comprising a nucleic acidsequence that is at least 90% identical to SEQ. ID. No. 3 or 4; and (b)introducing the cell from step b into the same host. The methodcomprises obtaining a sample of hematopoietic progenitor cells from ahost. Methods of isolating, transfecting, culturing, screening forstrong expression of transgene, and transplantation can be performed asdescribed herein.

In one embodiment, the method disclosed herein includes monitoring theRBC count of a host before and after the administration of the agent fortreatment of anemia. The RBC count performed before treatment providethe data for a physician to make a diagnosis of anemia and the RBC countalso serve a reference number from which after treatment RBC counts canbe compared with. Routine RBC count of samples of peripheral bloodshould be performed at 1, 2, 3 months or every bi-monthly aftertreatment or according to physician's decision in order to monitor theefficacy of the treatment.

In one embodiment, the method disclosed herein comprises treating anemiain conjunction with other known treatments such as with erythropoietin(EPO) and peptide mimetics of EPO. EPO is a hormone produced by thekidney that promotes the formation of red blood cells in the bonemarrow. The kidney cells that make EPO are specialized and are sensitiveto low oxygen levels in the blood. These cells release EPO when theoxygen level is low in the kidney. EPO then stimulates the bone marrowto produce more red cells and thereby increase the oxygen-carryingcapacity of the blood. EPO is the prime regulator of red blood cellproduction. Its major functions are to promote the differentiation anddevelopment of red blood cells and to initiate the production ofhemoglobin, the molecule within red cells that transports oxygen.

In one embodiment, the methods described herein can be implemented withother therapeutics associated with thrombocytopenia and anemia.

The present invention can be defined in any of the followingalphabetized paragraphs:

-   -   [A] The use of an agent that increases miR-150 expression in a        cell for the treatment of thrombocytopenia in a host in need        thereof.    -   [B] The use of an agent that increases miR-150 expression in a        cell in the manufacture of a medicament for the treatment of        thrombocytopenia.    -   [C] The use of paragraph [A] or [B], wherein the cell is a        progenitor cell.    -   [D] The use of paragraph [C], wherein the progenitor cell is a        hematopoietic progenitor cell.    -   [E] The use of paragraph [A] or [B], wherein the agent is a        vector comprising a nucleic acid sequence that is at least 90%        identical to SEQ. ID. No. 1.    -   [F] The use of paragraph [E], wherein the vector is a virus.    -   [G] The use of paragraph [A] or [B], wherein the agent is a        nucleic acid sequence that is at least 90% identical to SEQ. ID.        No. 1.    -   [H] A method of treating thrombocytopenia in a host in need        thereof, the method comprising administering an effective amount        of an agent that increases miR-150 expression in a cell to a        host.    -   [I] The method of paragraph [H], wherein the cell is a        progenitor cell.    -   [J] The method of paragraph [I], wherein the progenitor cell is        a hematopoietic progenitor cell.    -   [K] The method of paragraph [H], wherein the agent is a vector        comprising a nucleic acid sequence that is at least 90%        identical to SEQ. ID. No. 1.    -   [L] The method of paragraph [K], wherein the vector is a virus.    -   [M] The method of paragraph [H], wherein the agent is a nucleic        acid sequence that is at least 90% identical to SEQ. ID. No. 1.    -   [N] A method of treating thrombocytopenia in a host in need        thereof, the method comprising:        -   a. obtaining a sample of hematopoietic progenitor cells from            said host;        -   b. contacting the hematopoietic progenitor cells with a            vector comprising a nucleic acid sequence that is at least            90% identical to SEQ. ID. No. 1; and        -   c. introducing the cell from step b into the host.    -   [O] The use of an agent that inhibits miR-150 in a cell for the        treatment of anemia in a host in need thereof.    -   [P] The use of an agent that inhibits miR-150 in a cell in the        manufacture of a medicament for the treatment of anemia.    -   [Q] The use of either paragraph [O] or [P], wherein the cell is        a progenitor cell.    -   [R] The use of paragraph [Q], wherein the progenitor cell is a        hematopoietic progenitor cell.    -   [S] The use of paragraph [O] or [P], wherein the agent is an        antagomir of miR-150, an anti-miR-150 oligonucleotide, an        antisense oligonucleotide to miR-150 or a locked nucleic acid        that anneals to miR-150.    -   [T] The use of paragraph [O] or [P], wherein the agent is a        vector comprising a nucleic acid sequence that is at least 90%        identical to SEQ. ID. No. 3.    -   [U] The use of paragraph [T], wherein the vector is a virus.    -   [V] A method of treating anemia in a host in need thereof, the        method comprising administering an effective amount of an agent        that inhibits miR-150 in a cell to a host.    -   [W] The method of paragraph [V], wherein the cell is a        progenitor cell.    -   [X] The method of paragraph [W], wherein the progenitor cell is        a hematopoietic progenitor cell.    -   [Y] The method of paragraph [V], wherein the agent is a vector        comprising a nucleic acid sequence that is at least 90%        identical to SEQ. ID. No. 3.    -   [Z] The method of paragraph [V], wherein the agent is an        antagomir of miR-150, an anti-miR-150 oligonucleotide, an        antisense oligonucleotide to miR-150 or a locked nucleic acid        that anneals to miR-150.    -   [AA] A method of paragraph [Y], wherein the vector is a virus.    -   [BB] A method of treating anemia in a host in need thereof, the        method comprising:        -   a. obtaining a sample of hematopoietic progenitor cells from            said host;        -   b. contacting the hematopoietic progenitor cells with a            vector comprising a nucleic acid sequence that is at least            90% identical to SEQ. ID. No. 3; and        -   c. introducing the cell from step b into the same host.            Hematopoietic Progenitor Cells

Peripheral blood progenitor cells (PBPC) have become the preferredsource of hematopoetic progenitor cells for allogeneic and autologoustransplantation because of technical ease of collection and shorter timerequired for engraftment. Traditionally, granulocyte-colony stimulatingfactor (G-CSF) has been used to stimulate more PBPC and release ofhematopoetic progenitor cells from the bone marrow. Although regimensusing G-CSF usually succeed in collecting adequate numbers of PBPC fromhealthy donors, 5%-10% will mobilize stem cells poorly and may requiremultiple large volume apheresis or bone marrow harvesting.

AMD3100, is a bicyclam compound that inhibits the binding of stromalcell derived factor-1 (SDF-1) to its cognate receptor CXCR4. CXCR4 ispresent on CD34+ hematopoetic progenitor cells and its interaction withSDF-1 plays a pivotal role in the homing of CD34+ cells in the bonemarrow Inhibition of the CXCR4-SDF1 axis by AMD3100 releases CD34+ cellsinto the circulation, which can then be collected easily by apheresis.Recently, a published report demonstrated that large numbers of CD34+cells were rapidly mobilized in healthy volunteers following a singlesubcutaneous injection of AMD3100.

The hematopoietic progenitor cells can be isolated fresh and frozenmononuclear cells of peripheral blood, cord blood, and bone marrow usingits pan-hematopoietic antigen CD34 or by other methods that are known toone skilled in the art. For example, antibodies against CD34 can be usedfor immuno-isolating the CD34(+) hematopoietic progenitor cells from themononuclear cell fraction. The anti-CD34 antibodies can be conjugatedwith fluorophores or to magnetic beads for ease of separation by FACS ormagnets respectively.

Hematopoietic progenitor cells bearing the pan-hematopoietic antigenCD34 can also be isolated by using taking advantage of the cells abilityto bind galactose-conjugated proteins. This lectin-positivesub-population represents approximately 0.1 to 0.5% of the total bonemarrow cells, and contains 100% of the hematopoietic progenitor cells.The galactose-binding lectin on these cells is specific for this sugar.Additionally, highly proliferative hematopoietic progenitor cells withvery primitive phenotypes, including a newly identified progenitor cellthat produces multiple lineages, express this lectin. (Pipia and Long,Nature Biotechnology 15, 1007-1011 (1997)).

In vitro transfection of isolated hematopoietic progenitor cells from ahost facilitates targeted transfection of the miR-150 transgene intospecific progenitor cells. Transfection of progenitor cells can beaccomplished by any transfection methods known in the art, for example,calcium phosphate-mediated, DEAE-Dextran-mediated, calcium alginatemicrobeads, cation lipid-mediated, scrape-loading, and ballisticbombardment of nucleic acid gold particles. In one embodiment, isolationand culturing of progenitor cells is performed using the methods wellknown in to those skilled in the art, e.g. as described in U.S. Pat.Nos. 5,199,942, 5,474,687, 5,589,368, 5,612,211, 5,905,041, 6,355,237,and 7,345,025, which are hereby incorporated by reference in theirentirety. The identity of the isolated hematopoietic progenitor cellscan be confirmed by transglutaminase expression in culture as describedin WO2000/006766, which is also hereby incorporated by reference in itsentirety. After in vitro transfection, the miR-150 transfection levelcan be monitored by quantitative real-time PCR with specific primerpairs to the pre-miR-150 and the mature miR-150. The transfectedprogenitor cells carrying the transgene can be expanded in cultureaccording to methods described in U.S. Pat. Nos. 5,744,361, 5,905,041,and 6,326,198, which are hereby incorporated by reference in theirentirety. The expanded progenitor cells with the miR-150 transgene canthen be transplanted back into the original host. Transplantation ofprogenitor cells are described in U.S. Pat. Nos. 5,817,773, 5,858,782,and U.S. patent application Ser. No. 10/730,334 and they are herebyincorporated by reference in their entirety.

In one embodiment, the SEQ. ID. No. 1 (miR-150 gene) is cloned into theMDH.xdna murine retroviral vector and miR-150 retroviral vectors can betransfected into isolated hematopoietic progenitor cells. Forty-eighthours after transfection, total RNAs were isolated and loaded onto a 10%denaturing polyacrylamide gel. DNA oligo probes that were complementaryto each of the selected miRNAs were labeled and hybridized to themembrane to detect mature miR-150s that can be efficiently processed(20- to 24-nt). Constructs with high processing efficiency can beselected for bone marrow transplantation.

Expression Vectors and Expression Systems for Expression

Isolated nucleic acid sequences that are at least 90% identical to SEQ.ID. No. 1, 3 and 4 can be obtained using a number of standardtechniques. For example, the nucleic acids can be chemically synthesizedor recombinantly produced using methods known in the art. In oneembodiment, the nucleic acids are chemically synthesized usingappropriately protected ribonucleoside phosphoramidites and aconventional DNA/RNA synthesizer. Commercial suppliers of synthetic RNAmolecules or synthesis reagents include, e.g., Proligo (Hamburg,Germany), Dharmacon Research (Lafayette, Colo., U.S.A.), Pierce Chemical(part of Perbio Science, Rockford, Ill., U.S.A.), Glen Research(Sterling, Va., U.S.A.), ChemGenes (Ashland, Mass., U.S.A.) and Cruachem(Glasgow, UK).

Alternatively, the nucleic acids and their complementary strands can besynthesized as single strand DNA initially and then subsequently annealtogether to form duplex for cloning into vectors for gene expression asdescribed in Scheer M. et. al. supra. Restriction enzyme sites can bedesigned and incorporated at the ends of the eventual duplex tofacilitate ligating the duplex into a vector.

The human miR-150 stem loop (hsa-miR-150) is contained within a 473 bpgenomic fragment that includes the hairpin region of hsa-miR-150 and˜200 bp of flanking sequence on each side. This genomic expressioncassette can be PCR amplified from human genomic DNA (Roche AppliedScience) with primers containing 5′ linker sequences harboring relevantdigestion sites (core primer sequences: 5′ CAGCATAGGGTGGAGTGGGT3′ (Seq.ID. No. 5); 5′TACTTTGCGCATCACACAGA3′ (SEQ. ID. No. 6).

Once ligated into a vector, the nucleic acid can be subcloned intoseveral expression vectors, such as a viral expression vector or amammalian expression vector by PCR cloning, restriction digestionfollowed by ligation, or recombination reaction such as those of thelambda phage-based site-specific recombination using the GATEWAY® LR andBP CLONASE™ enzyme mixtures. Subcloning should be unidirectional suchthat the 5′ transcription start nucleotide of the nuclei acid sequenceis downstream of the promoter in the expression vector. Alternatively,when the nucleic acid sequence is cloned into pENTR/D-TOPO®,pENTR/SD/D-TOPO® (directional entry vectors), or any of the INVITROGEN'sGATEWAY® Technology pENTR (entry) vectors, the nucleic acid sequence canbe transferred into the various GATEWAY® expression vectors(destination) for protein expression in host cells in one singlerecombination reaction. Some of the GATEWAY® destination vectors aredesigned for the constructions of baculovirus, adenovirus,adeno-associated virus (AAV), retrovirus, and lentiviruses, which uponinfecting their respective host cells, facilitating ease of introducingthe transgene into the host cells. The GATEWAY® Technology uses lambdaphage-based site-specific recombination instead of restrictionendonuclease and ligase to insert a gene of interest into an expressionvector. The DNA recombination sequences (attL, attR, attB, and attP) andthe LR and BP CLONASE™ enzyme mixtures that mediate the lambdarecombination reactions are the foundation of GATEWAY® Technology.Transferring a gene into a destination vector is accomplished in justtwo steps: Step 1: Clone the nucleic acid sequence of interest into anentry vector such as pENTR/D-TOPO®, Step 2: Mix the entry clonecontaining the nucleic acid sequence of interest in vitro with theappropriate GATEWAY® expression vector (destination vector) and GATEWAY®LR CLONASE™ enzyme mix. There are GATEWAY® expression vectors forprotein expression in E. coli, insect cells, mammalian cells, and yeast.Site-specific recombination between the att sites (attR×attL andattB×attP) generates an expression vector and a by-product. Theexpression vector contains the nucleic acid sequence of interestrecombined into the destination vector backbone. Followingtransformation and selection in E. coli, the expression vector is readyto be used for expression in the appropriate host.

The nucleic acid sequence of interest can be expressed from recombinantcircular or linear DNA vector using any suitable promoter. Suitablepromoters for expressing RNA from a vector include, e.g., the U6 or H1RNA pol III promoter sequences, or the cytomegalovirus promoters.Selection of other suitable promoters is within the skill in the art.The expression vector should have the necessary 5′ upstream and 3′downstream regulatory elements such as promoter sequences, ribosomerecognition and binding TATA box, and 3′ UTR AAUAAA (SEQ. ID. No. 25)transcription termination sequence for the efficient gene transcriptionand translation in its respective host cell. The recombinant vectors canalso comprise inducible or regulatable promoters for expression of thenucleic acid sequence of interest in hematopoietic progenitor cells. Thenucleic acids that are expressed from recombinant vectors can also bedelivered to, and expressed directly in, cells. In one embodiment, thenucleic acids are expressed as RNA precursor molecules from a singlevector, and the precursor molecules are processed into the functionalmiR gene product by a suitable processing system, including, but notlimited to, processing systems extant within a cell. Other suitableprocessing systems include, e.g., the in vitro Drosophila cell lysatesystem (e.g., as described in U.S. Published Patent Application No.2002/0086356 to Tuschl et al., the entire disclosure of which isincorporated herein by reference) and the E. coli RNAse III system(e.g., as described in U.S. Published Patent Application No.2004/0014113 to Yang et al., the entire disclosure of which isincorporated herein by reference).

Selection of vectors suitable for expressing the nucleic acid sequence,methods for inserting nucleic acid sequences into vector to express thegene products, and methods of delivering the recombinant plasmid to thecells of interest are within the skill in the art. See, for example,Zeng et al. (2002), Molecular Cell 9:1327-1333; Tuschl (2002), Nat.Biotechnol, 20:446-448; Brummelkamp et al. (2002), Science 296:550-553;Miyagishi et al. (2002), Nat. Biotechnol. 20:497-500; Paddison et al.(2002), Genes Dev. 16:948-958; Lee et al. (2002), Nat. Biotechnol.20:500-505; and Paul et al. (2002), Nat. Biotechnol. 20:505-508, theentire disclosures of which are incorporated herein by reference.

Examples of expression vectors for mammalian host cells include but arenot limited to the strong CMV promoter-based pcDNA3.1 (INVITROGEN) andpCIneo vectors (Promega) for expression in mammalian cell lines such asCHO, COS, HEK-293, Jurkat, and MCF-7; replication incompetent adenoviralvector vectors pAdeno X, pAd5F35, pLP-Adeno-X-CMV (Clontech),pAd/CMV/V5-DEST, pAd-DEST vector (INVITROGEN) for adenovirus-mediatedgene transfer and expression in mammalian cells; pLNCX2, pLXSN, andpLAPSN retrovirus vectors for use with the RETRO-X™ system from Clontechfor retroviral-mediated gene transfer and expression in mammalian cells;pLENTI4/V5-DEST™, pLenti6/V5-DEST™, and pLENTI6.2/V5-GW/lacZ(INVITROGEN) for lentivirus-mediated gene transfer and expression inmammalian cells; adenovirus-associated virus expression vectors such aspAAV-MCS, pAAV-IRES-hrGFP, and pAAV-RC vector (Stratagene) foradeno-associated virus-mediated gene transfer and expression inmammalian cells;

A simplified system for generating recombinant adenoviruses is presentedby He T C. et. al. Proc. Natl. Acad. Sci. USA 95:2509-2514, 1998. Thegene of interest is first cloned into a shuttle vector, e.g.pAdTrack-CMV. The resultant plasmid is linearized by digesting withrestriction endonuclease Pme I, and subsequently cotransformed into E.coli. BJ5183 cells with an adenoviral backbone plasmid, e.g. pAdEasy-1of Stratagene's AdEASY™ Adenoviral Vector System. Recombinant adenovirusvectors are selected for kanamycin resistance, and recombinationconfirmed by restriction endonuclease analyses. Finally, the linearizedrecombinant plasmid is transfected into adenovirus packaging cell lines,for example HEK 293 cells (E1-transformed human embryonic kidney cells)or 911 (E1-transformed human embryonic retinal cells) (Human GeneTherapy 7:215-222, 1996). Recombinant adenovirus are generated withinthe HEK 293 cells.

In one embodiment, a recombinant lentivirus can be used for the deliveryand expression of a nucleic acid sequence that is at least 90% identicalto SEQ. ID. No. 1, 3 or 4 in either dividing and non-dividing mammaliancells. The HIV-1 based lentivirus can effectively transduce a broaderhost range than the Moloney Leukemia Virus (MoMLV)-base retroviralsystems. Preparation of the recombinant lentivirus can be achieved usingthe pLENTI4/V5-DEST™, pLENTI6/V5-DEST™ or pLenti vectors together withViraPower™ Lentiviral Expression systems from Invitrogen.

In one embodiment, a recombinant adeno-associated virus (rAAV) vectorcan be used for the expression of a nucleic acid sequence that is atleast 90% identical to SEQ. ID. No. 1, 3 or 4. Because AAV isnon-pathogenic and does not illicit an immune response, a multitude ofpre-clinical studies have reported excellent safety profiles. rAAVs arecapable of transducing a broad range of cell types and transduction isnot dependent on active host cell division. High titers, >10⁸ viralparticle/ml, are easily obtained in the supernatant and 10¹¹-10¹² viralparticle/ml with further concentration. The transgene is integrated intothe host genome so expression is long term and stable.

The use of alternative AAV serotypes other than AAV-2 (Davidson et al(2000), PNAS 97(7)3428-32; Passini et al (2003), J. Virol77(12):7034-40) has demonstrated different cell tropisms and increasedtransduction capabilities. With respect to brain cancers, thedevelopment of novel injection techniques into the brain, specificallyconvection enhanced delivery (CED; Bobo et al (1994), PNAS91(6):2076-80; Nguyen et al (2001), Neuroreport 12(9):1961-4), hassignificantly enhanced the ability to transduce large areas of the brainwith an AAV vector.

Large scale preparation of AAV vectors is made by a three-plasmidcotransfection of a packaging cell line: AAV vector carrying thechimeric DNA coding sequence, AAV RC vector containing AAV rep and capgenes, and adenovirus helper plasmid pDF6, into 50×150 mm plates ofsubconfluent 293 cells. Cells are harvested three days aftertransfection, and viruses are released by three freeze-thaw cycles or bysonication.

AAV vectors are then purified by two different methods depending on theserotype of the vector. AAV2 vector is purified by the single-stepgravity-flow column purification method based on its affinity forheparin (Auricchio, A., et. al., 2001, Human Gene therapy 12; 71-6;Summerford, C. and R. Samulski, 1998, J. Virol. 72:1438-45; Summerford,C. and R. Samulski, 1999, Nat. Med. 5: 587-88). AAV2/1 and AAV2/5vectors are currently purified by three sequential CsCl gradients.Delivery vectors can also included but are not limited toreplication-defective adenoviral vectors, cationic liposomes andprotein-cationic peptides. For example, one study reports a system todeliver DNA in vitro by covalently attaching the surfactant associatedprotein B (SP-B) to a 10 kDa poly-lysine. See, Baatz, J., et al., PNASUSA, 91:2547-2551 (1994). See, e.g., Longmuir, et al., 1992ASBMB/Biophysical Society abstract; Longmuir, et al., 1993 BiophysicalSociety abstract.

Therapeutic Uses and Administration

In one embodiment, a nucleic acid or vector administered to the hostcells comprise a non-cationic lipid for cytoplasmic and/or nucleardelivery, wherein the nucleic acid or vector is stable and is used inbiological extracellular fluids typically found in animals, particularlyblood serum.

Liposomes, spherical, self-enclosed vesicles composed of amphipathiclipids, have been widely studied and are employed as vectors for in vivoadministration of therapeutic agents. In particular, the so-called longcirculating liposomes formulations which avoid uptake by the organs ofthe mononuclear phagocyte system, primarily the liver and spleen, havefound commercial applicability. Such long-circulating liposomes includea surface coat of flexible water soluble polymer chains, which act toprevent interaction between the liposome and the plasma components whichplay a role in liposome uptake. Alternatively, hyaluronan has been usedas a surface coating to maintain long circulation.

In one embodiment, the liposome encapsulate the nucleic acid sequences,vectors or even the viral particles. In one embodiment, the nucleic acidsequences or vectors are condensed with a cationic polymer, e.g., PEI,polyamine spermidine, and spermine, or a cationic peptide, e.g.,protamine and poly-lysine, and encapsulated in the lipid particle. Theliposomes can comprise multiple layers assembled in a step-wise fashion.

Lipid materials well known and routinely utilized in the art to produceliposomes. Lipids may include relatively rigid varieties, such assphingomyelin, or fluid types, such as phospholipids having unsaturatedacyl chains. “Phospholipid” refers to any one phospholipid orcombination of phospholipids capable of forming liposomes.Phosphatidylcholines (PC), including those obtained from egg, soy beansor other plant sources or those that are partially or wholly synthetic,or of variable lipid chain length and unsaturation are suitable for usein the present invention. Synthetic, semisynthetic and natural productphosphatidylcholines including, but not limited to,distearoylphosphatidylcholine (DSPC), hydrogenated soyphosphatidylcholine (HSPC), soy phosphatidylcholine (soy PC), eggphosphatidylcholine (egg PC), hydrogenated egg phosphatidylcholine(HEPC), dipalmitoylphosphatidylcholine (DPPC) anddimyristoylphosphatidylcholine (DMPC) are suitable phosphatidylcholinesfor use in this invention. All of these phospholipids are commerciallyavailable. Further, phosphatidylglycerols (PG) and phosphatic acid (PA)are also suitable phospholipids for use in the present invention andinclude, but are not limited to, dimyristoylphosphatidylglycerol (DMPG),dilaurylphosphatidylglycerol (DLPG), dipalmitoylphosphatidylglycerol(DPPG), distearoylphosphatidylglycerol (DSPG) dimyristoylphosphatidicacid (DMPA), distearoylphosphatidic acid (DSPA), dilaurylphosphatidicacid (DLPA), and dipalmitoylphosphatidic acid (DPPA).Distearoylphosphatidylglycerol (DSPG) is the preferred negativelycharged lipid when used in formulations. Other suitable phospholipidsinclude phosphatidylethanolamines, phosphatidylinositols,sphingomyelins, and phosphatidic acids containing lauric, myristic,stearoyl, and palmitic acid chains. For the purpose of stabilizing thelipid membrane, it is preferred to add an additional lipid component,such as cholesterol. Preferred lipids for producing liposomes accordingto the invention include phosphatidylethanolamine (PE) andphosphatidylcholine (PC) in further combination with cholesterol (CH).According to one embodiment of the invention, a combination of lipidsand cholesterol for producing the liposomes of the invention comprise aPE:PC:Chol molar ratio of 3:1:1. Further, incorporation of polyethyleneglycol (PEG) containing phospholipids is also contemplated by thepresent invention.

In addition, in order to prevent the uptake of the liposomes into thecellular endothelial systems and enhance the uptake of the liposomesinto the tissue of interest, the outer surface of the liposomes may bemodified with a long-circulating agent. The modification of theliposomes with a hydrophilic polymer as the long-circulating agent isknown to enable to prolong the half-life of the liposomes in the blood

Liposomes encapsulating the nucleic acid sequences described herein canbe obtained by any method known to the skilled artisan. For example, theliposome preparation of the present invention can be produced by reversephase evaporation (REV) method (see U.S. Pat. No. 4,235,871), infusionprocedures, or detergent dilution. A review of these and other methodsfor producing liposomes may be found in the text Liposomes, Marc Ostro,ed., Marcel Dekker, Inc., New York, 1983, Chapter 1. See also Szoka Jr.et al., (1980, Ann. Rev. Biophys. Bioeng., 9:467).

The use of an therapeutically effective amount of the nucleic acidsequences or vectors disclosed herein for the treatment ofthrombocytopenia and anemia should preferably include but is not limitedto a composition of the nucleic acid segments in lactated Ringer'ssolution and the composition is sterile. Lactated Ringer's solution is asolution that is isotonic with blood and intended for intravenousadministration. Include are antioxidants, buffers, antibiotics andsolutes that render the compositions substantially isotonic with theblood of an intended recipient. In another embodiment, the compositioncomprise gene delivery vectors described herein. In another embodiment,the composition also include water, polyols, glycerine and vegetableoils, and nutrients for cells, for example. Compositions adapted forparenteral administration can be presented in unit-dose or multi-dosecontainers, in a pharmaceutically acceptable dosage form. Such dosageforms, along with methods for their preparation, are known in thepharmaceutical and cosmetic art. Harry's Cosmeticology (ChemicalPublishing, 7th ed. 1982); Remington's Pharmaceutical Sciences (MackPublishing Co., 18th ed. 1990).

In one embodiment, dosage forms include pharmaceutically acceptablecarriers that are inherently nontoxic and nontherapeutic. Examples ofsuch carriers include ion exchangers, alumina, aluminum stearate,lecithin, serum proteins, such as human serum albumin, buffer substancessuch as phosphates, glycine, sorbic acid, potassium sorbate, partialglyceride mixtures of saturated vegetable fatty acids, water, salts, orelectrolytes such as protamine sulfate, disodium hydrogen phosphate,potassium hydrogen phosphate, sodium chloride, zinc salts, colloidalsilica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-basedsubstances, and polyethylene glycol.

In one embodiment, other ingredients can be added, includingantioxidants, e.g., ascorbic acid; low molecular weight (less than aboutten residues) polypeptides, e.g., polyarginine or tripeptides; proteins,such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymerssuch as polyvinylpyrrolidone; amino acids, such as glycine, glutamicacid, aspartic acid, or arginine; monosaccharides, disaccharides, andother carbohydrates including cellulose or its derivatives, glucose,mannose, or dextrins; chelating agents such as EDTA; and sugar alcoholssuch as mannitol or sorbitol.

In one embodiment, the administration of the nucleic acid segments orgene delivery vectors disclosed herein are by any suitable route, andmeans, for example, parenterally, intravenous, intra-arterial,intracranial, intracerebrospinal, intratumoral, peritoneal, byinjection, by catheter, by implantation with or without a matrix or gelmaterial, or by gradual delivery device. In one embodiment, the nucleicacid segments or gene delivery vectors described herein can beadministered directly by injection.

The therapeutically effective amount amounts to be administered willdepend on the severity of the condition and individual patientparameters including age, physical condition, size, weight andconcurrent treatment. These factors are well known to those of ordinaryskill in the art and can be addressed with no more than routineexperimentation. It is preferred generally that a maximum dose be used,that is, the highest safe dose according to sound medical judgment. Itwill be understood by those of ordinary skill in the art; however, thata lower dose or tolerable dose may be administered for medical reasons,psychological reasons or for virtually any other reason.

This invention is further illustrated by the following example whichshould not be construed as limiting. The contents of all referencescited throughout this application, as well as the figures and table areincorporated herein by reference.

EXAMPLES Materials and Methods

MiRNA expression profiling and data analysis—miRNA expression profilingwas performed using the plate capture method unless otherwise stated.96-well PCR plates with N-oxysuccinimide surface (DNA-BIND plates,Corning Costar) were coated at room temperature for 1 hour with 5 μMmixture of 5′ amino-antisense oligonucleotides (see Table 4) at 20 μlper well according to manufacturer's protocol. Coated plates weresuccessively washed with (100 mM Tris-HCl, pH8.0, 150 mM NaCl, 1 mMEDTA) and (10 mM Tris-HCl, pH 8.0, 1 mM EDTA). Total RNA (10 ng orhigher) was diluted to 20 μl in 50 mM Tris-HCl, pH 8.0, 1 M NaCl, 1 mMEDTA, 1×RNAsecure (Ambion), containing pre-control synthetic miRNAmixture at the ratio previously described (1) miRNAs were captured inthe coated wells by denaturing at 80° C. for 5 minutes and graduallycooling to room temperature in 1.5 hours in a PCR machine, followed bythree 2×SSC washes. 3′ adaptor ligation and 5′ adaptor ligations werecarried out as described (1) in 20 μl reaction volumes, with four 2×SSCwashes after each ligation. Ligated miRNA were denatured for 5 minutesat 80° C. in 20 μl water with 2 μM adaptor-specific RT primer, chilledon ice, and reverse transcribed as described (1). RT products weredenatured at 95° C. for 5 minutes before 2 rounds of PCR amplificationwith described conditions (1), for 26 and 27 cycles respectively, toincorporate biotin labels for low input RNA profiling. Labeled miRNAswere hybridized to a bead-based detection platform (1), with updateddetection probes (Table 5). Median fluorescence intensities werequantitated on a Luminex 100S machine (Luminex Corp).

Data were normalized as described (1) with modifications. Averagereadings from 5 water-only labeled samples were used for probe-specificbackground subtraction.

Linear normalization among different bead sets for the same sample wasperformed using readings from 2 post-control probes with equalcontribution. Sample normalization was subsequently carried out assumingequal total fluorescence readings. To identify markers, all ERY sampleswere compared to all MEGA samples, with median-based t-test and 50,000permutations, using the Comparative Marker Selection module inGENEPATTERN (2).

Cell sorting and flow cytometry—Human umbilical cord blood was harvestedat Brigham and Women's Hospital with informed patient consent under anIRB approved protocol. Adult human bone marrow cells were obtained fromAllCells, LLC. Mononuclear cells were purified by Ficoll Hypaquesedimentation. Lineage depletion was performed using antibodies againstCD2, CD3, CD4, CD5, CD8, CD11b, CD14C, CD19, and CD56 with a magneticcolumn (Miltenyi Biotec). Populations were defined as follows: MEP(CD34+CD38iL

3Ra−CD45RA−), ERY1 (CD34+CD71+GlyA−), ERY2 (CD34−CD71+GlyA−), ERY3(CD34−CD71+GlyA+). Megakaryocytes were purified without lineagedepletion according to the following immunophenotypes: MEGA1(CD34+CD61+CD41+CD45−), MEGA2 (CD34−CD61+CD41+CD45−). Adult human bonemarrow cells were similarly sorted according to CD34−CD61+CD41+ andCD34−CD71+GlyA+. Sorting was performed with a Vantage SE Diva or with anAria (BD Biosciences). RNA was extracted using TRIZOL (INVITROGEN).

For the in vitro human primary culture experiment, approximately 500,000cells were stained with CD41-FITC, Ter119-PE and CD71-PE-Cy5 antibodiesfor 15 minutes on ice and washed twice before flow cytometry. Foranalysis of transplant recipients, murine bone marrow cells were labeledwith CD41-PE and Ter119-APC, or Ter119-APC and CD71-PE. Peripheral bloodcells were harvested into 0.3 8% sodium citrate and stained withCD41-PE.

Mouse MEPs were purified as described in (3). Briefly, bone marrow cellswere harvested from 8- to 10-week old C57Bl6/J mice and stained with anantibody cocktail containing biotinylated lineage markers includingTer119, CD3, CD4, CD8, CD11b/Mac-1 Gr-1 and B220, and followed bystaining with a second antibody cocktail containing streptavidin-PerCP,Sca-PE, cKit-APC, CD16/32 PE-Cy7 and CD34-FITC. MEPs are defined as theLin-cKit+Sca-CD34-CD16/32-population. Antibodies used for cell surfacemarkers are found in Table 2.

Constructs—Expression vectors for hsa-miR-150 contain a 473 bp genomicfragment that includes the hairpin region of hsa-miR-150 and ˜200 bp offlanking sequence on each side. This genomic expression cassette was PCRamplified from human genomic DNA (Roche Applied Science) with primerscontaining 5′ linker sequences harboring relevant digestion sites (coreprimer sequences: 5′ CAGCATAGGGTGGAGTGGGT3′ (SEQ. ID. No. 5);5′TACTTTGCGCATCACACAGA3′ (SEQ. ID. No. 6)). For the human CD34+ primaryculture experiment, the lenti-viral vector pLKO. 1 (obtained from TheRNAi Consortium, Broad Institute) was used, with the miR-150 expressioncassette, or an shRNA against luciferase (shLuc), cloned into the AgeIand EcoRI sites. hsa-miR-15b-16-2 was similarly cloned with a genomicDNA fragment through PCR amplification (core primer sequences:5′TTTCCTCAAAACAGGAAGG3′ (SEQ. ID. No. 7); 5′CCACCAAGTAAGTCATTTTC3′ (SEQ.ID. No. 8)). For expression in cell lines, the miR-150 expressioncassette, or EGFP coding sequence, was cloned into the pMSCV-puro vectorthrough the BglII and MluI sites. For in vivo transplantation assays,the pMSCV-puro vector was substituted with pMSCV-EGFP, in which the EGFPcoding sequence replaced that of the puromycin resistance gene inpMSCV-puro.

Mutant miR-150 constructs were created by PCR-mediated site-directedmutagenesis. Mutations were introduced into the 5′ seed region of maturehsa-miR-150, as well as into the opposite arm of the hairpin to maintainoverall hairpin structure. Primers used are listed below:

(SEQ. ID. No. 9) 5′CCCCATGGCCCTGTCTGGGAACCCTTGTACCAGTG3′(SEQ. ID. No. 10) 5′ CACTGGTACAAGGGTTCCCAGACAGGGCCATGGGG3′(SEQ. ID. No. 11) 5′ CCCTGGTACAGGCCTCCCGGACAGGGACCTG3′ (SEQ. ID. No. 12)5′ CAGGTCCCTGTCCGGGAGGCCTGTACCAGGG3′.

The MYB cDNA clone, containing only the coding sequence and Kozaksequence, was obtained from Invitrogen (Ultimate ORF collection) in theform of a Gateway entry vector. This clone, as well as a Gateway entryclone without insert (vector control), were recombined intopLenti6.2/V5DEST vector using LR recombination reactions (Invitrogen).

MYB 3′UTR luciferase reporter was created by inserting human MYB 3′UTR(according to RefSeq NM_(—)005375) into the XhoI and NotI sites in thepsiCHECK2 vector (Promega), downstream of the renilla luciferase codingsequence. MYB 3′UTR was amplified from human genomic DNA with thefollowing primers:

(SEQ. ID. No. 13) 5′TAACTCGAGACATTTCCAGAAAAGCATTATG3′, and(SEQ. ID. No. 14) 5′ATAGCGGCCGCAGGTAAAATAAGGGCACATC3′.

Mutations of putative miR-150 binding sites were created by PCR-mediatedsite-directed mutagenesis. Primers used are listed below.

Site 1: (SEQ. ID. No. 15) 5′ACTTTTCATGAATCCCAGAAGAACCTAT3′(SEQ. ID. No. 16) 5′ATAGGTTCTTCTGGGATTCATGAAAAGT3′ Site 2:(SEQ. ID. No. 17) 5′TGAAAACTTGTTTCCCAGACTCTGCATT3′ (SEQ. ID. No. 18)5′AATGCAGAGTCTGGGAAACAAGTTTTCA3′ Site 3: (SEQ. ID. No. 19)5′TGCACTTCTTTTTTCCCAGATGTGTGTTGT3′ (SEQ. ID. No. 20)5′ACAACACACAT CT GGGAAAAAAGAAGT GCA3′ Site 4: (SEQ. ID. No. 21)5′CTGTTTTATAATTTCCCAGTTCTGCATTTG3′ (SEQ. ID. No. 22) 5′CAAAT GCAGAAC T GGGAAAT TATAAAACAG3′

Short hairpin RNAs against human MYB were obtained from The RNAiConsortium (world wide web “period” broad “period” mit “period” edu“forward slash” genome “underscore” bio “forward slash” trc “forwardslash”). The IDs of the shMYB-1 and shMYB-2 clones are TRCN0000040058and TRCN0000009853.

Quantitative RT-PCR—Quantitative RT-PCR primers and probes were allobtained from Applied Biosystems. Reverse transcription reactions wereperformed following the manufacturer's protocol with minormodifications. Briefly, 1 ng to 10 ng of total RNA were reversetranscribed using the MultiScribe cDNA synthesis system (AppliedBiosystems) in 5 μl volume with either miRNA gene specific RT primers,or with 6.25 ng random primers (Invitrogen). Duplicate or triplicate RTreactions were performed for each sample and each RT primer. RT productswere diluted 2.5 fold before PCR. PCR reactions were performed induplicate for each RT product, following the manufacturer's protocol andusing assays from Applied Biosystems on an ABI HT7900 real time PCRmachine. Reactions for eukaryotic 18S ribosomal RNA and messenger RNAswere performed with random-primer-based RT products, whereas reactionsfor miRNAs used corresponding gene-specific RT products. Thresholdcycles (using a manual cutoff of 0.2) or genes of interest werenormalized by Ct values of corresponding 18S rRNA reactions. ΔCt values(Ct of 18S minus Ct of gene of interest) were used unless specifiedotherwise. Quantitative RT-PCR assays used in this study are found inTable 1.

In vitro primary culture of human CD34+ cells-Cryopreserved human adultbone marrow CD34+ cells were obtained from Cambrex (Poietics; Cambrex).Cells were cultured in Serum Free Expansion Medium (SFEM, Stem CellTechnologies) supplemented with 100 U/mL penicillin/streptomycin, 2 mMglutamine, and 40 μg/mL lipids (SIGMA ALDRICH). Erythroid andmegakaryocytic differentiation were supported in a single liquidculture, similarly as described (4), in the presence of 50 ng/mL TPO,100 ng/mL SCF, 10 ng/mL IL-3, 10 ng/mL IL-6, and 0.5 U/mL EPO. Theconcentration of EPO was increased to 3 IU/mL on day 7. Cells wereharvested for flow cytometry following 10 days of liquid culture.Lentiviral infection was performed starting one day after thawing cells.Where indicated, cDNA construct and miRNA construct were infected onconsecutive days. Cells were selected with 2 μg/mL puromycin or 3 μg/mLblasticidin one day after infection.

Murine bone marrow transplant—All mice were purchased from the JacksonLaboratory. Murine bone marrow transplant was performed similarly aspreviously described (5), and approved by the MGH Subcommittee onResearch Animal Care. Donor C57Bl6/J mice (˜8 weeks) were primed with150 mg/kg 5FU for four days. Bone marrow cells were purified by Ficoll(GE Healthcare) density gradient centrifugation, following themanufacturer's protocol. Cells were transduced with empty vector ormiR-150 retrovirus in X-VIVO 15 medium (Biowhittaker) supplemented with100 ng/mL SCF, 50 ng/mL TPO, 50 ng/mL Flt3 ligand and 20 ng/mL IL3 bycentrifugation onto plates coated with retronectin (TAKARA). Lethallyirradiated (9.5 Gy) recipient mice were transplanted with 2.5-4 millioncells the day after infection. Hematopoeitic recovery was monitored bycomplete blood count. Bone marrow cells of 7 pairs of recipients wereanalyzed at 5 to 8 weeks post-transplantation respectively. Plateletswere analyzed 7-weeks post-transplantation.

Cell culture—K562 and 293T cells were obtained from ATCC, and werecultured according to ATCC instructions.

Mouse bone marrow cells were treated with antagomir (50 μg/ml) or PBSfor three days in X-VIVO 15 medium (Biowhittaker) supplemented with 50ng/mL SCF, 50 ng/mL TPO, 50 ng/mL Flt3 ligand and 20 ng/mL IL3. Cellswere then harvested for RNA analysis.

Oligonucleotides and antagomirs-DNA oligonucleotides were synthesized byIDT Technology. RNA oligonucleotides, including antagomirs and DNA-RNAhybrids, were synthesized by Dharmacon. Antagomir stock solution wasprepared in PBS.

Antagomir-150: (SEQ. ID. No. 23) 5′mC(*)mA(*)mCmUmGmGmUmAmCmAmAmGmGmGmUmUmGmGmG (*)mA(*)mG(*)mA (*)(3′-Chl) 3′. Antagomir-scrambled: (SEQ. ID. No. 24)5′mC(*)mU(*)mCmGmCmGmUmAmGmAmAmGmAmGmUmAmGmGmU(*)mG(*)mG(*)mA(*) (3′-Chl) 3′.(mN: 2′OMe base; *: phosphorothioate linkage; Chl: cholesterol).

Colony assay—Megakaryocyte colony assay was performed using theMegaCult-C kit (Stem Cell Technology) according to the manufacturer'sprotocol. Bone marrow cells from recipient mice 7 to 10 weeks aftertransplantation were sorted into GFP− and GFP+ populations. Tworecipient mice were analyzed for each construct, and each population ofcells was assayed in duplicates with 100,000 sorted bone marrow cellsper well. Cultures were maintained for 8 days before stained foracetylcholinesterase activity and scored. For antagomir treatment, 1000LKS cells or 4000 MEPs were FACS-sorted and assayed in the presence ofantagomir (50 μg/ml) or PBS and maintained in culture for 11 days beforestaining and scoring. In all cases, a colony with ≧3acetylcholinesterase-positive cells was scored as a megakaryocytecolony.

For erythoid colony assay, 5FU primed wild type C57Bl6/J marrow wastransduced as described above. Forty-eight hours after viraltransduction, 30,000 GFP+ cells were FACS-sorted and plated intomethylcellulose (StemCell Technologies, M3334) which only contains EPO.

Anemic response—Phenylhydrazine hydrochloride (Sigma) solution in PBSwas injected intraperitoneally into 10- to 12-week wild type C57Bl6/Jmouse (60 mg/kg body weight) on each of days 0, 1, and 2. On the 3rdday, mice were euthanized by CO2 inhalation and bone marrow washarvested and stained with a lineage marker antibody cocktail asdescribed in cell sorting and flow cytometry. Lineage negative cellswere FACS sorted into TRIZOL reagent for RNA preparation.

Western blot analysis—Western blot analysis was performed as previouslydescribed (6). MYB antibody (clone 1-1) was from Upstate Biotechnology.Beta tubulin antibody (ab6046) was from Abcam.

Luciferase reporter assay—293T cells were plated in 96 well plates at5000 cells per well the day before transfection. Transfection wascarried out in 8 replicates using FuGENE 6 (Roche), with 100 ng ofplasmid mixture (90 ng of expression vector and 10 ng of reporter vectorin the psiCHECK2 backbone). Luciferase assays for both firefly andrenilla luciferase were performed 2 days after transfection, using theDual-Glo Luciferase assay kit (Promega). Luminescence was quantitated ona Tecan Spectrafluor Plus machine. Renilla luciferase readings werenormalized against the firefly luciferase activity in the correspondingwell.

Statistical Analysis—Student's t-test (2 tailed, unequal variance) wasused for statistical analysis on experiments, unless otherwisespecified.

Example 1 miRNA Expression in Hematopoietic Progenitor Cells

Mammalian developmental cell fate can be guided at least in part bydifferent mechanism of gene regulation, such as by miRNAs. Theserecently discovered ˜22 nt non-coding RNAs negatively regulate theexpression of target proteins either by inhibiting translation of theircognate mRNAs, or by inducing mRNA degradation, primarily through sitesin the 3′UTR (see review (6)). Previous miRNA expression patterns encodedevelopmental history supports a role of miRNAs in lineage specification(7). Here, MEP differentiation was used as a model system to test thatmiRNA can regulate cell fate, starting with the profiling of theexpression of miRNAs in MEPs, erythroid and megakaryocytic primarycells.

Unfortunately, the small number of precursor cells obtainable from humandonors has precluded a thorough analysis of miRNA expression inhematopoiesis (and other systems) using conventional miRNA profilingmethods, which generally require either large amounts of input RNA, orare not amenable to genome-wide, high throughput applications. Toaddress this technical challenge, a method was developed in which maturemiRNAs are captured in 96-well plates using immobilized5′-amino-modified oligonucleotides complementary to the mature miRNAsequence of more than 300 human miRNAs (from the miRBASE (8) release7.0). This plate-based capture obviates the need for gel-purification ofsmall RNAs which, in addition to being labor-intensive, results insignificant loss of input miRNAs. The captured miRNAs were ligated withadaptors on 3′ and 5′ ends successively, reverse transcribed, andamplified via PCR (FIG. 1A). The biotinylated PCR products were thendetected by hybridization to fluorescent beads coupled to captureoligonucleotides complementary to the mature miRNA sequence. The beadswere then analyzed by flow cytometry, where the color of the beadindicates the identity of the miRNA and the phycoerythrin channelindicates the abundance of that particular miRNA (7). In contrast topreviously reported method (7) that required ˜10 μg of input RNA, thepresent method yields similarly informative results with as little as 10ng of total RNA (FIG. 5). FIG. 5A shows the reproducibility performanceof the plate capture method of miRNA labeling. Two experiments of miRNAprofiling with the plate capture method were performed on total RNA fromMCF-7, 293T or K562 cells. Data were normalized and log 2-transformed.Data from experiment 1 were plotted against data from experiment 2. Eachdot represents the reading of one miRNA in one sample. FIG. 5B showsdata that were normalized and log 2-transformed. The differences of log2-transformed data between MCF-7 and 293T cells, which reflect the foldchange, were plotted to compare the two labeling methods. Each dotrepresents one miRNA. Note that most dots are close to the diagonal,indicating the two labeling methods captured similar results.

With a suitable miRNA profiling method in hand, the miRNA expressionpattern in MEPs and early megakaryocytic and erythroid populationsobtained from FACS-sorted human umbilical cord blood samples wereexamined. Using well-established surface markers, 6 populations of cellswere purified, and them are referred to as MEP (CD34+,CD38+,IL-3Rα−,CD45RA−), MEGA1 (CD34+,CD41+,CD61+,CD45−), MEGA2(CD34−,CD41+,CD61+,CD45−), ERY1 (CD34+,CD71+,GlyA−), ERY2(CD34−,CD71+,GlyA−) and ERY3 (CD34−, CD71+,GlyA+). These 6 populationsthus capture the bifurcation of the megakaryocytic and erythroidlineages with fine granularity (FIG. 1C).

Profiling of 320 miRNAs was performed to identify those mostdifferentially expressed across the megakaryocytic and erythroidpopulations. The profiling result (FIG. 1B, Table 6) captured andextended known miRNA expression patterns. For example, miR-451 andmiR-144 were highly expressed in CD71+GlyA+ erythrocytes, and miR-222was down-regulated during erythropoiesis (9, 10) (FIG. 1B). Among allmiRNAs, differential analysis (Table 3) identified miR-150 with the mostdivergent expression between early megakaryocytic and erythroid cells,being expressed >15-fold higher in megakaryocytes (FIG. 1C).Quantitative RT-PCR analysis in sorted umbilical cord blood cellsconfirmed miR-150 as being highly expressed in megakaryocytes, weaklyexpressed in erythrocytes and moderately expressed in MEPs (FIG. 1D,FIG. 16). Similarly, miR-150 was expressed more highly in CD41+CD61+megakaryocytes than in CD71+ GlyA+ erythrocytes in human adult bonemarrow (FIG. 6B).

Example 2 Function of miR-150 in Differentiation of Progenitor Cells

While high level expression of miR-150 was observed in themegakaryocytic lineage, it is conceivable that it may not play afunctional role in the specification of megakaryocytes versuserythrocytes. Arguing for its functional importance is its exquisitesequence conservation across organisms with functional erythrocytic andthrombocytic systems, exhibiting identical sequence in the 5′ seedregion that mediates target recognition (FIG. 7). To assess a potentialcausal role of miR-150 in the specification of megakaryocytes versuserythrocytes, a series of gain- and loss-of-function experiments wereperformed.

First, a bi-lineage primary cell culture was used, in which human CD34+hematopoietic progenitor cells isolated from adult human bone marrow,when cultured in the presence of thrombopoietin and erythropoietin,differentiate along the megakaryocytic and erythroid lineages in vitro.This system allowed the quantitative perturbation in the balance ofmegakaryocytic and erythroid development from progenitor cells. CD34+cells were transfected with a lentiviral construct harboring miR-150,resulting in a physiological level of miR-150 expression that is similarto that observed in primary megakaryocytes (FIG. 8).

The function of miR-150 was assayed in an in vitro primary culture.CD34+ hematopoietic progenitors derived from human adult bone marrowcells were transduced with constructs expressing a control hairpin(shLuc), miR-150, a mutant miR-150 or miR-15b-16-2. The culture wasanalyzed after 10 days of differentiation, using flow cytometry withlineage markers CD41 (megakaryocytic) and GlyA (erythroid). Transducedcells were allowed to differentiate. Megakaryocytes were then enumeratedby flow cytometry measuring the CD41+GlyA− population. Compared to CD34+cells transduced with a control vector (shLuc, expressing a shorthairpin RNA against luciferase), mutant miR-150, or an irrelevant miRNAconstruct (miR-15b-16-2), the miR-150 expressing cells yielded anaverage of 8-fold enrichment of megakaryocytes (FIG. 2A, 2B). Thisresult indicates that miR-150 shifts the balance ofmegakaryocytic-erythroid differentiation towards megakaryocytes, andfurther indicates its role in governing the fate of MEPs.

Example 3 Function of miR-150 in In Vivo Differentiation of ProgenitorCells

Having established a functionally important role of miR-150 in a humanin vitro model of MEP differentiation, the functions of miR-150 in vivowere examined to address whether miR-150 inhibits the erythroid lineage,promotes the megakaryocytic lineage, or both. To this end, a murine bonemarrow transplantation model was used, in whichstem/progenitor-cell-enriched bone marrow cells from donor mice weretransduced with either miR-150 retrovirus or control virus at low titer.The vectors carry a GFP marker, thus labeling transduced cells and cellsderived from them with green fluorescence. The mixture of transduced andnon-transduced donor cells was transplanted into lethally irradiatedrecipients. Bone marrow and peripheral blood of recipients were analyzed5 to 8 weeks post transplantation, when the hematopoietic system hadlargely recovered in the hosts. Both viral vectors carry GFP as amarker, allowed the distinguishing between donor-derived cells that weretransduced from those that were not (FIG. 9).

miR-150 was expressed from a retroviral vector with a GFP marker. Thisconstruct, or a control vector, was assayed by murine bone marrowtransplant. Recipient mice were analyzed 5 to 8 weekspost-transplantation on transduced (GFP+) and non-transduced (GFP−)cells. Flow cytometry was used to assay the bone marrow cells withmegakaryocyte-(CD41) and erythrocyte-(Ter119) specific markers.Strikingly, compared to either non-transduced (GFP−) cells in miR-150recipients, or vector control recipient mice, miR-150 transduced (GFP+)bone marrow cells exhibited a dramatic (>15-fold on average) expansionof megakaryocytes (CD41+Ter119−) in relation to all transduced cells inthe bone marrow (FIG. 2C, 2E, 10). Recipient bone marrow cells were FACSsorted into GFP+ and GFP− populations, and measured for PF4 expressionusing quantitative RT-PCR. Each pair of bars represents data from onerecipient mouse. It was observed that a strong elevation in theexpression of the megakaryocyte-specific gene PF4 (11) occurred inmiR-150 transduced bone marrow cells (FIG. 2F). In addition, thecirculating platelets were analyzed in the peripheral blood of recipientanimals 7-week post-transplantation. The ratio of GFP+ plateletpercentage to the percentage of GFP+ bone marrow cells was plotted toreflect the thrombocytogenic potential of bone marrow cells. n=5. Therewas a consistent 2- to 14-fold enrichment in GFP+ circulating plateletsin miR-150 animals compared to control vector recipients (FIG. 2G, 11).These results proved that miR-150 expression led to a bona fide increasein bone marrow megakaryocytes that were competent to produce matureplatelets in circulation.

In contrast, an over 60% decrease in GFP+ erythrocytes (Ter119+CD41−)was observed, again in relation to all GFP+ cells in the bone marrow(FIG. 2D, 2E). Importantly, the absolute numbers of GFP+ megakaryocytesin the bone marrow increased, whereas that of erythrocytes decreased inthe presence of miR-150 expression (FIG. 12). Bone marrow cells withCD71 and Ter119 were examined, which distinguish different stages ofmurine erythroid differentiation (12). The R1 to R4 gates on CD71/Ter119plot show that miR-150 expressing cells displayed a strong shift towardan earlier (immature) erythroid state, compared to controls (FIG. 2H,2I, 2J). The percentage of R1 population among all erythrocytes (sum ofR1 to R4) was used to derive a ratio between GFP+ and GFP− populationwithin the same recipient mouse. n=7. P<0.002. Specifically, miR-150expression led to an average of 8-fold increase in the immature R1population, and a more than 60% decrease in the late R4 stage. Theseexperiments indicate that ectopic miR-150 expression induces a blockagein the earliest definable stage of murine adult erythropoiesis, inaddition to causing a significant reduction in the total erythroidpopulation.

The megakaryocyte-promoting effect of miR-150 could be due to its effecton MEP commitment, or simply an effect on post-commitment megakaryocyticproliferation or survival. To address this, colony formation assay wasused to quantify the megakaryocytic potential of progenitor cells at thesingle cell level. Erythroid colony formation assays were performed with30,000 transduced bone marrow cells. Bone marrow cells from 5FU treatedmice were transduced with a control vector or miR-150. GFP+ cells weresorted two days after transduction and assayed for erythroid colonyforming units (CFU-E). Using the bone marrow cells from the transplantrecipients, it was found that miR-150 overexpression resulted in astatistically significant increase in megakaryocyte colony-forming units(CFU-Mk) (FIG. 3A), coupled with a dramatic decrease in erythroid colonyformation (FIG. 13). Representative erythroid colonies from controlvector- or miR-150-transduced bone marrow cells. Note that rareerythroid colonies formed from miR-150 transduced cells showed reducedcell number. These gain of function experiments indicate that miR-150regulates MEP fate, and not simply post-commitment megakaryocyteexpansion.

Example 4 Effects of Loss of Function of miR-150 in In VitroDifferentiation of Progenitor Cells

To complement these miR-150 forced expression studies, aloss-of-function approach was used. MEP cells were isolated from bonemarrow, and assayed for megakaryocyte colony formation in the presenceor absence of an antagomir (a cholesterol-modified antisenseoligonucleotide (13) directed against miR-150. Murine bone marrow cellswere cultured in the presence of solvent (PBS), antagomir againstmiR-150 (anti-150) or a scrambled antagomir. miR-150 expression wasmeasured with quantitative RT-PCR after 3 days of treatment (FIG. 14).Data represent 2ΔCt. Error bars represent standard deviation ofmeasurement. MEPs treated with antagomir-150 showed more than a 4-folddecrease in CFU-Mk, compared to controls (see FIG. 3B). A similar effectwas observed using purified uncommitted Lin-Kit+Sca+ hematopoietic stemcells (FIG. 3C). Interestingly, miR-150 knock-down megakaryocytecolonies showed normal morphology and acetylcholinesterase activity(FIG. 15), indicating that miR-150 might be dispensable once MEPcommitment to the megakaryocyte lineage is established. To confirm arole of miR-150 in the physiological regulation of MEP fate, we treatedmice with the anemia-inducing drug phenylhydrazine, and then measuredmiR-150 expression in lineage-negative bone marrow cells. miR-150expression was significantly decreased in this setting of increaseddemand for erythropoiesis, consistent with miR-150's role in promotingmegakaryopoiesis at the expense of erythropoiesis (FIG. 3D).

Example 5 miR-150 Regulates the c-myc Gene

The experiments described above firmly establish an important role ofmiR-150 in the specification of megakaryocytes from MEPs. To determinethe mRNA targets of miR-150 that explain its effect onmegakaryocytic/erythroid outcome, the targets predicted in common amongseveral sequence-based prediction algorithms (14-16) were analyzed. MYB(also known as c-myb) was tested as a candidate because several recentlyreported mouse models, in which MYB activity was reduced due to eithermutation or the serendipitous integration of a transgene near the MYBlocus, displayed thrombocytosis and anemia (17-21). The expression ofMYB messenger RNA, however, is not immediately indicative of a role inMEP differentiation, as similar expression in MEPs and early erythroidand megakaryocyte populations were noted (FIG. 16). Examination of thehuman MYB 3′UTR, however, identified multiple conserved miR-150 putativesites (FIG. 17). To establish miR-150 as a functional negative regulatorof MYB, the erythroblastic cell line K562 was experimented in, which hasthe potential to be induced to differentiate into erythroid ormegakaryocytic cells. A dramatic reduction in MYB protein level uponectopic expression of miR-150 (FIG. 4A) was observed. Next, the MYB 3′UTR was cloned into a luciferase reporter, and it was found that miR-150repressed reporter activity by more than 6-fold, again consistent withmiR-150 targeting MYB. Importantly, mutation of the 4 candidate miR-150binding sites abrogated miR-150 repression, and a mutant miR-150construct designed to be complementary to the mutant MYB 3′UTR bindingsites restored miR-150 mediated repression, but did not affect thewild-type MYB 3′UTR (FIG. 4B, 4C). These experiments establish thatmiR-150 negatively regulates the protein level of MYB directly throughits 3′ UTR.

Lastly, the question of whether miR-150 repression of MYB explainsmiR-150's erythroid/megakaryocytic effects was addressed. Using the invitro CD34+ human bone marrow cell culture, consistent with reports thatmice with reduced MYB activity display megakaryocytosis (17-21), twoindependent shRNA constructs that knocked down MYB expression (FIG. 18A)promoted megakaryocyte development (FIG. 18B). In contrast, forcedexpression of a MYB cDNA construct lacking its 3′UTR resulted in adecrease in megakaryocytes (FIG. 4D, 4E). Moreover, the MYB expressionconstruct rescued the megakaryocytopoiesis-promoting effect of miR-150to a large extent, indicating that MYB is a functionally relevantdownstream effector of miR-150 (FIG. 4D, 4E). This MYB effect isconsistent with a recent study showing MEPs with reduced MYB activityfavor decision towards megakaryocytic as opposed to erythroiddifferentiation (20). In contrast to total loss of MYB function, whichresults in complete hematopoietic failure (19), our data indicate thatmodest modulation of MYB expression levels by miRNA can have importanteffects on lineage specification. These results are particularlyinteresting in light of the recent report of miR-150 regulation of MYBactivity in B-lineage lymphocytes (22). It has been generally assumedthat miRNAs have a plethora of targets that vary depending on cellularcontext. Remarkably, MYB appears to be a critical target of miR-150 bothin establishing MEP fate and in regulating the differentiation oflineage-committed B-cells. This observation indicates that a single mRNAtarget of miRNAs might explain much of the miRNAs function, even incompletely different developmental contexts. Our studies, of course, donot exclude the possibility that additional factors may also contributeto the establishment of MEP fate.

REFERENCES

-   1. J. Zhu, S. G. Emerson, Oncogene 21, 3295 (May 13, 2002).-   2. A. B. Cantor, S. H. Orkin, Oncogene 21, 3368 (May 13, 2002).-   3. A. D. Friedman, Oncogene 21, 3377 (May 13, 2002).-   4. M. Ye, T. Graf, Curr Opin Immunol 19, 123 (April, 2007).-   5. W. Zheng, R. A. Flavell, Cell 89, 587 (May 16, 1997).-   6. D. P. Bartel, Cell 116, 281 (Feb. 23, 2004).-   7. J. Lu et al., Nature 435, 834 (Jun. 9, 2005).-   8. S. Griffiths-Jones, R. J. Grocock, S. van Dongen, A.    Bateman, A. J. Enright, Nucleic Acids Res 34, D140 (Jan. 1, 2006).-   9. N. Felli et al., Proc Natl Acad Sci USA 102, 18081 (Dec. 13,    2005).-   10. M. Zhan, C P Miller, T. Papayannopoulou, G.    Stamatoyannopoulos, C. Z. Song, Exp Hematol 35, 1015 (July, 2007).-   11. K. Ravid, D. L. Beeler, M. S. Rabin, H. E. Ruley, R. D.    Rosenberg, Proc Natl Acad Sci USA 88, 1521 (Feb. 15, 1991).-   12. M. Socolovsky et al., Blood 98, 3261 (Dec. 1, 2001).-   13. J. Krutzfeldt et al., Nature 438, 685 (Dec. 1, 2005).-   14. A. Krek et al., Nat Genet. 37, 495 (May, 2005).-   15. B. P. Lewis, C. B. Burge, D. P. Bartel, Cell 120, 15 (Jan. 14,    2005).-   16. X. Xie et al., Nature 434, 338 (Mar. 17, 2005).-   17. N. Emambokus et al., Embo J 22, 4478 (Sep. 1, 2003).-   18. L. H. Kasper et al., Nature 419, 738 (Oct. 17, 2002).-   19. M. L. Mucenski et al., Cell 65, 677 (May 17, 1991).-   20. H. Y. Mukai et al., Mol Cell Biol 26, 7953 (November, 2006).-   21. M. L. Sandberg et al., Dev Cell 8, 153 (February, 2005).-   22. C. Xiao et al., Cell 131, 146 (Oct. 5, 2007).

TABLE 1 Quantitative RT-PCR assays used in this study Gene of interestAssay Human Myb Hs00193527_m1 Eukaryotic 18S 4333760T miR-150 4373127Mouse PF4 Mm00451315_g1

TABLE 2 Antibodies for cell surface markers Antigen Fluorophore CloneSource Mouse CD71 PE C2 BD Pharmingen Mouse Ter119 APC TER-1 19 BDPharmingen Mouse CD41 PE MWReg30 BD Pharmingen Mouse CD3ε biotin 145-2C11 BD Pharmingen Mouse CD4 biotin L3T4 BD Pharmingen Mouse CD8a biotin53-6.7 BD Pharmingen Mouse biotin RA3-6B2 BD Pharmingen CD45R/B220 MouseTer119 biotin TER-1 19 BD Pharmingen Mouse CD1 1b biotin M1/70 BDPharmingen Mouse Gr1 biotin RB6-8C5 BD Pharmingen Mouse c-Kit APC 2B8 BDPharmingen Mouse Sca-1 PE Cat# MSCA04-3 Caltag Mouse CD34 Pacific RAM34eBioscience blue Mouse PE-Cy7 93 eBioscience CD16/32 Streptavidine PerCPCat# 554064 BD Pharmingen Human CD71 FITC and C2 BD Pharmingen PE-Cy5Human CD34 APC 581 BD Pharmingen Humn CD61 FITC 2C9.G2 BD PharmingenHuman CD41 PE and HIP8 BD Pharmingen FITC Human CD45 APC-Cy7 2D1 BDPharmingen Human CD45RA FITC L48 BD Pharmingen Human GlyA PE CLB-ery-1CALTAG/ (AME-1) Invitrogen

TABLE 3 Comparative marker selection result for ERY samples vs. MEGAsamples Feature Description TTEST_Score Feature P FDR(BH) Q Value FWEREAM217 hmr-miR- −6.134193365 6.00E−04 0.00373 0.00197 0.00148150_rfam7.0 EAM161 hmr-miR- −4.939403406 7.60E−04 0.00441 0.002250.02214 28_rfam7.0 EAM hmr-miR-142- −3.738371725 0.0012 0.00653 0.003330.26634 163 3p_rfam7.0 EAM371 hmr-miR- −3.42554054 6.00E−04 0.003730.00197 0.45006 342_rfam7.0 EAM278 hmr-miR-98 rfam7.0 −2.9874174050.00524 0.02682 0.01368 0.76548 EAM263 hmr-miR- −2.93748816 0 0 00.79334 26a_rfam7.0 EAM224 hmr-miR-17- 2.052993319 0.00604 0.029190.01489 0.99828 5p_rfam7.0

Normalized miRNA expression data for ERY populations (ERY1, ERY2, ERY3)and MEGA populations (MEGA1, MEGA2) were log 2 transformed, thresholdedat 6, and filtered to retain miRNAs with maximum expression over 8.Markers were selected using the ComparativeMarkerSelection module inGenePattern, with median-based t-test and 50,000 permutations. The tablebelow shows features with BH-FDR of less than 0.05. Negative TTEST_Scoremeans higher expression in MEGA samples, whereas positive numberreflects higher expression in ERY samples. The table was sortedaccording to TTEST_Score. Feature: miRNA detection probe ID;Description: Detection probe annotation based on miRBASE 7.0;TTEST_Score: Median-based t-test score; Feature P: Nominal P value,after 50,000 permutations; FDR(BH): Benjamini-Hochberg false discoveryrate; Q Value: q-value; FWER: Family-wise error rate.

TABLE 4 List of capture probes for initial miRNA capture/5AmMC6/ indicates 5′ amino modification. Probes were synthesized by IDT. /5AmMC6/ACTCAGAAGGACAAGTAGAGTTTT/5AmMC6/GTGGTAATCCCTGGCAATGTGAT (SEQ. ID. No. 26) (SEQ. ID. No. 27)/5AmMC6/ACACTCTAAAGGGAACCATTTT /5AmMC6/GGAAATCCCTGGCAATGTGAT(SEQ. ID. No. 28) (SEQ. ID. No. 29) /5AmMC6/AAAGAAGTGCACCATGTTTGTTT/5AmMC6/AAAGTGTCAGATACGGTGTGG (SEQ. ID. No. 30) (SEQ. ID. No. 31)/5AmMC6/AAGAAGTGCACCGCGAATGT /5AmMC6/ACAGTTCTTCAACTGGCAGCTT(SEQ. ID. No. 32) (SEQ. ID. No. 33) /5AmMC6/AACACTCTGAAGGGAAGCGC/5AmMC6/CTACCTGCACTATAAGCACTTTA (SEQ. ID. No. 34) (SEQ. ID. No. 35)/5AmMC6/CACTCTAAAAGGATGCACTTT /5AmMC6/TCAGTTTTGCATGGATTTGCACA(SEQ. ID. No. 36) (SEQ. ID. No. 37) /5AmMC6/TTCACCAAAGGGAAGCACTTT/5AmMC6/CCCAACAACATGAAACTACCTA (SEQ. ID. No. 38) (SEQ. ID. No. 39)/5AmMC6/ACACTCTAAAGGGAAGTGCGTT /5AmMC6/ACAAAGTTCTGTAGTGCACTGA(SEQ. ID. No. 40) (SEQ. ID. No. 41) /5AmMC6/CTCCCTTCTTTCCTCCCGTC/5AmMC6/CTAGTACATCATCTATACTGTA (SEQ. ID. No. 42) (SEQ. ID. No. 43)/5AmMC6/CTCACACCTAGGTTCCAAGGATT /5AmMC6/tgAGCTACAGTGCTTCATCTCA(SEQ. ID. No. 44) (SEQ. ID. No. 45) /5AmMC6/TTACAGATGGATACCGTGCAATT/5AmMC6/CCATCTTTACCAGACAGTGTT (SEQ. ID. No. 46) (SEQ. ID. No. 47)/5AmMC6/CCACGACCGACGCCACGCC /5AmMC6/CTACCATAGGGTAAAACCACT(SEQ. ID. No. 48) (SEQ. ID. No. 49) /5AmMC6/CCTCTAAAAGGAAGCACTTTCT/5AmMC6/TGGAGACACGTGCACTGTAGA (SEQ. ID. No. 50) (SEQ. ID. No. 51)/5AmMC6/GAACATACAAAGGGTATCCTCT /5AmMC6/TTCACATAGGAATAAAAAGCCATA(SEQ. ID. No. 52) (SEQ. ID. No. 53) /5AmMC6/CGAATATAACACGGTCGATCT/5AmMC6/ACAGCTGGTTGAAGGGGACCAA (SEQ. ID. No. 54) (SEQ. ID. No. 55)/5AmMC6/CCTCCAGCCCCTCCAGGGCT /5AmMC6/GGGGTATTTGACAAACTGACA(SEQ. ID. No. 56) (SEQ. ID. No. 57) /5AmMC6/TCAATCACAGATAGCACCCCT/5AmMC6/GCAAAAATGTGCTAGTGCCAAA (SEQ. ID. No. 58) (SEQ. ID. No. 59)/5AmMC6/GTAGTGCAACTATGCAAAACT /5AmMC6/TCATACAGCTAGATAACCAAAGA(SEQ. ID. No. 60) (SEQ. ID. No. 61) /5AmMC6/TGGTGGCAGTGGTGGGAT/5AmMC6/CTTCCAGTCGGGGATGTTTACA (SEQ. ID. No. 62) (SEQ. ID. No. 63)/5AmMC6/ACACTCTAAAGGGATGCACGAT /5AmMC6/ACACAAATTCGGTTCTACAGGG(SEQ. ID. No. 64) (SEQ. ID. No. 65) /5AmMC6/AAAGTGCTTCTTACCTCCAGAT/5AmMC6/ACCCTCCACCATGCAAGGGATG (SEQ. ID. No. 66) (SEQ. ID. No. 67)/5AmMC6/ACCTCTAAAGGGGAGCGCTT /5AmMC6/CCTATCTCCCCTCTGGACC(SEQ. ID. No. 68) (SEQ. ID. No. 69) /5AmMC6/ACACTCTAAAGGGAGGCACTTT/5AmMC6/GGCTGTCAATTCATAGGTCAG (SEQ. ID. No. 70) (SEQ. ID. No. 71)/5AmMC6/TCCAGGAGCTCACAATCTAGTG /5AmMC6/CGGCTGCAACACAAGACACGA(SEQ. ID. No. 72) (SEQ. ID. No. 73) /5AmMC6/GTTACCGCAGGCTGCTCTGG/5AmMC6/CAGTGAATTCTACCAGTGCCATA (SEQ. ID. No. 74) (SEQ. ID. No. 75)/5AmMC6/AGAAAGCGCTTCCCTGTAGAG /5AmMC6/TGTGAGTTCTACCATTGCCAAA(SEQ. ID. No. 76) (SEQ. ID. No. 77) /5AmMC6/AGCCAAGTAATGGAGAACAGG/5AmMC6/CGAAGGCAACACGGATAACCTA (SEQ. ID. No. 78) (SEQ. ID. No. 79)/5AmMC6/AGAAAGCGCTTCCCTCTAGAG /5AmMC6/TCACTTTTGTGACTATGCAA(SEQ. ID. No. 80) (SEQ. ID. No. 81) /5AmMC6/ACAGAAAGGGCTTCCCTTTGC/5AmMC6/CCAAGTTCTGTCATGCACTGA (SEQ. ID. No. 82) (SEQ. ID. No. 83)/5AmMC6/TCGGTCCCTCGGGCCAGGG /5AmMC6/GGAGTGAAGACACGGAGCCAGA(SEQ. ID. No. 84) (SEQ. ID. No. 85) /5AmMC6/TCTAAGCCACCATGTGAAACCA/5AmMC6/ACAAAGTTCTGTGATGCACTGA (SEQ. ID. No. 86) (SEQ. ID. No. 87)/5AmMC6/GCAAGGCAGTGGCCTGTACA /5AmMC6/GCTGAGAGTGTAGGATGTTTACA(SEQ. ID. No. 88) (SEQ. ID. No. 89) /5AmMC6/TCCAGCAAAGGGAAGCGCTT/5AmMC6/AACCGATTTCAGATGGTGCTAG (SEQ. ID. No. 90) (SEQ. ID. No. 91)/5AmMC6/ACCCTCTATAGGGAAGCGCGT /5AmMC6/GTCATCATTACCAGGCAGTATTA(SEQ. ID. No. 92) (SEQ. ID. No. 93) /5AmMC6/CAGGTAACAACTCGCCGCTC/5AmMC6/AACCAATGTGCAGACTACTGTA (SEQ. ID. No. 94) (SEQ. ID. No. 95)/5AmMC6/ACTGCACTTTTATGAATAAGCTC /5AmMC6/GCTGGGTGGAGAAGGTGGTGAA(SEQ. ID. No. 96) (SEQ. ID. No. 97) /5AmMC6/AACGCTCCAAAAGAAGGCACT/5AmMC6/GCCAATATTTCTGTGCTGCTA (SEQ. ID. No. 98) (SEQ. ID. No. 99)/5AmMC6/ACCAGAACTGAGTCCACAGGG /5AmMC6/CGCAAGGTCGGTTCTACGGGTG(SEQ. ID. No. 100) (SEQ. ID. No. 101) /5AmMC6/TCCCGTCGCCAGCGGAGGC/5AmMC6/ACACCGAGGAGCCCATCATGAT (SEQ. ID. No. 102) (SEQ. ID. No. 103)/5AmMC6/ACTGAAACCAAGTATGGGTCGC /5AmMC6/CCTGCATGACGGCCTGCAAGACA(SEQ. ID. No. 104) (SEQ. ID. No. 105) /5AmMC6/CAGCCCTCCTGGTGGCTGG/5AmMC6/ATAAGGATTTTTAGGGGCATTA (SEQ. ID. No. 106) (SEQ. ID. No. 107)/5AmMC6/ATCTACACTGGCTACTGAGCC /5AmMC6/TATTAGGAACACATCGCAAAAA(SEQ. ID. No. 108) (SEQ. ID. No. 109) /5AmMC6/CGCGACTGCGTCACCGGCC/5AmMC6/ACCAGCTAACAATACACTGCCA (SEQ. ID. No. 110) (SEQ. ID. No. 111)/5AmMC6/CCTGCGCCATCTCCTCTAC /5AmMC6/ATGGGACATCCTACATATGCAA(SEQ. ID. No. 112) (SEQ. ID. No. 113) /5AmMC6/ACTGTGTTTCAGCTCAGTAGGCA/5AmMC6/TTCAAAACATGAATTGCTGCTG (SEQ. ID. No. 114) (SEQ. ID. No. 115)/5AmMC6/CGAACACAGCAGGGATAACCAC /5AmMC6/GTACCCCTGGAGATTCTGATAA(SEQ. ID. No. 116) (SEQ. ID. No. 117) /5AmMC6/ACTGCAGAACTGTTCCCGCTG/5AmMC6/TCACGCGAGCCGAACGAACAAA (SEQ. ID. No. 118) (SEQ. ID. No. 119)/5AmMC6/AGAAAATGCCCCTCAGTTTTGA /5AmMC6/ACAAAAGTTGCCTTTGTGTGAT(SEQ. ID. No. 120) (SEQ. ID. No. 121) /5AmMC6/AGACGGGAGGAGAGGAGTGA/5AmMC6/ACACAGGACCTGGAGTCAGGAG (SEQ. ID. No. 122) (SEQ. ID. No. 123)/5AmMC6/ATCGGGAGGGGACTGAGCCT /5AmMC6/CCTACGTTCCATAGTCTACCA(SEQ. ID. No. 124) (SEQ. ID. No. 125) /5AmMC6/CTCGGGGCAGCTCAGTACAG/5AmMC6/GCGCATGTTCTATGGTCAACCA (SEQ. ID. No. 126) (SEQ. ID. No. 127)/5AmMC6/CGAGCCGGTCGAGGTCCGGT /5AmMC6/ACAGAGAGCTTGCCCTTGTATA(SEQ. ID. No. 128) (SEQ. ID. No. 129) /5AmMC6/TCTCGTGACATGATGATCCCCG/5AmMC6/TATGAACAATTTCTAGGAAT (SEQ. ID. No. 130) (SEQ. ID. No. 131)/5AmMC6/AGAAAGCGCTTTCCTTTGTAGA /5AmMC6/GGCGGACACGACATTCCCGAT(SEQ. ID. No. 132) (SEQ. ID. No. 133) /5AmMC6/CACATGGCCAAAACAGAGAAGA/5AmMC6/GTCTCAGTTTCCTCTGCAAACA (SEQ. ID. No. 134) (SEQ. ID. No. 135)/5AmMC6/CCACCCAATGACCTACTCCAAG /5AmMC6/GCTGTAAACATCCGACTGAAAG(SEQ. ID. No. 136) (SEQ. ID. No. 137) /5AmMC6/TCATCTCGCCCGCAAAGACC/5AmMC6/ATGCTTTTTGGGGTAAGGGCTT (SEQ. ID. No. 138) (SEQ. ID. No. 139)/5AmMC6/AGAAAGTGCTTTCTTTTGGAGAA /5AmMC6/ACGGCATTACCAGACAGTATTA(SEQ. ID. No. 140) (SEQ. ID. No. 141) /5AmMC6/GAAAGTGCTTCTTTCCTCGAGAA/5AmMC6/TCTCTGCAGGCCCTGTGCTTTGC (SEQ. ID. No. 142) (SEQ. ID. No. 143)/5AmMC6/CACAGGTTAAAGGGTCTCAGGGA /5AmMC6/TGTTGCAGCGCTTCATGTTT(SEQ. ID. No. 144) (SEQ. ID. No. 145) /5AmMC6/ACAAATTCGGTTCTACAGGGTA/5AmMC6/AGCCACAGTCACCTTCTGATCT (SEQ. ID. No. 146) (SEQ. ID. No. 147)/5AmMC6/TGATAGCCCTGTACAATGCTGCT /5AmMC6/CATGCATACATGCACACATACAT(SEQ. ID. No. 148)  (SEQ. ID. No. 149) /5AmMC6/TCATAGCCCTGTACAATGCTGCT/5AmMC6/CAACAAACATTTAATGAGGCC (SEQ. ID. No. 150)  (SEQ. ID. No. 151)/5AmMC6/AACTATACAATCTACTACCTCA /5AmMC6/TGATGGACAACAAATTAGGTA(SEQ. ID. No. 152) (SEQ. ID. No. 153) /5AmMC6/ACTATGCAACCTACTACCTCT/5AmMC6/TATCTCACAGAATAAACTTGGTA (SEQ. ID. No. 154) (SEQ. ID. No. 155)/5AmMC6/TTCAGCTATCACAGTACTGTA /5AmMC6/TCACATCAGTGCCATTCTAAATA(SEQ. ID. No. 156) (SEQ. ID. No. 157) /5AmMC6/CTATACAACCTCCTACCTCA/5AmMC6/GTCTTATGTGTGCGTGTATGTAT (SEQ. ID. No. 158) (SEQ. ID. No. 159)/5AmMC6/CTCAATAGACTGTGAGCTCCTT /5AmMC6/GTGTAGGTGTGTGTATGTATAT(SEQ. ID. No. 160) (SEQ. ID. No. 161) /5AmMC6/AACCTATCCTGAATTACTTGAA/5AmMC6/CAGACACACGCACATCAGTCATA (SEQ. ID. No. 162) (SEQ. ID. No. 163)/5AmMC6/TCCATCATCAAAACAAATGGAGT /5AmMC6/GGACACCAAGATCAATGAAAGAGGCA(SEQ. ID. No. 164)  (SEQ. ID. No. 165) /5AmMC6/AGGCAAAGGATGACAAAGGGAA/5AmMC6/TCACCAGTGCCAGTCCAAGAA (SEQ. ID. No. 166) (SEQ. ID. No. 167)/5AmMC6/GAACAGGTAGTCTAAACACTGGG /5AmMC6/TGTGAAAAGCACTATACTACGTA(SEQ. ID. No. 168) (SEQ. ID. No. 169) /5AmMC6/ATCCAGTCAGTTCCTGATGCAGTA/5AmMC6/AGACTAGATATGGAAGGGTGA (SEQ. ID. No. 170) (SEQ. ID. No. 171)/5AmMC6/GCTGCAAACATCCGACTGAAAG /5AmMC6/TCTGGGCACACGGAGGGAGA(SEQ. ID. No. 172) (SEQ. ID. No. 173) /5AmMC6/TAACCGATTTCAAATGGTGCTA/5AmMC6/ACGGTCAGGCTTTGGCTAGAT (SEQ. ID. No. 174) (SEQ. ID. No. 175)/5AmMC6/AACAATACAACTTACTACCTCA /5AmMC6/AGAGGCAGGCACTCAGGCAGA(SEQ. ID. No. 176) (SEQ. ID. No. 177) /5AmMC6/ATACATACTTCTTTACATTCCA/5AmMC6/TGGGCGACCCAGAGGGACA (SEQ. ID. No. 178) (SEQ. ID. No. 179)/5AmMC6/GCTGAGTGTAGGATGTTTACA /5AmMC6/AGAGGTTAAGACAGCAGGGCTG(SEQ. ID. No. 180) (SEQ. ID. No. 181) /5AmMC6/ATGCCCTTTTAACATTGCACTG/5AmMC6/GGTTCAAACCATGAGTCGAGCT (SEQ. ID. No. 182) (SEQ. ID. No. 183)/5AmMC6/CTACGCGTATTCTTAAGCAATAA /5AmMC6/GGAGTCGAGTGATGGTTCAAA(SEQ. ID. No. 184) (SEQ. ID. No. 185) /5AmMC6/AGAACAATGCCTTACTGAGTA/5AmMC6/GAATAATGACAGGCTCACCGTA (SEQ. ID. No. 186) (SEQ. ID. No. 187)/5AmMC6/TCTTCCCATGCGCTATACCTCT /5AmMC6/TACTATGCAACCTACTACTCT(SEQ. ID. No. 188) (SEQ. ID. No. 189) /5AmMC6/CCACACACTTCCTTACATTCCA/5AmMC6/CTGAGGGGCCTCAGACCGAGCT (SEQ. ID. No. 190) (SEQ. ID. No. 191)/5AmMC6/GAGGGAGGAGAGCCAGGAGAAGC /5AmMC6/TAACTGCACTAGATGCACCTTA(SEQ. ID. No. 192) (SEQ. ID. No. 193) /5AmMC6/ACAAGCTTTTTGCTCGTCTTAT/5AmMC6/CTACCTGCACTATGAGCACTTTG (SEQ. ID. No. 194) (SEQ. ID. No. 195)/5AmMC6/GGCCGTGACTGGAGACTGTTA /5AmMC6/GGGGACGAAATCCAAGCGCAGC(SEQ. ID. No. 196) (SEQ. ID. No. 197) /5AmMC6/CACAGTTGCCAGCTGAGATTA/5AmMC6/AATAGGTCAACCGTGTATGATT (SEQ. ID. No. 198) (SEQ. ID. No. 199)/5AmMC6/ACATGGTTAGATCAAGCACAA /5AmMC6/GCAGAAGCATTTCCACACAC(SEQ. ID. No. 200) (SEQ. ID. No. 201) /5AmMC6/ACAACCAGCTAAGACACTGCCA/5AmMC6/CCCCTATCACGATTAGCATTAA (SEQ. ID. No. 202) (SEQ. ID. No. 203)/5AmMC6/AGGCGAAGGATGACAAAGGGAA /5AmMC6/ACAAGTGCCTTCACTGCAGT(SEQ. ID. No. 204) (SEQ. ID. No. 205) /5AmMC6/GTCTGTCAATTCATAGGTCAT/5AmMC6/TCCAGCACTGTCCGGTAAGATG (SEQ. ID. No. 206) (SEQ. ID. No. 207)/5AmMC6/ATCCAATCAGTTCCTGATGCAGTA /5AmMC6/AAAGCAAGTACATCCACGTTTA(SEQ. ID. No. 208) (SEQ. ID. No. 209) /5AmMC6/ACTACCTGCACTGTAAGCACTTTG/5AmMC6/AAGCGGTTTACCATCCCACATA (SEQ. ID. No. 210) (SEQ. ID. No. 211)/5AmMC6/TATCTGCACTAGATGCACCTTA /5AmMC6/TAGTTGGCAAGTCTAGAACCA(SEQ. ID. No. 212) (SEQ. ID. No. 213) /5AmMC6/AACCCACCGACAGCAATGAATGTT/5AmMC6/CTACTAAAACATGGAAGCACTTA (SEQ. ID. No. 214) (SEQ. ID. No. 215)/5AmMC6/GAACAGGTAGTCTGAACACTGGG /5AmMC6/AGAAAGCACTTCCATGTTAAAGT(SEQ. ID. No. 216) (SEQ. ID. No. 217) /5AmMC6/GAACAGATAGTCTAAACACTGGG/5AmMC6/CCACTGAAACATGGAAGCACTTA (SEQ. ID. No. 218) (SEQ. ID. No. 219)/5AmMC6/TCAGTTTTGCATAGATTTGCACA /5AmMC6/CAGCAGGTACCCCCATGTTA(SEQ. ID. No. 220) (SEQ. ID. No. 221) /5AmMC6/CTAGTGGTCCTAAACATTTCAC/5AmMC6/ACACTCAAACATGGAAGCACTTA (SEQ. ID. No. 222) (SEQ. ID. No. 223)/5AmMC6/AGGCATAGGATGACAAAGGGAA /5AmMC6/ACTTACTGGACACCTACTAGG(SEQ. ID. No. 224) (SEQ. ID. No. 225) /5AmMC6/CAGCCGCTGTCACACGCACAG/5AmMC6/AAAGGCATCATATAGGAGCTGGA (SEQ. ID. No. 226) (SEQ. ID. No. 227)/5AmMC6/CTGCCTGTCTGTGCCTGCTGT /5AmMC6/GCCCTGGACTAGGAGTCAGCA(SEQ. ID. No. 228) (SEQ. ID. No. 229) /5AmMC6/CACAAGTTCGGATCTACGGGTT/5AmMC6/AGAGGCAGGCATGCGGGCAG (SEQ. ID. No. 230) (SEQ. ID. No. 231)/5AmMC6/GCTACCTGCACTGTAAGCACTTTT /5AmMC6/TCACCATTGCTAAAGTGCAATT(SEQ. ID. No. 232) (SEQ. ID. No. 233) /5AmMC6/CACAAATTCGGATCTACAGGGTA/5AmMC6/AAACGTGGAATTTCCTCTATGT (SEQ. ID. No. 234) (SEQ. ID. No. 235)/5AmMC6/ACAAACACCATTGTCACACTCCA /5AmMC6/AAAGATCAACCATGTATTATT(SEQ. ID. No. 236) (SEQ. ID. No. 237) /5AmMC6/CGCGTACCAAAAGTAATAATG/5AmMC6/AGCCACAATCACCTTCTGATCT (SEQ. ID. No. 238) (SEQ. ID. No. 239)/5AmMC6/GCCCTTTCATCATTGCACTG /5AmMC6/TCTCTGCAGGCCGTGTGCTTTGC(SEQ. ID. No. 240) (SEQ. ID. No. 241) /5AmMC6/TCCCTCTGGTCAACCAGTCACA/5AmMC6/ACGGTTTTACCAGACAGTATTA (SEQ. ID. No. 242) (SEQ. ID. No. 243)/5AmMC6/GTAGTGCTTTCTACTTTATG /5AmMC6/ACGTGGATTTTCCTCTATGAT(SEQ. ID. No. 244) (SEQ. ID. No. 245) /5AmMC6/CCCCTATCACAATTAGCATTAA/5AmMC6/GGCCTTCTGACTCCAAGTCCAG (SEQ. ID. No. 246) (SEQ. ID. No. 247)/5AmMC6/TGTAAACCATGATGTGCTGCTA /5AmMC6/AAGATGTGGACCATATTACATA(SEQ. ID. No. 248) (SEQ. ID. No. 249) /5AmMC6/ACTCACCGACAGGTTGAATGTT/5AmMC6/GGCCTTCTGACCCTAAGTCCAG (SEQ. ID. No. 250) (SEQ. ID. No. 251)/SAmMC6/CACAAACCATTATGTGCTGCTA /SAmMC6/AAAGAGGTTAACCAGGTGTGTT(SEQ. ID. No. 252) (SEQ. ID. No. 253) /5AmMC6/TAACTGTACAAACTACTACCTCA/5AmMC6/CGAACTCACCACGGACAACCTC (SEQ. ID. No. 254) (SEQ. ID. No. 255)/5AmMC6/ACAGGCCGGGACAAGTGCAATAT /5AmMC6/CTTCTTTGCAGATGAGACTGA(SEQ. ID. No. 256) (SEQ. ID. No. 257) /5AmMC6/TAACCCATGGAATTCAGTTCTCA/5AmMC6/TGCAAAGTTGCTCGGGTAACCT (SEQ. ID. No. 258) (SEQ. ID. No. 259)/SAmMC6/AACCATACAACCTACTACCTCA /SAmMC6/AACATGGATTTTCCTCTATGAT(SEQ. ID. No. 260) (SEQ. ID. No. 261) /SAmMC6/AACAACAAAATCACTAGTCTTCCA/SAmMC6/GAATTCATCACGGCCAGCCTCT (SEQ. ID. No. 262) (SEQ. ID. No. 263)/5AmMC6/ACTTTCGGTTATCTAGCTTTAT /5AmMC6/AGAGGAGAGCCGTGTATGAC(SEQ. ID. No. 264) (SEQ. ID. No. 265) /5AmMC6/ACAGCACAAACTACTACCTCA/5AmMC6/TTGAGAGTGCCATTATCTGGG (SEQ. ID. No. 266) (SEQ. ID. No. 267)/5AmMC6/AACTATACAACCTACTACCTCA /5AmMC6/GCTGCCGTATATGTGATGTCACT(SEQ. ID. No. 268) (SEQ. ID. No. 269) /5AmMC6/AACCACACAACCTACTACCTCA/5AmMC6/CAGCATGGAGTCCTCCAGGTTG (SEQ. ID. No. 270) (SEQ. ID. No. 271)/5AmMC6/CCGACCATGGCTGTAGACTGTTA /5AmMC6/TCCTCATGGAAGGGTTCCCCACT(SEQ. ID. No. 272) (SEQ. ID. No. 273) /5AmMC6/ACACCAATGCCCTAGGGGATGCG/5AmMC6/TGACTGCAGAGCAAAAGACAC (SEQ. ID. No. 274) (SEQ. ID. No. 275)/5AmMC6/TGGCATTCACCGCGTGCCTTA /5AmMC6/AGCCTATGGAATTCAGTTCTCA(SEQ. ID. No. 276) (SEQ. ID. No. 277) /5AmMC6/TCACAAGTTAGGGTCTCAGGGA/5AmMC6/AAAGAAGTATATGCATAGGAAA (SEQ. ID. No. 278) (SEQ. ID. No. 279)/5AmMC6/CACAAGATCGGATCTACGGGT /5AmMC6/TTTTCCCATGCCCTATACCTCT(SEQ. ID. No. 280) (SEQ. ID. No. 281) /5AmMC6/CGCCAATATTTACGTGCTGCTA/5AmMC6/AAGAATCTTGTCCCGCAGGTCCT (SEQ. ID. No. 282) (SEQ. ID. No. 283)/5AmMC6/AACACTGATTTCAAATGGTGCTA /5AmMC6/AATGAAAGCCTACCATGTACAA(SEQ. ID. No. 284) (SEQ. ID. No. 285) /5AmMC6/CTTCAGTTATCACAGTACTGTA/5AmMC6/AGACATGGAGGAGCCATCCAG (SEQ. ID. No. 286) (SEQ. ID. No. 287)/5AmMC6/ACAGGAGTCTGAGCATTTGA /5AmMC6/AAGAGGTTTCCCGTGTATGTTTCA(SEQ. ID. No. 288) (SEQ. ID. No. 289) /5AmMC6/ATCTGCACTGTCAGCACTTTA/5AmMC6/GGAGATTGGCCATGTAATACT (SEQ. ID. No. 290) (SEQ. ID. No. 291)/5AmMC6/GCATTATTACTCACGGTACGA /5AmMC6/ACAAACCACAGTGTGCTGCTG(SEQ. ID. No. 292) (SEQ. ID. No. 293) /5AmMC6/AGCCAAGCTCAGACGGATCCGA/5AmMC6/AACCCACCGACAACAATGAATGTT (SEQ. ID. No. 294) (SEQ. ID. No. 295)/5AmMC6/ACTGATATCAGCTCAGTAGGCAC /5AmMC6/GAAAGTGCCCTCAAGGCTGAGTG(SEQ. ID. No. 296) (SEQ. ID. No. 297) /5AmMC6/TCCATCATTACCCGGCAGTATTA/5AmMC6/GACCTCAGCTATGACAGCACTT (SEQ. ID. No. 298) (SEQ. ID. No. 299)/5AmMC6/TAAACGGAACCACTAGTGACTTG /5AmMC6/GAAAAACGCCCCCTGGCTTGAAA(SEQ. ID. No. 300) (SEQ. ID. No. 301) /5AmMC6/TCAGACCGAGACAAGTGCAATG/5AmMC6/CCCTCAAAAAGGAAGCACTTT (SEQ. ID. No. 302) (SEQ. ID. No. 303)/5AmMC6/GGCGGAACTTAGCCACTGTGAA /5AmMC6/GAAAGTGCTCCCTTTTGGAGAA(SEQ. ID. No. 304) (SEQ. ID. No. 305) /5AmMC6/ACAGGATTGAGGGGGGGCCCT/5AmMC6/ACACTCTAAAAGGAGGCACTTT (SEQ. ID. No. 306) (SEQ. ID. No. 307)/5AmMC6/ATGTATGTGGGACGGTAAACCA /5AmMC6/ATCCTCTAAAAAGATGCACTTT(SEQ. ID. No. 308) (SEQ. ID. No. 309) /5AmMC6/GCTTTGACAATACTATTGCACTG/5AmMC6/AGAAAGTACTTCCCTCTGGAG (SEQ. ID. No. 310) (SEQ. ID. No. 311)/5AmMC6/TCACCAAAACATGGAAGCACTTA /5AmMC6/ACAGTCCAAAGGGAAGCACTTT(SEQ. ID. No. 312) (SEQ. ID. No. 313) /5AmMC6/GCTTCCAGTCGAGGATGTTTACA/5AmMC6/AACAGAAAGTGCTTCCCTCAAGAG (SEQ. ID. No. 314) (SEQ. ID. No. 315)/5AmMC6/TCCAGTCAAGGATGTTTACA /5AmMC6/GCCTCTAAAAGGAAGCACTTT(SEQ. ID. No. 316) (SEQ. ID. No. 317) /5AmMC6/CAGCTATGCCAGCATCTTGCCT/5AmMC6/AAACCTCTAAAAGGATGCACTTT (SEQ. ID. No. 318) (SEQ. ID. No. 319)/5AmMC6/GCAACTTAGTAATGTGCAATA /5AmMC6/AGAAAGTGCATCCCTCTGGAG(SEQ. ID. No. 320) (SEQ. ID. No. 321) /5AmMC6/CAATCAGCTAATGACACTGCCT/5AmMC6/GCTCTAAAGGGAAGCGCCTTC (SEQ. ID. No. 322) (SEQ. ID. No. 323)/5AmMC6/GCAATCAGCTAACTACACTGCCT /5AmMC6/AGAGAAAGTGCTTCCCTCTAGAG(SEQ. ID. No. 324) (SEQ. ID. No. 325) /5AmMC6/CTACCTGCACGAACAGCACTTTG/5AmMC6/TCCTCTAAAGAGAAGCGCTTT (SEQ. ID. No. 326) (SEQ. ID. No. 327)/5AmMC6/TGCTCAATAAATACCCGTTGAA /5AmMC6/CAGAAAGTGCTTCCCTCCAGAGA(SEQ. ID. No. 328) (SEQ. ID. No. 329) /5AmMC6/AGCAAGCCCAGACCGCAAAAAG/5AmMC6/CACTCTAAAGAGAAGCGCTTTG (SEQ. ID. No. 330) (SEQ. ID. No. 331)/5AmMC6/AGAAAGGCAGCAGGTCGTATAG /5AmMC6/GAGAAAGTGCTTCCCTTTGTAG(SEQ. ID. No. 332) (SEQ. ID. No. 333) /5AmMC6/TACCTGCACTGTTAGCACTTTG/5AmMC6/ACTCCAAAGGGAAGCGCCTTC (SEQ. ID. No. 334) (SEQ. ID. No. 335)/5AmMC6/CACATAGGAATGAAAAGCCATA /5AmMC6/AGACAGTGCTTCCATCTAGAGG(SEQ. ID. No. 336) (SEQ. ID. No. 337) /5AmMC6/CCTCAAGGAGCCTCAGTCTAGT/5AmMC6/CAGAAAGGGCTTCCCTTTGTAGA (SEQ. ID. No. 338) (SEQ. ID. No. 339)/5AmMC6/ACAAGTGCCCTCACTGCAGT /5AmMC6/AACCCACCAAAGAGAAGCACTTT(SEQ. ID. No. 340) (SEQ. ID. No. 341) /5AmMC6/TAAACGGAACCACTAGTGACTTA/5AmMC6/ACACTCTAAAGGGAAGCACTTTGT (SEQ. ID. No. 342) (SEQ. ID. No. 343)/5AmMC6/AAAAAGTGCCCCCATAGTTTGAG /5AmMC6/AACCCTCTGAAAGGAAGCACTT(SEQ. ID. No. 344) (SEQ. ID. No. 345) /5AmMC6/GGCACACAAAGTGGAAGCACTTT/5AmMC6/GCTCCAAAGGGAAGCGCTTTG (SEQ. ID. No. 346) (SEQ. ID. No. 347)/5AmMC6/AGAGAGGGCCTCCACTTTGATG /5AmMC6/AAAGGGCTTCCCTTTGCAGA(SEQ. ID. No. 348) (SEQ. ID. No. 349) /5AmMC6/ACACTCAAAACCTGGCGGCACTT/5AmMC6/ACACTCTAAAAGGATGCACGAT (SEQ. ID. No. 350) (SEQ. ID. No. 351)/5AmMC6/CAAAAGAGCCCCCAGTTTGAGT /5AmMC6/TTAAACATCACTGCAAGTCTTAA(SEQ. ID. No. 352) (SEQ. ID. No. 353) /5AmMC6/ACACTACAAACTCTGCGGCACT/5AmMC6/CAGAATCCTTGCCCAGGTGCAT (SEQ. ID. No. 354) (SEQ. ID. No. 355)/5AmMC6/ACACACAAAAGGGAAGCACTTT /5AmMC6/TCTCACCCAGGGACAAAGGATT(SEQ. ID. No. 356) (SEQ. ID. No. 357) /5AmMC6/AGACTCAAAAGTAGTAGCACTTT/5AmMC6/TAGCACCCAGATAGCAAGGAT (SEQ. ID. No. 358) (SEQ. ID. No. 359)/5AmMC6/CATGCACATGCACACATACAT /5AmMC6/CTGCAGAACTGTTCCCGCTGCTA(SEQ. ID. No. 360) (SEQ. ID. No. 361) /5AmMC6/GGAAGAACAGCCCTCCTCTGCC/5AmMC6/ATAGAGTGCAGACCAGGGTCT (SEQ. ID. No. 362) (SEQ. ID. No. 363)/5AmMC6/GAAGAGAGCTTGCCCTTGCATA /5AmMC6/ATAAATGACACCTCCCTGTGAA(SEQ. ID. No. 364) (SEQ. ID. No. 365) /5AmMC6/AGAGGTCGACCGTGTAATGTGC/5AmMC6/TCTACTCAGAAGGGTGCCTTA (SEQ. ID. No. 366) (SEQ. ID. No. 367)/5AmMC6/CCAGCAGCACCTGGGGCAGT /5AmMC6/TTCACTCCAAAAGGTGCAAAA(SEQ. ID. No. 368) (SEQ. ID. No. 369) /5AmMC6/ACACTTACTGAGCACCTACTAGG/5AmMC6/TCTACTCCAAAAGGCTACAATCA (SEQ. ID. No. 370) (SEQ. ID. No. 371)/5AmMC6/ACTGGAGGAAGGGCCCAGAGG /5AmMC6/TCTACCCACAGACGTACCAATCA(SEQ. ID. No. 372) (SEQ. ID. No. 373) /5AmMC6/ACGGAAGGGCAGAGAGGGCCAG/5AmMC6/TGTGATTGCCACTCTCCTGAGTA (SEQ. ID. No. 374) (SEQ. ID. No. 375)/5AmMC6/AAAAAGGTTAGCTGGGTGTGTT /5AmMC6/CTACTCACAGAAGTGTCAAT(SEQ. ID. No. 376) (SEQ. ID. No. 377) /5AmMC6/TTCTAGGATAGGCCCAGGGGC/5AmMC6/TTCAATTTCTGCCGCAAAAG (SEQ. ID. No. 378) (SEQ. ID. No. 379)/5AmMC6/AAAGGCATCATATAGGAGCTGAA /5AmMC6/GCTATCTGCTGCAACAGAATTT(SEQ. ID. No. 380) (SEQ. ID. No. 381) /5AmMC6/GGCTATAAAGTAACTGAGACGGA/5AmMC6/GTGTGCTTACACACTTCCCGTTA (SEQ. ID. No. 382) (SEQ. ID. No. 383)/5AmMC6/ACTGACCGACCGACCGATCGA /5AmMC6/AGCACGTCACTTCCACTAAGA(SEQ. ID. No. 384) (SEQ. ID. No. 385) /5AmMC6/ACAGTCAGGCTTTGGCTAGATCA/5AmMC6/GCAAGGGCGAATGCAGAAAA (SEQ. ID. No. 386) (SEQ. ID. No. 387)/5AmMC6/GCACTGGACTAGGGGTCAGCA /5AmMC6/AACTCCGGGGCTGATCAGGT(SEQ. ID. No. 388) (SEQ. ID. No. 389) /5AmMC6/AGAGGCAGGCACTCGGGCAGA/5AmMC6/CTTGTACCAGTTATCTGCAA (SEQ. ID. No. 390) (SEQ. ID. No. 391)/5AmMC6/CAATCAGCTAATTACACTGCCTA /5AmMC6/TTGTACGTTTACATGGAGGTC(SEQ. ID. No. 392) (SEQ. ID. No. 393) /5AmMC6/GTGAAAGTGTATGGGCTTTGTGAA/5AmMC6/CTGACTGACTGACTGACTGACTG (SEQ. ID. No. 394)  (SEQ. ID. No. 395)/5AmMC6/CAGGCTCAAAGGGCTCCTCAGG /5AmMC6/CCATAAAGTAGGAAACACTA(SEQ. ID. No. 396) (SEQ. ID. No. 397) /5AmMC6/AACAAAATCACAAGTCTTCCA/5AmMC6/TCACCGACAGCGTTGAATGT (SEQ. ID. No. 398) (SEQ. ID. No. 399)/5AmMC6/TGTAAGTGCTCGTAATGCAGT /5AmMC6/CGGGACTTTGAGGGCCAGT(SEQ. ID. No. 400) (SEQ. ID. No. 401) /5AmMC6/ACCCTCATGCCCCTCAAGG/5AmMC6/GAATCCACCACGAACAACTT (SEQ. ID. No. 402) (SEQ. ID. No. 403)/5AmMC6/AAAAGTAACTAGCACACCAC /5AmMC6/AGAGACCGGTTCACTGTGA(SEQ. ID. No. 404) (SEQ. ID. No. 405) /5AmMC6/ACATTTTTCGTTATTGCTCTT/5AmMC6/AGAGACCGGTTCACTGTGA (SEQ. ID. No. 406) (SEQ. ID. No. 407)/5AmMC6/TATGGCAGACTGTGATTTGTTG /5AmMC6/CCTGATTCACAACACCAGCT(SEQ. ID. No. 408) (SEQ. ID. No. 409) /5AmMC6/CATCGTTACCAGACAGTGTTA/5AmMC6/GGATTCCTGGGAAAACTGGA (SEQ. ID. No. 410) (SEQ. ID. No. 411)/5AmMC6/TCCACATGGAGTTGCTGTTACA /5AmMC6/ACTGGTACAAGGGTTGGGAG(SEQ. ID. No. 412) (SEQ. ID. No. 413) /5AmMC6/AACAGCTGCTTTTGGGATTCTG/5AmMC6/CTGGGACTTTGTAGGCCAGT (SEQ. ID. No. 414) (SEQ. ID. No. 415)/5AmMC6/ACCTAATATATCAAACATATCA /5AmMC6/AGACTCCGGTGGAATGAAGG(SEQ. ID. No. 416) (SEQ. ID. No. 417) /5AmMC6/AAGCCCAAAAGGAGAATTCTTTG/5AmMC6/CAACATCAGTCTGATAAGCTA (SEQ. ID. No. 418) (SEQ. ID. No. 419)/5AmMC6/AGGAACTGCCTTTCTCTCCAA /5AmMC6/GTACAATCAACGGTCGATGG(SEQ. ID. No. 420) (SEQ. ID. No. 421) /5AmMC6/ACCCTTATCAGTTCTCCGTCCA/5AmMC6/AGAATTGCGTTTGGACAATC (SEQ. ID. No. 422) (SEQ. ID. No. 423)/5AmMC6/TAGCTGGTTGAAGGGGACCAA /5AmMC6/ACCCAGCAGACAATGTAGC(SEQ. ID. No. 424) (SEQ. ID. No. 425) /5AmMC6/CCTCAAGGAGCTTCAGTCTAGT/5AmMC6/ACCCAGTAGCCAGATGTAGC (SEQ. ID. No. 426) (SEQ. ID. No. 427)/5AmMC6/CCAACAACAGGAAACTACCTA /5AmMC6/GCCCTCTCAACCCAGCTTT(SEQ. ID. No. 428) (SEQ. ID. No. 429) /5AmMC6/CCAGGTTCCACCCCAGCAGG/5AmMC6/GCAATGCAACTACAATGCAC (SEQ. ID. No. 430) (SEQ. ID. No. 431)/5AmMC6/ACACTCAAAAGATGGCGGCA /5AmMC6/AACAAAATCACTGATGCTGG(SEQ. ID. No. 432) (SEQ. ID. No. 433) /5AmMC6/ACGCTCAAATGTCGCAGCAC/5AmMC6/GAGCTCCTGGAGGACAGGG (SEQ. ID. No. 434) (SEQ. ID. No. 435)/5AmMC6/ACACCCCAAAATCGAAGCAC /5AmMC6/GGGTGCGATTTCTGTGTGAG(SEQ. ID. No. 436) (SEQ. ID. No. 437) /5AmMC6/GGAAAGCGCCCCCATTTTGA/5AmMC6/ACTCAGTAATGGTAACGGTT (SEQ. ID. No. 438) (SEQ. ID. No. 439)/5AmMC6/CACTTATCAGGTTGTATTATAA /5AmMC6/GAGGAAACCAGCAAGTGTTG(SEQ. ID. No. 440) (SEQ. ID. No. 441) /5AmMC6/GTCTGTCAAATCATAGGTCAT/5AmMC6/GCAATGCAACAGCAATGCAC (SEQ. ID. No. 442) (SEQ. ID. No. 443)/5AmMC6/GGGGTTCACCGAGCAACATTC /5AmMC6/GTCCGTGGTTCTACCCTGTGG(SEQ. ID. No. 444) (SEQ. ID. No. 445) /5AmMC6/CAGGCCATCTGTGTTATATT/5AmMC6/ATACTAGACTGTGAGCTCCTCGA (SEQ. ID. No. 446) (SEQ. ID. No. 447)/5AmMC6/AGTGGATGTTCCTCTATGAT /5AmMC6/CCAGAAGGAGCACTTAGGGCAG(SEQ. ID. No. 448) (SEQ. ID. No. 449) /5AmMC6/CGTGGATTTTCCTCTACGAT/5AmMC6/GCTGGATGCAAACCTGCAAAAC (SEQ. ID. No. 450) (SEQ. ID. No. 451)/5AmMC6/GAGGGTTAGTGGACCGTGTT /5AmMC6/AATCCCATCCCCAGGAACCC(SEQ. ID. No. 452) (SEQ. ID. No. 453) /5AmMC6/GATGTGGACCATACTACATA/5AmMC6/CGGCTCTGTCGTCGAGGCGC (SEQ. ID. No. 454) (SEQ. ID. No. 455)/5AmMC6/GGCTAGTGGACCAGGTGAAG /5AmMC6/AAAGTCTCGCTCTCTGCCCCT(SEQ. ID. No. 456) (SEQ. ID. No. 457) /5AmMC6/CAGAACTTAGCCACTGTGAA/5AmMC6/TCAACGGGAGTGATCGTGTCAT (SEQ. ID. No. 458) (SEQ. ID. No. 459)/5AmMC6/AGCCTATCCTGGATTACTTGAA /5AmMC6/AGCATTGCAACCGATCCCAAC(SEQ. ID. No. 460) (SEQ. ID. No. 461) /5AmMC6/CTGTTCCTGCTGAACTGAGCCA/5AmMC6/GCAGCAAACATCTGACTGAAAG (SEQ. ID. No. 462) (SEQ. ID. No. 463)

TABLE 5 miRNA detection probesProbeID: Unique identifier for each probe sequence.Annotation: miRNAs recognized by the probe, based on miRBASE release7.0. “h” stands for human, “m” for mouse and “r” for rat.Sequence: sequence of probe. /5AmMC6/ indicates 5′ amino modification.Probe Annotation Sequence EAM190 h-miR-10b_rfam7.0/5AmMC6/ACAAATTCGGTTCTACAGGGTA (SEQ. ID. No. 464) EAM187hmr-miR-107_rfam7.0 /5AmMC6/TGATAGCCCTGTACAATGCTGCT (SEQ. ID. No. 465)EAM185 hmr-miR-103_rfam7.0 /5AmMC6/TCATAGCCCTGTACAATGCTGCT(SEQ. ID. No. 466) EAM181 hmr-let-7f_rfam7.0/5AmMC6/AACTATACAATCTACTACCTCA (SEQ. ID. No. 467) EAM179hmr-let-7d_rfam7.0 /5AmMC6/ACTATGCAACCTACTACCTCT (SEQ. ID. No. 468)EAM177 mr-miR-101b_rfam7.0 /5AmMC6/TTCAGCTATCACAGTACTGTA(SEQ. ID. No. 469) EAM175 hmr-miR-320_rfam7.0/5AmMC6/TCGCCCTCTCAACCCAGCTTTT (SEQ. ID. No. 470) EAM168hmr-let-7e_rfam7.0 /5AmMC6/CTATACAACCTCCTACCTCA (SEQ. ID. No. 471)EAM161 hmr-miR-28_rfam7.0 /5AmMC6/CTCAATAGACTGTGAGCTCCTT(SEQ. ID. No. 472) EAM160 hmr-miR-26b_rfam7.0/5AmMC6/AACCTATCCTGAATTACTTGAA (SEQ. ID. No. 473) EAM155hmr-miR-136_rfam7.0 /5AmMC6/TCCATCATCAAAACAAATGGAGT (SEQ. ID. No. 474)EAM283 mr-miR-211_rfam7.0 /5AmMC6/AGGCAAAGGATGACAAAGGGAA(SEQ. ID. No. 475) EAM282 m-miR-199b_rfam7.0/5AmMC6/GAACAGGTAGTCTAAACACTGGG (SEQ. ID. No. 476) EAM281mr-miR-217_rfam7.0 /5AmMC6/ATCCAGTCAGTTCCTGATGCAGTA (SEQ. ID. No. 477)EAM280 hmr-miR-30a-3p rfam7.0 /5AmMC6/GCTGCAAACATCCGACTGAAAG(SEQ. ID. No. 478) EAM279 hmr-miR-29c_rfam7.0/5AmMC6/TAACCGATTTCAAATGGTGCTA (SEQ. ID. No. 479) EAM278hmr-miR-98_rfam7.0 /5AmMC6/AACAATACAACTTACTACCTCA (SEQ. ID. No. 480)EAM238 hm-miR-1_rfam7.0 /5AmMC6/ATACATACTTCTTTACATTCCA(SEQ. ID. No. 481) EAM270 hmr-miR-30b_rfam7.0/5AmMC6/GCTGAGTGTAGGATGTTTACA (SEQ. ID. No. 482) EAM159hmr-miR-130a rfam7.0 /5AmMC6/ATGCCCTTTTAACATTGCACTG (SEQ. ID. No. 483)EAM163 hmr-miR-142-3p_rfam7.0 /5AmMC6/TCCATAAAGTAGGAAACACTACA(SEQ. ID. No. 484) EAM171 hmr-miR-137_rfam7.0/5AmMC6/CTACGCGTATTCTTAAGCAATAA (SEQ. ID. No. 485) EAM306m-miR-201_rfam7.0 /5AmMC6/AGAACAATGCCTTACTGAGTA (SEQ. ID. No. 486)EAM307 m-miR-202_rfam7.0 /5AmMC6/TCTTCCCATGCGCTATACCTCT(SEQ. ID. No. 487) EAM308 hmr-miR-206_rfam7.0/5AmMC6/CCACACACTTCCTTACATTCCA (SEQ. ID. No. 488) EAM309m-miR-207_rfam7.0 /5AmMC6/GAGGGAGGAGAGCCAGGAGAAGC (SEQ. ID. No. 489)EAM310 hmr-miR-208_rfam7.0 /5AmMC6/ACAAGCTTTTTGCTCGTCTTAT(SEQ. ID. No. 490) EAM247 hmr-miR-212_rfam7.0/5AmMC6/GGCCGTGACTGGAGACTGTTA (SEQ. ID. No. 491) EAM251hmr-miR-216_rfam7.0 /5AmMC6/CACAGTTGCCAGCTGAGATTA (SEQ. ID. No. 492)EAM253 hmr-miR-218_rfam7.0 /5AmMC6/ACATGGTTAGATCAAGCACAA(SEQ. ID. No. 493) EAM275 hmr-miR-34a_rfam7.0/5AmMC6/ACAACCAGCTAAGACACTGCCA (SEQ. ID. No. 494) EAM246h-miR-211_rfam7.0 /5AmMC6/AGGCGAAGGATGACAAAGGGAA (SEQ. ID. No. 495)EAM250 h-miR-215_rfam7.0 /5AmMC6/GTCTGTCAATTCATAGGTCAT(SEQ. ID. No. 496) EAM252 h-miR-217_rfam7.0/5AmMC6/ATCCAATCAGTTCCTGATGCAGTA (SEQ. ID. No. 497) EAM224hmr-miR-17-5p_rfam7.0 /5AmMC6/ACTACCTGCACTGTAAGCACTTTG(SEQ. ID. No. 498) EAM225 hmr-miR-18a_rfam7.0/5AmMC6/TATCTGCACTAGATGCACCTTA (SEQ. ID. No. 499) EAM226hmr-miR-181a_rfam7.0 /5AmMC6/ACTCACCGACAGCGTTGAATGTT (SEQ. ID. No. 500)EAM227 hmr-miR-181b_rfam7.0 /5AmMC6/AACCCACCGACAGCAATGAATGTT(SEQ. ID. No. 501) EAM234 hmr-miR-199a_rfam7.0/5AmMC6/GAACAGGTAGTCTGAACACTGGG (SEQ. ID. No. 502) EAM235h-miR-199b_rfam7.0 /5AmMC6/GAACAGATAGTCTAAACACTGGG (SEQ. ID. No. 503)EAM236 hmr-miR-19a_rfam7.0 /5AmMC6/TCAGTTTTGCATAGATTTGCACA(SEQ. ID. No. 504) EAM241 hmr-miR-203 rfam7.0/5AmMC6/CTAGTGGTCCTAAACATTTCAC (SEQ. ID. No. 505) EAM242hmr-miR-204_rfam7.0 /5AmMC6/AGGCATAGGATGACAAAGGGAA (SEQ. ID. No. 506)EAM243 hmr-miR-205_rfam7.0 /5AmMC6/CAGACTCCGGTGGAATGAAGGA(SEQ. ID. No. 507) EAM245 hmr-miR-210_rfam7.0/5AmMC6/CAGCCGCTGTCACACGCACAG (SEQ. ID. No. 508) EAM249hmr-miR-214_rfam7.0 /5AmMC6/CTGCCTGTCTGTGCCTGCTGT (SEQ. ID. No. 509)EAM184 hmr-miR-100 rfam7.0 /5AmMC6/CACAAGTTCGGATCTACGGGTT(SEQ. ID. No. 510) EAM186 h-miR-106a_rfam7.0/5AmMC6/GCTACCTGCACTGTAAGCACTTTT (SEQ. ID. No. 511) EAM189hmr-miR-10a_rfam7.0 /5AmMC6/CACAAATTCGGATCTACAGGGTA (SEQ. ID. No. 512)EAM191 hmr-miR-122a_rfam7.0 /5AmMC6/ACAAACACCATTGTCACACTCCA(SEQ. ID. No. 513) EAM192 hmr-miR-126*_rfam7.0/5AmMC6/CGCGTACCAAAAGTAATAATG (SEQ. ID. No. 514) EAM198hmr-miR-130b_rfam7.0 /5AmMC6/GCCCTTTCATCATTGCACTG (SEQ. ID. No. 515)EAM202 hmr-miR-134_rfam7.0 /5AmMC6/TCCCTCTGGTCAACCAGTCACA(SEQ. ID. No. 516) EAM209 hmr-miR-142-5p_rfam7.0/5AmMC6/GTAGTGCTTTCTACTTTATG (SEQ. ID. No. 517) EAM221 m-miR-155_rfam7.0/5AmMC6/CCCCTATCACAATTAGCATTAA (SEQ. ID. No. 518) EAM223hmr-miR-15b_rfam7.0 /5AmMC6/TGTAAACCATGATGTGCTGCTA (SEQ. ID. No. 519)EAM228 hmr-miR-181c_rfam7.0 /5AmMC6/ACTCACCGACAGGTTGAATGTT(SEQ. ID. No. 520) EAM222 hm-miR-15a_rfam7.0/5AmMC6/CACAAACCATTATGTGCTGCTA (SEQ. ID. No. 521) EAM111hm-let-7g_rfam7.0 /5AmMC6/TAACTGTACAAACTACTACCTCA (SEQ. ID. No. 522)EAM131 hmr-miR-92_rfam7.0 /5AmMC6/ACAGGCCGGGACAAGTGCAATAT(SEQ. ID. No. 523) EAM139 hmr-miR-146a_rfam7.0/5AmMC6/TAACCCATGGAATTCAGTTCTCA (SEQ. ID. No. 524) EAM145hmr-let-7c_rfam7.0 /5AmMC6/AACCATACAACCTACTACCTCA (SEQ. ID. No. 525)EAM109 hmr-miR-7_rfam7.0 /5AmMC6/AACAACAAAATCACTAGTCTTCCA(SEQ. ID. No. 526) EAM152 hm-miR-9*_rfam7.0/5AmMC6/ACTTTCGGTTATCTAGCTTTAT (SEQ. ID. No. 527) JLA215hmr-let-7i_rfam7.0 /5AmMC6/ACAGCACAAACTACTACCTCA (SEQ. ID. No. 528)EAM153 hmr-let-7a rfam7.0 /5AmMC6/AACTATACAACCTACTACCTCA(SEQ. ID. No. 529) EAM147 hmr-let-7b_rfam7.0/5AmMC6/AACCACACAACCTACTACCTCA (SEQ. ID. No. 530) EAM137hmr-miR-132_rfam7.0 /5AmMC6/CCGACCATGGCTGTAGACTGTTA (SEQ. ID. No. 531)EAM133 hmr-miR-324-5p_rfam7.0 /5AmMC6/ACACCAATGCCCTAGGGGATGCG(SEQ. ID. No. 532) EAM103 hmr-miR-124a_rfam7.0/5AmMC6/TGGCATTCACCGCGTGCCTTA (SEQ. ID. No. 533) EAM105hmr-miR-125b rfam7.0 /5AmMC6/TCACAAGTTAGGGTCTCAGGGA (SEQ. ID. No. 534)EAM121 hmr-miR-99a_rfam7.0 /5AmMC6/CACAAGATCGGATCTACGGGT(SEQ. ID. No. 535) EAM115 hmr-miR-16_rfam7.0/5AmMC6/CGCCAATATTTACGTGCTGCTA (SEQ. ID. No. 536) EAM119hmr-miR-29b_rfam7.0 /5AmMC6/AACACTGATTTCAAATGGTGCTA (SEQ. ID. No. 537)EAM311 hmr-miR-101_rfam7.0 /5AmMC6/CTTCAGTTATCACAGTACTGTA(SEQ. ID. No. 538) EAM312 h-miR-105_rfam7.0 /5AmMC6/ACAGGAGTCTGAGCATTTGA(SEQ. ID. No. 539) EAM313 hmr-miR-106b_rfam7.0/5AmMC6/ATCTGCACTGTCAGCACTTTA (SEQ. ID. No. 540) EAM314hmr-miR-126_rfam7.0 /5AmMC6/GCATTATTACTCACGGTACGA (SEQ. ID. No. 541)EAM315 hmr-miR-127_rfam7.0 /5AmMC6/AGCCAAGCTCAGACGGATCCGA(SEQ. ID. No. 542) EAM320 hm-miR-189_rfam7.0/5AmMC6/ACTGATATCAGCTCAGTAGGCAC (SEQ. ID. No. 543) JLA216hmr-miR-200c_rfam7.0 /5AmMC6/TCCATCATTACCCGGCAGTATTA (SEQ. ID. No. 544)EAM323 h-miR-224_rfam7.0 /5AmMC6/TAAACGGAACCACTAGTGACTTG(SEQ. ID. No. 545) EAM324 hmr-miR-25_rfam7.0/5AmMC6/TCAGACCGAGACAAGTGCAATG (SEQ. ID. No. 546) EAM386r-miR-336_rfam7.0 /5AmMC6/AGACTAGATATGGAAGGGTGA (SEQ. ID. No. 547)JLA218 r-miR-343_rfam7.0 /5AmMC6/TCTGGGCACACGGAGGGAGA (SEQ. ID. No. 548)EAM388 r-miR-344_rfam7.0 /5AmMC6/ACGGTCAGGCTTTGGCTAGAT(SEQ. ID. No. 549) EAM338 h-miR-95_rfam7.0/5AmMC6/TGCTCAATAAATACCCGTTGAA (SEQ. ID. No. 550) JLA214hmr-miR-129_rfam7.0 /5AmMC6/AGCAAGCCCAGACCGCAAAAAG (SEQ. ID. No. 551)EAM340 mr-let-7d*_rfam7.0 /5AmMC6/AGAAAGGCAGCAGGTCGTATAG(SEQ. ID. No. 552) EAM341 m-miR-106a_rfam7.0/5AmMC6/TACCTGCACTGTTAGCACTTTG (SEQ. ID. No. 553) EAM342hmr-miR-135b_rfam7.0 /5AmMC6/CACATAGGAATGAAAAGCCATA (SEQ. ID. No. 554)EAM343 mr-miR-151 rfam7.0 /5AmMC6/CCTCAAGGAGCCTCAGTCTAGT(SEQ. ID. No. 555) EAM344 m-miR-17-3p_rfam7.0/5AmMC6/ACAAGTGCCCTCACTGCAGT (SEQ. ID. No. 556) EAM345 m-miR-224_rfam7.0/5AmMC6/TAAACGGAACCACTAGTGACTTA (SEQ. ID. No. 557) EAM346mr-miR-290_rfam7.0 /5AmMC6/AAAAAGTGCCCCCATAGTTTGAG (SEQ. ID. No. 558)EAM347 mr-miR-291-3p_rfam7.0 /5AmMC6/GGCACACAAAGTGGAAGCACTTT(SEQ. ID. No. 559) EAM348 mr-miR-291-5p rfam7.0/5AmMC6/AGAGAGGGCCTCCACTTTGATG (SEQ. ID. No. 560) EAM349mr-miR-292-3p_rfam7.0 /5AmMC6/ACACTCAAAACCTGGCGGCACTT (SEQ. ID. No. 561)EAM350 mr-miR-292-5p_rfam7.0 /5AmMC6/CAAAAGAGCCCCCAGTTTGAGT(SEQ. ID. No. 562) EAM351 m-miR-293_rfam7.0/5AmMC6/ACACTACAAACTCTGCGGCACT (SEQ. ID. No. 563) EAM352m-miR-294_rfam7.0 /5AmMC6/ACACACAAAAGGGAAGCACTTT (SEQ. ID. No. 564)EAM353 m-miR-295_rfam7.0 /5AmMC6/AGACTCAAAAGTAGTAGCACTTT(SEQ. ID. No. 565) EAM354 m-miR-297_rfam7.0/5AmMC6/CATGCACATGCACACATACAT (SEQ. ID. No. 566) EAM355mr-miR-298_rfam7.0 /5AmMC6/GGAAGAACAGCCCTCCTCTGCC (SEQ. ID. No. 567)EAM356 mr-miR-300_rfam7.0 /5AmMC6/GAAGAGAGCTTGCCCTTGCATA(SEQ. ID. No. 568) EAM358 hmr-miR-323_rfam7.0/5AmMC6/AGAGGTCGACCGTGTAATGTGC (SEQ. ID. No. 569) EAM359hmr-miR-324-3p_rfam7.0 /5AmMC6/CCAGCAGCACCTGGGGCAGT (SEQ. ID. No. 570)EAM360 mr-miR-325_rfam7.0 /5AmMC6/ACACTTACTGAGCACCTACTAGG(SEQ. ID. No. 571) EAM361 hmr-miR-326_rfam7.0/5AmMC6/ACTGGAGGAAGGGCCCAGAGG (SEQ. ID. No. 572) EAM362hmr-miR-328_rfam7.0 /5AmMC6/ACGGAAGGGCAGAGAGGGCCAG (SEQ. ID. No. 573)EAM363 mr-miR-329_rfam7.0 /5AmMC6/AAAAAGGTTAGCTGGGTGTGTT(SEQ. ID. No. 574) EAM365 hmr-miR-331_rfam7.0/5AmMC6/TTCTAGGATAGGCCCAGGGGC (SEQ. ID. No. 575) EAM366mr-miR-337_rfam7.0 /5AmMC6/AAAGGCATCATATAGGAGCTGAA (SEQ. ID. No. 576)EAM367 hmr-miR-338_rfam7.0 /5AmMC6/TCAACAAAATCACTGATGCTGGA(SEQ. ID. No. 577) EAM368 hmr-miR-339_rfam7.0/5AmMC6/TGAGCTCCTGGAGGACAGGGA (SEQ. ID. No. 578) EAM369hmr-miR-340 rfam7.0 /5AmMC6/GGCTATAAAGTAACTGAGACGGA (SEQ. ID. No. 579)EAM370 mr-miR-341_rfam7.0 /5AmMC6/ACTGACCGACCGACCGATCGA(SEQ. ID. No. 580) EAM371 hmr-miR-342_rfam7.0/5AmMC6/GACGGGTGCGATTTCTGTGTGAGA (SEQ. ID. No. 581) EAM372m-miR-344_rfam7.0 /5AmMC6/ACAGTCAGGCTTTGGCTAGATCA (SEQ. ID. No. 582)EAM373 mr-miR-345_rfam7.0 /5AmMC6/GCACTGGACTAGGGGTCAGCA(SEQ. ID. No. 583) EAM374 m-miR-346 rfam7.0/5AmMC6/AGAGGCAGGCACTCGGGCAGA (SEQ. ID. No. 584) EAM375mr-miR-34b_rfam7.0 /5AmMC6/CAATCAGCTAATTACACTGCCTA (SEQ. ID. No. 585)JLA217 mr-miR-350_rfam7.0 /5AmMC6/GTGAAAGGTATGGGCTTTGTGAA(SEQ. ID. No. 586) EAM377 mr-miR-351_rfam7.0/5AmMC6/CAGGCTCAAAGGGCTCCTCAGG (SEQ. ID. No. 587) EAM378mr-miR-7b_rfam7.0 /5AmMC6/AACAAAATCACAAGTCTTCCA (SEQ. ID. No. 588)EAM382 r-miR-20*_rfam7.0 /5AmMC6/TGTAAGTGCTCGTAATGCAGT(SEQ. ID. No. 589) EAM383 r-miR-327_rfam7.0 /5AmMC6/ACCCTCATGCCCCTCAAGG(SEQ. ID. No. 590) EAM384 r-miR-333_rfam7.0 /5AmMC6/AAAAGTAACTAGCACACCAC(SEQ. ID. No. 591) EAM385 hmr-miR-335_rfam7.0/5AmMC6/ACATTTTTCGTTATTGCTCTT (SEQ. ID. No. 592) EAM393 r-miR-7*_rfam7.0/5AmMC6/TATGGCAGACTGTGATTTGTTG (SEQ. ID. No. 593) EAM304hmr-miR-200a_rfam7.0 /5AmMC6/CATCGTTACCAGACAGTGTTA (SEQ. ID. No. 594)EAM298 hmr-miR-194_rfam7.0 /5AmMC6/TCCACATGGAGTTGCTGTTACA(SEQ. ID. No. 595) JLA221 hmr-miR-191_rfam7.0/5AmMC6/AACAGCTGCTTTTGGGATTCTG (SEQ. ID. No. 596) EAM295hmr-miR-190_rfam7.0 /5AmMC6/ACCTAATATATCAAACATATCA (SEQ. ID. No. 597)EAM292 hmr-miR-186_rfam7.0 /5AmMC6/AAGCCCAAAAGGAGAATTCTTTG(SEQ. ID. No. 598) JLA219 hmr-miR-185_rfam7.0/5AmMC6/AGGAACTGCCTTTCTCTCCAA (SEQ. ID. No. 599) EAM290hmr-miR-184_rfam7.0 /5AmMC6/ACCCTTATCAGTTCTCCGTCCA (SEQ. ID. No. 600)EAM402 hm-miR-133b_rfam7.0 /5AmMC6/TAGCTGGTTGAAGGGGACCAA(SEQ. ID. No. 601) EAM403 h-miR-151_rfam7.0/5AmMC6/CCTCAAGGAGCTTCAGTCTAGT (SEQ. ID. No. 602) EAM404hmr-miR-196b_rfam7.0 /5AmMC6/CCAACAACAGGAAACTACCTA (SEQ. ID. No. 603)EAM418 hm-miR-370_rfam7.0 /5AmMC6/CCAGGTTCCACCCCAGCAGG(SEQ. ID. No. 604) EAM419 h-miR-371 rfam7.0 /5AmMC6/ACACTCAAAAGATGGCGGCA(SEQ. ID. No. 605) EAM420 h-miR-372_rfam7.0 /5AmMC6/ACGCTCAAATGTCGCAGCAC(SEQ. ID. No. 606) EAM421 h-miR-373_rfam7.0 /5AmMC6/ACACCCCAAAATCGAAGCAC(SEQ. ID. No. 607) EAM422 h-miR-373*_rfam7.0/5AmMC6/GGAAAGCGCCCCCATTTTGA (SEQ. ID. No. 608) EAM423 h-miR-374_rfam7.0/5AmMC6/CACTTATCAGGTTGTATTATAA (SEQ. ID. No. 609) EAM426m-miR-215 rfam7.0 /5AmMC6/GTCTGTCAAATCATAGGTCAT (SEQ. ID. No. 610)EAM427 hm-miR-409-3p_rfam7.0 /5AmMC6/GGGGTTCACCGAGCAACATTC(SEQ. ID. No. 611) EAM428 hm-miR-410_rfam7.0/5AmMC6/CAGGCCATCTGTGTTATATT (SEQ. ID. No. 612) EAM429m-miR-376b_rfam7.0 /5AmMC6/AGTGGATGTTCCTCTATGAT (SEQ. ID. No. 613)EAM430 m-miR-376a_rfam7.0 /5AmMC6/CGTGGATTTTCCTCTACGAT(SEQ. ID. No. 614) EAM431 m-miR-411_rfam7.0 /5AmMC6/GAGGGTTAGTGGACCGTGTT(SEQ. ID. No. 615) EAM432 m-miR-380-3p_rfam7.0/5AmMC6/GATGTGGACCATACTACATA (SEQ. ID. No. 616) EAM433hm-miR-412_rfam7.0 /5AmMC6/GGCTAGTGGACCAGGTGAAG (SEQ. ID. No. 617)EAM264 hmr-miR-27b_rfam7.0 /5AmMC6/CAGAACTTAGCCACTGTGAA(SEQ. ID. No. 618) EAM263 hmr-miR-26a_rfam7.0/5AmMC6/AGCCTATCCTGGATTACTTGAA (SEQ. ID. No. 619) EAM262hmr-miR-24_rfam7.0 /5AmMC6/CTGTTCCTGCTGAACTGAGCCA (SEQ. ID. No. 620)EAM261 hmr-miR-23b_rfam7.0 /5AmMC6/GTGGTAATCCCTGGCAATGTGAT(SEQ. ID. No. 621) EAM260 hmr-miR-23a_rfam7.0/5AmMC6/GGAAATCCCTGGCAATGTGAT (SEQ. ID. No. 622) EAM256h-miR-220_rfam7.0 /5AmMC6/AAAGTGTCAGATACGGTGTGG (SEQ. ID. No. 623)EAM255 hmr-miR-22_rfam7.0 /5AmMC6/ACAGTTCTTCAACTGGCAGCTT(SEQ. ID. No. 624) EAM248 hmr-miR-213_rfam7.0/5AmMC6/GGTACAATCAACGGTCGATGGT (SEQ. ID. No. 625) EAM244hmr-miR-21_rfam7.0 /5AmMC6/TCAACATCAGTCTGATAAGCTA (SEQ. ID. No. 626)EAM240 hmr-miR-20a_rfam7.0 /5AmMC6/CTACCTGCACTATAAGCACTTTA(SEQ. ID. No. 627) EAM237 hmr-miR-19b_rfam7.0/5AmMC6/TCAGTTTTGCATGGATTTGCACA (SEQ. ID. No. 628) EAM233hmr-miR-196a rfam7.0 /5AmMC6/CCCAACAACATGAAACTACCTA (SEQ. ID. No. 629)EAM214 hm-miR-148a_rfam7.0 /5AmMC6/ACAAAGTTCTGTAGTGCACTGA(SEQ. ID. No. 630) EAM212 hmr-miR-145_rfam7.0/5AmMC6/AAGGGATTCCTGGGAAAACTGGAC (SEQ. ID. No. 631) EAM211hmr-miR-144_rfam7.0 /5AmMC6/CTAGTACATCATCTATACTGTA (SEQ. ID. No. 632)EAM210 hmr-miR-143_rfam7.0 /5AmMC6/tgAGCTACAGTGCTTCATCTCA(SEQ. ID. No. 633) EAM389 r-miR-346 rfam7.0/5AmMC6/AGAGGCAGGCACTCAGGCAGA (SEQ. ID. No. 634) EAM390r-miR-347_rfam7.0 /5AmMC6/TGGGCGACCCAGAGGGACA (SEQ. ID. No. 635) EAM391r-miR-349_rfam7.0 /5AmMC6/AGAGGTTAAGACAGCAGGGCTG (SEQ. ID. No. 636)JLA223 hmr-miR-33_rfam7.0 /5AmMC6/TGCAATGCAACTACAATGCACC(SEQ. ID. No. 637) EAM277 hmr-miR-96_rfam7.0/5AmMC6/GCAAAAATGTGCTAGTGCCAAA (SEQ. ID. No. 638) EAM276hmr-miR-9_rfam7.0 /5AmMC6/TCATACAGCTAGATAACCAAAGA (SEQ. ID. No. 639)EAM272 hmr-miR-30d_rfam7.0 /5AmMC6/CTTCCAGTCGGGGATGTTTACA(SEQ. ID. No. 640) EAM288 mr-miR-10b_rfam7.0/5AmMC6/ACACAAATTCGGTTCTACAGGG (SEQ. ID. No. 641) EAM293hm-miR-188_rfam7.0 /5AmMC6/ACCCTCCACCATGCAAGGGATG (SEQ. ID. No. 642)EAM297 hmr-miR-193a_rfam7.0 /5AmMC6/CTGGGACTTTGTAGGCCAGTT(SEQ. ID. No. 643) EAM301 h-miR-198_rfam7.0 /5AmMC6/CCTATCTCCCCTCTGGACC(SEQ. ID. No. 644) EAM232 hmr-miR-192_rfam7.0/5AmMC6/GGCTGTCAATTCATAGGTCAG (SEQ. ID. No. 645) EAM231hmr-miR-187_rfam7.0 /5AmMC6/CGGCTGCAACACAAGACACGA (SEQ. ID. No. 646)EAM230 hmr-miR-183_rfam7.0 /5AmMC6/CAGTGAATTCTACCAGTGCCATA(SEQ. ID. No. 647) EAM229 hm-miR-182_rfam7.0/5AmMC6/TGTGAGTTCTACCATTGCCAAA (SEQ. ID. No. 648) EAM220hmr-miR-154_rfam7.0 /5AmMC6/CGAAGGCAACACGGATAACCTA (SEQ. ID. No. 649)EAM219 hmr-miR-153_rfam7.0 /5AmMC6/TCACTTTTGTGACTATGCAA(SEQ. ID. No. 650) EAM218 hmr-miR-152_rfam7.0/5AmMC6/CCAAGTTCTGTCATGCACTGA (SEQ. ID. No. 651) EAM217hmr-miR-150_rfam7.0 /5AmMC6/ACACTGGTACAAGGGTTGGGAGA (SEQ. ID. No. 652)EAM216 hm-miR-149_rfam7.0 /5AmMC6/GGAGTGAAGACACGGAGCCAGA(SEQ. ID. No. 653) EAM215 hmr-miR-148b_rfam7.0/5AmMC6/ACAAAGTTCTGTGATGCACTGA (SEQ. ID. No. 654) EAM271hmr-miR-30c rfam7.0 /5AmMC6/GCTGAGAGTGTAGGATGTTTACA (SEQ. ID. No. 655)EAM268 hmr-miR-29a_rfam7.0 /5AmMC6/AACCGATTTCAGATGGTGCTAG(SEQ. ID. No. 656) EAM305 hmr-miR-200b_rfam7.0/5AmMC6/GTCATCATTACCAGGCAGTATTA (SEQ. ID. No. 657) EAM303hm-miR-199a*_rfam7.0 /5AmMC6/AACCAATGTGCAGACTACTGTA (SEQ. ID. No. 658)EAM300 h-miR-197_rfam7.0 /5AmMC6/GCTGGGTGGAGAAGGTGGTGAA(SEQ. ID. No. 659) EAM299 hmr-miR-195 rfam7.0/5AmMC6/GCCAATATTTCTGTGCTGCTA (SEQ. ID. No. 660) JLA91hmr-miR-99b_rfam7.0 /5AmMC6/CGCAAGGTCGGTTCTACGGGTG (SEQ. ID. No. 661)JLA92 hmr-miR-433_rfam7.0 /5AmMC6/ACACCGAGGAGCCCATCATGAT(SEQ. ID. No. 662) JLA93 hmr-miR-431_rfam7.0/5AmMC6/CCTGCATGACGGCCTGCAAGACA (SEQ. ID. No. 663) JLA94hmr-miR-365_rfam7.0 /5AmMC6/ATAAGGATTTTTAGGGGCATTA (SEQ. ID. No. 664)JLA95 hmr-miR-450_rfam7.0 /5AmMC6/TATTAGGAACACATCGCAAAAA(SEQ. ID. No. 665) JLA96 hmr-miR-449_rfam7.0/5AmMC6/ACCAGCTAACAATACACTGCCA (SEQ. ID. No. 666) JLA99hmr-miR-448_rfam7.0 /5AmMC6/ATGGGACATCCTACATATGCAA (SEQ. ID. No. 667)JLA103 hmr-miR-424_rfam7.0 /5AmMC6/TTCAAAACATGAATTGCTGCTG(SEQ. ID. No. 668) JLA105 hm-miR-361_rfam7.0/5AmMC6/GTACCCCTGGAGATTCTGATAA (SEQ. ID. No. 669) JLA106hm-miR-375_rfam7.0 /5AmMC6/TCACGCGAGCCGAACGAACAAA (SEQ. ID. No. 670)JLA107 hm-miR-377_rfam7.0 /5AmMC6/ACAAAAGTTGCCTTTGTGTGAT(SEQ. ID. No. 671) JLA108 hm-miR-378_rfam7.0/5AmMC6/ACACAGGACCTGGAGTCAGGAG (SEQ. ID. No. 672) JLA109hm-miR-379_rfam7.0 /5AmMC6/CCTACGTTCCATAGTCTACCA (SEQ. ID. No. 673)JLA110 hm-miR-380-5p_rfam7.0 /5AmMC6/GCGCATGTTCTATGGTCAACCA(SEQ. ID. No. 674) JLA111 hm-miR-381_rfam7.0/5AmMC6/ACAGAGAGCTTGCCCTTGTATA (SEQ. ID. No. 675) JLA112hm-miR-382_rfam7.0 /5AmMC6/CGAATCCACCACGAACAACTTC (SEQ. ID. No. 676)JLA115 hm-miR-384_rfam7.0 /5AmMC6/TATGAACAATTTCTAGGAAT(SEQ. ID. No. 677) JLA116 hm-miR-425_rfam7.0/5AmMC6/GGCGGACACGACATTCCCGAT (SEQ. ID. No. 678) JLA117hm-miR-452 rfam7.0 /5AmMC6/GTCTCAGTTTCCTCTGCAAACA (SEQ. ID. No. 679)JLA118 hm-miR-30e-3p_rfam7.0 /5AmMC6/GCTGTAAACATCCGACTGAAAG(SEQ. ID. No. 680) JLA104 mr-miR-129-3p_rfam7.0/5AmMC6/ATGCTTTTTGGGGTAAGGGCTT (SEQ. ID. No. 681) JLA98mr-miR-429_rfam7.0 /5AmMC6/ACGGCATTACCAGACAGTATTA (SEQ. ID. No. 682)JLA101 mr-miR-330_rfam7.0 /5AmMC6/TCTCTGCAGGCCCTGTGCTTTGC(SEQ. ID. No. 683) JLA102 mr-miR-322 rfam7.0/5AmMC6/TGTTGCAGCGCTTCATGTTT (SEQ. ID. No. 684) JLA114 m-miR-383_rfam7.0/5AmMC6/AGCCACAGTCACCTTCTGATCT (SEQ. ID. No. 685) JLA5 hmr-miR-451/5AmMC6/AAACTCAGTAATGGTAACGGTTT (SEQ. ID. No. 686) JLA201r-miR-421_rfam7.0 /5AmMC6/CAACAAACATTTAATGAGGCC (SEQ. ID. No. 687)JLA202 m-miR-463_rfam7.0 /5AmMC6/TGATGGACAACAAATTAGGTA(SEQ. ID. No. 688) JLA203 m-miR-464_rfam7.0/5AmMC6/TATCTCACAGAATAAACTTGGTA (SEQ. ID. No. 689) JLA204m-miR-465_rfam7.0 /5AmMC6/TCACATCAGTGCCATTCTAAATA (SEQ. ID. No. 690)JLA205 m-miR-466_rfam7.0 /5AmMC6/GTCTTATGTGTGCGTGTATGTAT(SEQ. ID. No. 691) JLA206 m-miR-467_rfam7.0/5AmMC6/GTGTAGGTGTGTGTATGTATAT (SEQ. ID. No. 692) JLA207m-miR-468_rfam7.0 /5AmMC6/CAGACACACGCACATCAGTCATA (SEQ. ID. No. 693)JLA208 m-miR-469_rfam7.0 /5AmMC6/GGACACCAAGATCAATGAAAGAGGCA(SEQ. ID. No. 694) JLA209 m-miR-470_rfam7.0/5AmMC6/TCACCAGTGCCAGTCCAAGAA (SEQ. ID. No. 695) JLA210m-miR-471_rfam7.0 /5AmMC6/TGTGAAAAGCACTATACTACGTA (SEQ. ID. No. 696)EAM325 hmr-miR-27a_rfam7.0 /5AmMC6/GGCGGAACTTAGCCACTGTGAA(SEQ. ID. No. 697) EAM326 hmr-miR-296_rfam7.0/5AmMC6/ACAGGATTGAGGGGGGGCCCT (SEQ. ID. No. 698) EAM327hmr-miR-299-5p_rfam7.0 /5AmMC6/ATGTATGTGGGACGGTAAACCA (SEQ. ID. No. 699)EAM328 hmr-miR-301_rfam7.0 /5AmMC6/GCTTTGACAATACTATTGCACTG(SEQ. ID. No. 700) EAM329 hm-miR-302a_rfam7.0/5AmMC6/TCACCAAAACATGGAAGCACTTA (SEQ. ID. No. 701) EAM330hmr-miR-30a-5p_rfam7.0 /5AmMC6/GCTTCCAGTCGAGGATGTTTACA(SEQ. ID. No. 702) EAM331 hmr-miR-30e-5p_rfam7.0/5AmMC6/TCCAGTCAAGGATGTTTACA (SEQ. ID. No. 703) EAM332hmr-miR-31_rfam7.0 /5AmMC6/CAGCTATGCCAGCATCTTGCCT (SEQ. ID. No. 704)EAM333 hmr-miR-32 rfam7.0 /5AmMC6/GCAACTTAGTAATGTGCAATA(SEQ. ID. No. 705) EAM335 h-miR-34b_rfam7.0/5AmMC6/CAATCAGCTAATGACACTGCCT (SEQ. ID. No. 706) EAM336hmr-miR-34c_rfam7.0 /5AmMC6/GCAATCAGCTAACTACACTGCCT (SEQ. ID. No. 707)EAM337 hmr-miR-93_rfam7.0 /5AmMC6/CTACCTGCACGAACAGCACTTTG(SEQ. ID. No. 708) EAM208 hmr-miR-141_rfam7.0/5AmMC6/CCATCTTTACCAGACAGTGTT (SEQ. ID. No. 709) EAM207hmr-miR-140 rfam7.0 /5AmMC6/CTACCATAGGGTAAAACCACT (SEQ. ID. No. 710)JLA222 hmr-miR-139_rfam7.0 /5AmMC6/TGGAGACACGTGCACTGTAGA(SEQ. ID. No. 711) JLA220 hmr-miR-138_rfam7.0/5AmMC6/CCTGATTCACAACACCAGCTG (SEQ. ID. No. 712) EAM203hmr-miR-135a_rfam7.0 /5AmMC6/TTCACATAGGAATAAAAAGCCATA (SEQ. ID. No. 713)EAM200 hmr-miR-133a_rfam7.0 /5AmMC6/ACAGCTGGTTGAAGGGGACCAA(SEQ. ID. No. 714) EAM195 hmr-miR-128b_rfam7.0/5AmMC6/GAAAGAGACCGGTTCACTGTGA (SEQ. ID. No. 715) EAM194hmr-miR-128a_rfam7.0 /5AmMC6/AAAAGAGACCGGTTCACTGTGA (SEQ. ID. No. 716)EAM254 hmr-miR-219_rfam7.0 /5AmMC6/AGAATTGCGTTTGGACAATCA(SEQ. ID. No. 717) EAM257 hmr-miR-221_rfam7.0/5AmMC6/GAAACCCAGCAGACAATGTAGCT (SEQ. ID. No. 718) EAM258hmr-miR-222_rfam7.0 /5AmMC6/GAGACCCAGTAGCCAGATGTAGCT (SEQ. ID. No. 719)EAM259 hmr-miR-223_rfam7.0 /5AmMC6/GGGGTATTTGACAAACTGACA(SEQ. ID. No. 720) JLA211 m-miR-434-5p_rfam7.0/5AmMC6/GGTTCAAACCATGAGTCGAGCT (SEQ. ID. No. 721) JLA212m-miR-434-3p_rfam7.0 /5AmMC6/GGAGTCGAGTGATGGTTCAAA (SEQ. ID. No. 722)JLA213 m-miR-433-5p_rfam7.0 /5AmMC6/GAATAATGACAGGCTCACCGTA(SEQ. ID. No. 723) JLA2 hsa-miR-522 /5AmMC6/ACACTCTAAAGGGAACCATTTT(SEQ. ID. No. 724) JLA3 hsa-miR-495 /5AmMC6/AAAGAAGTGCACCATGTTTGTTT(SEQ. ID. No. 725) JLA200 r-miR-297_rfam7.0/5AmMC6/CATGCATACATGCACACATACAT (SEQ. ID. No. 726) JLA6 hsa-miR-518e/5AmMC6/AACACTCTGAAGGGAAGCGC (SEQ. ID. No. 727) JLA7 hsa-miR-519a/5AmMC6/CACTCTAAAAGGATGCACTTT (SEQ. ID. No. 728) JLA8 hsa-mir-527*/5AmMC6/TTCACCAAAGGGAAGCACTTT (SEQ. ID. No. 729) JLA72hmr-miR-140*_rfam7.0 /5AmMC6/GTCCGTGGTTCTACCCTGTGG (SEQ. ID. No. 730)JLA10 hsa-miR-521 /5AmMC6/ACACTCTAAAGGGAAGTGCGTT (SEQ. ID. No. 731)JLA12 hsa-miR-362 /5AmMC6/CTCACACCTAGGTTCCAAGGATT (SEQ. ID. No. 732)JLA74 hsa-mir-18* /5AmMC6/CCAGAAGGAGCACTTAGGGCAG (SEQ. ID. No. 733)JLA14 hm-miR-363 /5AmMC6/TTACAGATGGATACCGTGCAATT (SEQ. ID. No. 734)JLA77 hsa-mir-19b-1* /5AmMC6/GCTGGATGCAAACCTGCAAAAC (SEQ. ID. No. 735)JLA17 hsa-mir-520c, b, f /5AmMC6/CCTCTAAAAGGAAGCACTTTCT(SEQ. ID. No. 736) JLA79 hsa-mir-23a* /5AmMC6/AATCCCATCCCCAGGAACCC(SEQ. ID. No. 737) JLA20 hsa-miR-369-5p /5AmMC6/CGAATATAACACGGTCGATCT(SEQ. ID. No. 738) JLA81 hsa-mir-339* /5AmMC6/CGGCTCTGTCGTCGAGGCGC(SEQ. ID. No. 739) JLA23 hsa-mir-342* /5AmMC6/TCAATCACAGATAGCACCCCT(SEQ. ID. No. 740) JLA24 hsa-mir-19a* /5AmMC6/GTAGTGCAACTATGCAAAACT(SEQ. ID. No. 741) JLA26 hsa-miR-517a, b /5AmMC6/ACACTCTAAAGGGATGCACGAT(SEQ. ID. No. 742) JLA27 hsa-miR-516-5p /5AmMC6/AAAGTGCTTCTTACCTCCAGAT(SEQ. ID. No. 743) JLA28 hsa-miR-518b /5AmMC6/ACCTCTAAAGGGGAGCGCTT(SEQ. ID. No. 744) JLA29 hsa-miR-519d /5AmMC6/ACACTCTAAAGGGAGGCACTTT(SEQ. ID. No. 745) JLA73 hr-mir-151* /5AmMC6/ATACTAGACTGTGAGCTCCTCGA(SEQ. ID. No. 746) JLA31 hsa-mir-28* /5AmMC6/TCCAGGAGCTCACAATCTAGTG(SEQ. ID. No. 747) JLA33 hsa-mir-519a-2* /5AmMC6/AGAAAGCGCTTCCCTGTAGAG(SEQ. ID. No. 748) JLA34 hsa-mir-26b* /5AmMC6/AGCCAAGTAATGGAGAACAGG(SEQ. ID. No. 749) JLA35 hsa-miR-526c /5AmMC6/AGAAAGCGCTTCCCTCTAGAG(SEQ. ID. No. 750) JLA36 hsa-miR-527 /5AmMC6/ACAGAAAGGGCTTCCCTTTGC(SEQ. ID. No. 751) JLA38 hsa-mir-29b-2* /5AmMC6/TCTAAGCCACCATGTGAAACCA(SEQ. ID. No. 752) JLA39 hsa-let-7g* /5AmMC6/GCAAGGCAGTGGCCTGTACA(SEQ. ID. No. 753) JLA40 hsa-miR-518a /5AmMC6/TCCAGCAAAGGGAAGCGCTT(SEQ. ID. No. 754) JLA41 hsa-mi R-523 /5AmMC6/ACCCTCTATAGGGAAGCGCGT(SEQ. ID. No. 755) JLA44 hsa-miR-515-3p /5AmMC6/AACGCTCCAAAAGAAGGCACT(SEQ. ID. No. 756) JLA45 hsa-mir-146b* /5AmMC6/ACCAGAACTGAGTCCACAGGG(SEQ. ID. No. 757) JLA49 hsa-mir-222* /5AmMC6/ATCTACACTGGCTACTGAGCC(SEQ. ID. No. 758) JLA53 hsa-mir-24* /5AmMC6/ACTGTGTTTCAGCTCAGTAGGCA(SEQ. ID. No. 759) JLA55 hsa-miR-503 /5AmMC6/ACTGCAGAACTGTTCCCGCTG(SEQ. ID. No. 760) JLA57 hsa-mir-505 /5AmMC6/AGAGGAAACCAGCAAGTGTTGA(SEQ. ID. No. 761) JLA82 hsa-mir-423* /5AmMC6/AAAGTCTCGCTCTCTGCCCCT(SEQ. ID. No. 762) JLA66 hsa-miR-432 /5AmMC6/CCACCCAATGACCTACTCCAAG(SEQ. ID. No. 763) JLA83 hsa-mir-425* /5AmMC6/TCAACGGGAGTGATCGTGTCAT(SEQ. ID. No. 764) JLA84 hsa-mir-92-1* /5AmMC6/AGCATTGCAACCGATCCCAAC(SEQ. ID. No. 765) JLA69 hsa-mir-193* /5AmMC6/TCATCTCGCCCGCAAAGACC(SEQ. ID. No. 766) JLA70 hsa-miR-515-5p /5AmMC6/AGAAAGTGCTTTCTTTTGGAGAA(SEQ. ID. No. 767) JLA71 hsa-mir-516-1* /5AmMC6/GAAAGTGCTTCTTTCCTCGAGAA(SEQ. ID. No. 768) JLA85 hsa-mir-30d* /5AmMC6/GCAGCAAACATCTGACTGAAAG(SEQ. ID. No. 769) JLA125 h-miR-20b_rfam7.0/5AmMC6/CTACCTGCACTATGAGCACTTTG (SEQ. ID. No. 770) JLA198h-miR-191*_rfam7.0 /5AmMC6/GGGGACGAAATCCAAGCGCAGC (SEQ. ID. No. 771)JLA199 h-miR-154*_rfam7.0 /5AmMC6/AATAGGTCAACCGTGTATGATT(SEQ. ID. No. 772) EAM316 h-miR-147_rfam7.0 /5AmMC6/GCAGAAGCATTTCCACACAC(SEQ. ID. No. 773) EAM317 h-miR-155_rfam7.0/5AmMC6/CCCCTATCACGATTAGCATTAA (SEQ. ID. No. 774) EAM318h-miR-17-3p_rfam7.0 /5AmMC6/ACAAGTGCCTTCACTGCAGT (SEQ. ID. No. 775)JLA195 h-miR-200a*_rfam7.0 /5AmMC6/TCCAGCACTGTCCGGTAAGATG(SEQ. ID. No. 776) JLA196 h-miR-302a*_rfam7.0/5AmMC6/AAAGCAAGTACATCCACGTTTA (SEQ. ID. No. 777) JLA197h-miR-299-3p_rfam7.0 /5AmMC6/AAGCGGTTTACCATCCCACATA (SEQ. ID. No. 778)EAM319 h-miR-182* rfam7.0 /5AmMC6/TAGTTGGCAAGTCTAGAACCA(SEQ. ID. No. 779) EAM405 h-miR-302b_rfam7.0/5AmMC6/CTACTAAAACATGGAAGCACTTA (SEQ. ID. No. 780) EAM406h-miR-302b*_rfam7.0 /5AmMC6/AGAAAGCACTTCCATGTTAAAGT (SEQ. ID. No. 781)EAM392 r-miR-352_rfam7.0 /5AmMC6/TACTATGCAACCTACTACTCT(SEQ. ID. No. 782) JLA123 h-miR-423_rfam7.0/5AmMC6/CTGAGGGGCCTCAGACCGAGCT (SEQ. ID. No. 783) JLA124h-miR-18b_rfam7.0 /5AmMC6/TAACTGCACTAGATGCACCTTA (SEQ. ID. No. 784)

TABLE 6 Normalized miRNA expression profiling data for MEP, ERY and MEGAsamples ProbeID Description MEP_1 MEP_2 MEP_3 MEP_4 MEP_5 MEP_6 MEP_7MEP_8 ERY1_1 EAM190 h-miR-10b 6.00 6.78 6.00 6.00 6.44 6.00 6.06 6.006.00 EAM187 hmr-miR-107 7.17 6.00 6.65 6.88 6.00 7.44 6.00 6.97 6.85EAM185 hmr-miR-103 7.59 6.00 7.28 7.38 6.00 7.94 6.00 7.60 7.26 EAM181hmr-let-7f 9.18 9.82 10.08 10.11 9.68 9.80 9.61 8.96 9.40 EAM179hmr-let-7d 7.47 9.56 8.99 9.45 8.89 9.76 9.10 9.03 8.76 EAM177mr-miR-101b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM175hmr-miR-320 9.41 8.52 8.86 9.14 9.42 9.49 9.67 9.85 9.17 EAM168hmr-let-7e 6.00 6.39 6.35 6.00 6.00 6.00 6.00 6.00 6.19 EAM161hmr-miR-28 6.00 6.00 6.00 6.00 6.00 6.00 7.60 6.00 6.00 EAM160hmr-miR-26b 8.92 8.03 9.08 9.13 8.76 8.24 8.82 7.56 8.36 EAM155hmr-miR-136 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM283mr-miR-211 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM282m-miR-199b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM281mr-miR-217 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM280hmr-miR-30a- 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 3p EAM279hmr-miR-29c 6.00 6.98 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM278hmr-miR-98 6.00 7.19 7.59 6.00 7.17 6.00 6.00 6.00 6.74 EAM270hmr-miR-30b 7.89 7.61 8.70 9.14 8.89 9.10 9.01 9.49 8.81 EAM159hmr-miR-130a 7.76 8.35 8.79 8.49 8.39 8.29 8.96 9.53 8.41 EAM163hmr-miR-142- 6.00 6.00 6.00 6.42 6.00 7.29 6.77 6.00 6.39 3p EAM171hmr-miR-137 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM306m-miR-201 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM307 m-miR-2026.00 6.00 6.00 6.00 6.42 6.00 6.00 6.00 6.00 EAM308 hmr-miR-206 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM309 m-miR-207 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 EAM310 hmr-miR-208 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 EAM247 hmr-miR-212 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 EAM251 hmr-miR-216 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 EAM253 hmr-miR-218 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 EAM275 hmr-miR-34a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 EAM246 h-miR-211 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00EAM250 h-miR-215 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM252h-miR-217 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM224hmr-miR-17-5p 11.37 11.51 11.39 10.79 11.11 11.33 11.35 11.44 11.52EAM225 hmr-miR-18a 6.00 6.00 6.00 7.67 6.07 6.00 6.00 8.32 8.14 EAM226hmr-miR-181a 6.26 8.16 7.40 8.99 9.49 8.48 8.90 7.90 8.54 EAM227hmr-miR-181b 6.00 6.00 8.18 8.18 6.59 7.95 7.59 9.07 7.76 EAM234hmr-miR-199a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM235h-miR-199b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM236hmr-miR-19a 7.89 7.04 8.46 8.23 8.32 7.24 7.94 7.49 8.65 EAM241hmr-miR-203 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM242hmr-miR-204 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM243hmr-miR-205 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM245hmr-miR-210 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM249hmr-miR-214 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM184hmr-miR-100 6.00 6.00 6.26 6.00 6.00 6.00 6.00 6.00 6.00 EAM186h-miR-106a 11.10 11.31 11.28 10.79 10.90 11.00 11.02 11.32 11.22 EAM189hmr-miR-10a 8.48 7.98 7.43 7.74 7.44 6.44 7.37 6.00 7.48 EAM191hmr-miR-122a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM192hmr-miR-126* 7.32 6.00 7.66 6.20 6.62 6.00 6.76 7.63 7.39 EAM198hmr-miR-130b 6.00 6.00 6.36 6.44 6.68 6.00 6.00 6.68 6.00 EAM202hmr-miR-134 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM209hmr-miR-142- 6.00 7.72 7.42 6.95 8.16 6.62 7.29 7.92 6.00 5p EAM221m-miR-155 7.57 8.58 7.87 7.76 7.43 7.79 7.65 7.47 7.97 EAM223hmr-miR-15b 10.67 8.82 10.83 10.79 10.29 10.53 10.47 9.94 10.59 EAM228hmr-miR-181c 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM222hm-miR-15a 8.94 6.00 8.11 9.87 8.82 8.92 8.20 8.39 8.30 EAM111 hm-let-7g10.22 9.62 10.09 10.09 9.76 10.06 9.73 9.61 9.34 EAM131 hmr-miR-92 11.0611.53 11.55 10.98 11.69 11.74 11.75 11.88 11.30 EAM139 hmr-miR-146a 9.039.70 6.00 9.07 9.31 6.00 8.53 9.49 9.22 EAM145 hmr-let-7c 9.28 9.27 9.039.67 9.39 9.04 9.24 9.14 8.71 EAM109 hmr-miR-7 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 EAM152 hm-miR-9* 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 JLA215 hmr-let-7i 9.03 8.00 8.07 8.44 7.26 8.38 8.85 7.71 9.25EAM153 hmr-let-7a 11.22 10.91 10.80 10.07 11.01 10.77 11.09 10.93 10.63EAM147 hmr-let-7b 9.07 6.31 9.13 8.64 9.00 9.63 10.04 9.43 7.66 EAM137hmr-miR-132 6.00 6.00 6.00 6.00 6.34 6.00 6.00 6.00 6.00 EAM133hmr-miR-324- 7.74 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 5p EAM103hmr-miR-124a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM105hmr-miR-125b 6.00 7.69 7.56 8.05 8.75 8.32 6.81 7.30 8.45 EAM121hmr-miR-99a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM115hmr-miR-16 12.32 12.42 12.31 11.40 11.87 12.30 11.83 11.81 12.08 EAM119hmr-miR-29b 6.00 6.00 6.00 6.93 6.00 6.00 6.00 6.00 6.00 EAM311hmr-miR-101 6.00 6.00 6.00 6.00 6.00 6.00 6.39 6.00 6.00 EAM312h-miR-105 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM313hmr-miR-106b 9.31 9.44 8.80 9.39 9.18 9.09 8.34 8.86 8.75 EAM314hmr-miR-126 8.75 9.89 8.72 10.12 9.41 8.10 9.63 8.69 10.57 EAM315hmr-miR-127 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM320hm-miR-189 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA216hmr-miR-200c 6.00 6.00 6.00 6.00 6.00 6.00 8.00 6.00 7.19 EAM323h-miR-224 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM324 hmr-miR-256.00 9.01 6.41 7.40 8.30 7.82 8.26 8.59 7.82 EAM386 r-miR-336 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA218 r-miR-343 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 EAM388 r-miR-344 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 EAM338 h-miR-95 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 JLA214 hmr-miR-129 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00EAM340 mr-let-7d* 7.71 6.00 6.00 6.00 6.00 7.41 6.00 6.00 6.00 EAM341m-miR-106a 10.34 11.12 10.40 9.97 10.46 10.70 10.47 10.68 10.60 EAM342hmr-miR-135b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM343mr-miR-151 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM344m-miR-17-3p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM345m-miR-224 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM346 mr-miR-2906.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM347 mr-miR-291-3p 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM348 mr-miR-291-5p 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM349 mr-miR-292-3p 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 EAM350 mr-miR-292-5p 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 EAM351 m-miR-293 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 EAM352 m-miR-294 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 EAM353 m-miR-295 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00EAM354 m-miR-297 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM355mr-miR-298 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM356mr-miR-300 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM358hmr-miR-323 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM359hmr-miR-324-3p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 7.59 6.00 EAM360mr-miR-325 7.36 6.93 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM361hmr-miR-326 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM362hmr-miR-328 6.00 6.00 6.98 6.00 6.00 6.00 6.00 6.00 6.00 EAM363mr-miR-329 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM365hmr-miR-331 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM366mr-miR-337 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM367hmr-miR-338 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM368hmr-miR-339 6.00 6.00 6.00 6.00 6.10 6.00 6.00 6.00 6.00 EAM369hmr-miR-340 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM370mr-miR-341 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM371hmr-miR-342 9.66 9.70 6.00 10.47 9.48 9.58 10.06 9.41 8.70 EAM372m-miR-344 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM373 mr-miR-3456.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM374 m-miR-346 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM375 mr-miR-34b 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 JLA217 mr-miR-350 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 EAM377 mr-miR-351 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 EAM378 mr-miR-7b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00EAM382 r-miR-20* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM383r-miR-327 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM384 r-miR-3336.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM385 hmr-miR-335 6.917.60 8.50 7.99 7.28 6.00 7.20 7.07 7.65 EAM393 r-miR-7* 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 EAM304 hmr-miR-200a 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 EAM298 hmr-miR-194 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 JLA221 hmr-miR-191 7.79 6.44 7.74 8.72 8.73 8.288.34 8.43 7.85 EAM295 hmr-miR-190 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 EAM292 hmr-miR-186 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 JLA219 hmr-miR-185 6.00 6.00 6.00 6.07 7.36 7.59 6.40 6.00 6.00EAM290 hmr-miR-184 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM402hm-miR-133b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM403h-miR-151 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM404hmr-miR-196b 6.00 6.00 6.00 6.52 6.00 6.00 6.00 6.00 6.00 EAM418hm-miR-370 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM419 h-miR-3716.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM420 h-miR-372 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM421 h-miR-373 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 EAM422 h-miR-373* 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 EAM423 h-miR-374 6.00 6.69 6.19 7.70 7.86 6.00 6.69 6.607.31 EAM426 m-miR-215 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00EAM427 hm-miR-409-3p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM428hm-miR-410 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM429m-miR-376b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM430m-miR-376a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM431 m-miR-4116.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM432 m-miR-380-3p 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM433 hm-miR-412 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 EAM264 hmr-miR-27b 7.18 6.00 6.78 7.568.20 6.00 6.00 6.80 7.55 EAM263 hmr-miR-26a 9.87 9.50 10.10 9.97 9.689.23 9.40 10.04 10.07 EAM262 hmr-miR-24 6.00 6.25 6.00 6.94 6.00 6.006.00 6.00 7.29 EAM261 hmr-miR-23b 7.42 7.66 7.78 8.90 8.11 7.19 9.178.50 7.90 EAM260 hmr-miR-23a 7.78 8.15 7.85 9.30 7.94 8.13 8.87 8.838.09 EAM256 h-miR-220 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00EAM255 hmr-miR-22 6.00 6.24 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM248hmr-miR-213 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM244hmr-miR-21 6.39 7.99 8.45 8.89 8.32 9.27 8.02 7.77 7.86 EAM240hmr-miR-20a 11.36 11.38 11.87 11.08 11.27 11.19 11.27 11.27 11.50 EAM237hmr-miR-19b 8.88 7.38 9.64 9.13 8.68 8.34 8.68 8.09 9.38 EAM233hmr-miR-196a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM214hm-miR-148a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM212hmr-miR-145 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM211hmr-miR-144 9.13 7.29 6.00 6.37 6.88 7.86 6.00 6.00 6.00 EAM210hmr-miR-143 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM389r-miR-346 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM390 r-miR-3476.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM391 r-miR-349 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA223 hmr-miR-33 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 EAM277 hmr-miR-96 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 EAM276 hmr-miR-9 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 EAM272 hmr-miR-30d 7.05 6.00 7.40 8.82 8.29 8.37 8.23 8.50 8.82EAM288 mr-miR-10b 6.74 8.16 6.94 6.48 7.41 6.00 6.56 6.00 6.00 EAM293hm-miR-188 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM297hmr-miR-193a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM301h-miR-198 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM232hmr-miR-192 6.11 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM231hmr-miR-187 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM230hmr-miR-183 6.00 6.00 6.00 6.00 6.29 6.00 6.00 6.00 6.00 EAM229hm-miR-182 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM220hmr-miR-154 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM219hmr-miR-153 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM218hmr-miR-152 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM217hmr-miR-150 6.00 7.22 6.00 6.00 6.00 7.52 6.00 6.00 6.78 EAM216hm-miR-149 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM215hmr-miR-148b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM271hmr-miR-30c 7.66 7.76 8.70 9.30 9.01 9.25 9.17 9.58 8.66 EAM268hmr-miR-29a 6.19 7.88 6.00 6.00 6.00 6.68 6.00 6.00 6.90 EAM305hmr-miR-200b 6.00 6.00 6.00 6.00 6.28 6.00 7.02 6.00 6.46 EAM303hm-miR-199a* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM300h-miR-197 7.59 6.00 6.82 7.62 8.19 7.13 6.99 8.12 8.11 EAM299hmr-miR-195 9.34 9.94 9.20 8.70 8.93 9.57 8.49 8.73 9.15 JLA91hmr-miR-99b 9.43 8.63 6.00 9.99 7.89 8.23 7.06 7.31 6.00 JLA92hmr-miR-433 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA93hmr-miR-431 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA94hmr-miR-365 8.38 6.00 8.96 7.30 7.15 6.00 6.43 6.00 6.00 JLA95hmr-miR-450 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA96hmr-miR-449 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA99hmr-miR-448 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA103hmr-miR-424 6.00 6.20 6.81 7.28 6.00 6.00 6.66 6.00 7.64 JLA105hm-miR-361 6.00 6.01 6.00 7.74 7.07 7.28 7.99 6.00 7.46 JLA106hm-miR-375 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA107hm-miR-377 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA108hm-miR-378 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA109hm-miR-379 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA110hm-miR-380-5p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA111hm-miR-381 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA112hm-miR-382 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA115hm-miR-384 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA116hm-miR-425 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA117hm-miR-452 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA118hm-miR-30e-3p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA104mr-miR-129-3p 9.27 6.00 9.25 6.00 8.52 6.00 7.63 7.12 6.00 JLA98mr-miR-429 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA101mr-miR-330 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA102mr-miR-322 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA114 m-miR-3836.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA5 hmr-miR-451 9.95 8.326.00 6.85 9.54 8.59 6.00 6.33 6.00 JLA201 r-miR-421 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 JLA202 m-miR-463 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 JLA203 m-miR-464 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 JLA204 m-miR-465 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00JLA205 m-miR-466 7.94 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA206m-miR-467 8.36 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA207 m-miR-4686.05 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA208 m-miR-469 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA209 m-miR-470 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 JLA210 m-miR-471 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 EAM325 hmr-miR-27a 8.16 6.00 7.67 8.75 8.56 6.00 6.007.93 8.44 EAM326 hmr-miR-296 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 EAM327 hmr-miR-299-5p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00EAM328 hmr-miR-301 6.25 6.00 6.00 6.00 6.00 6.00 6.00 6.56 6.16 EAM329hm-miR-302a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM330hmr-miR-30a-5p 6.00 6.01 6.00 7.29 6.25 6.55 6.00 6.78 7.23 EAM331hmr-miR-30e-5p 6.00 6.21 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM332hmr-miR-31 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM333hmr-miR-32 7.38 6.00 6.21 6.00 6.00 6.00 6.00 6.00 6.00 EAM335 h-miR-34b6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM336 hmr-miR-34c 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM337 hmr-miR-93 8.93 9.74 9.149.92 8.36 10.06 10.35 9.58 10.28 EAM208 hmr-miR-141 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 EAM207 hmr-miR-140 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 JLA222 hmr-miR-139 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 JLA220 hmr-miR-138 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 EAM203 hmr-miR-135a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 EAM200 hmr-miR-133a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00EAM hmr-miR-128b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAMhmr-miR-128a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM254hmr-miR-219 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM257hmr-miR-221 7.93 6.55 6.23 6.00 6.00 6.00 6.00 6.00 6.29 EAM258hmr-miR-222 6.00 8.99 9.28 8.07 8.88 8.98 9.45 8.55 8.72 EAM259hmr-miR-223 7.82 7.94 7.94 8.62 7.50 8.85 8.28 8.36 8.42 JLA211m-miR-434-5p 6.65 6.49 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA212m-miR-434-3p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA213m-miR-433-5p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA2hsa-miR-522 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA3hsa-miR-495 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA200r-miR-297 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA6 hsa-miR-518e6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA7 hsa-miR-519a 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA8 hsa-mir-527* 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 JLA72 hmr-miR-140* 8.13 6.00 6.00 7.81 7.886.14 6.00 6.44 6.00 JLA10 hsa-miR-521 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 JLA12 hsa-miR-362 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00JLA74 hsa-mir-18* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA14hm-miR-363 6.31 6.77 6.00 7.17 6.26 6.00 6.00 7.78 6.35 JLA77hsa-mir-19b-1* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA17hsa-mir- 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 520c,b,f JLA79hsa-mir-23a* 6.00 7.27 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA20hsa-miR-369-5p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA81hsa-mir-339* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA23hsa-mir-342* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.10 6.00 JLA24hsa-mir-19a* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA26hsa-miR-517a,b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 7.45 JLA27hsa-miR-516-5p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.26 JLA28hsa-miR-518b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA29hsa-miR-519d 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.43 JLA73hr-mir-151* 7.12 6.00 6.00 6.00 7.45 7.00 7.48 6.00 6.35 JLA31hsa-mir-28* 6.00 6.00 6.00 6.31 6.00 6.00 6.00 6.00 6.00 JLA33hsa-mir-519a-2* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA34hsa-mir-26b* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA35hsa-miR-526c 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA36hsa-miR-527 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA38hsa-mir-29b-2* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA39hsa-let-7g* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA40hsa-miR-518a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA41hsa-miR-523 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA44hsa-miR-515-3p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA45hsa-mir-146b* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA49hsa-mir-222* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA53hsa-mir-24* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA55hsa-miR-503 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA57hsa-mir-505 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA82hsa-mir-423* 10.00 10.80 10.94 10.76 10.93 10.75 10.65 10.87 10.46 JLA66hsa-miR-432 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA83hsa-mir-425* 6.00 6.00 6.77 7.81 8.68 7.65 7.36 6.86 6.00 JLA84hsa-mir-92-1* 6.00 6.00 6.00 7.03 6.00 6.00 6.00 6.00 6.00 JLA69hsa-mir-193* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA70hsa-miR-515-5p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA71hsa-mir-516-1* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA85hsa-mir-30d* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA125h-miR-20b 10.18 10.08 10.29 9.65 9.78 10.07 9.95 10.22 10.08 JLA198h-miR-191* 6.00 6.00 6.00 6.00 6.00 6.36 6.00 6.00 6.00 JLA199h-miR-154* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM316 h-miR-1476.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM317 h-miR-155 9.59 10.479.67 10.45 9.61 9.58 9.48 9.42 9.75 EAM318 h-miR-17-3p 6.00 6.00 6.006.00 6.00 6.00 6.00 7.19 6.00 JLA195 h-miR-200a* 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 JLA196 h-miR-302a* 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 JLA197 h-miR-299-3p 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 7.25 EAM319 h-miR-182* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 EAM405 h-miR-302b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00EAM406 h-miR-302b* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM392r-miR-352 6.25 7.91 7.30 8.16 7.22 8.24 7.61 7.55 7.24 JLA123 h-miR-4236.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA124 h-miR-18b 6.00 6.006.00 7.59 6.00 6.00 6.00 8.06 8.14 ProbeID Description ERY1_2 ERY1_3ERY1_4 ERY2_1 ERY2_2 ERY2_3 ERY3_1 ERY3_2 MEGA1_1 EAM190 h-miR-10b 6.006.99 6.75 6.00 6.00 7.96 6.06 6.00 6.00 EAM187 hmr-miR-107 8.25 6.007.84 6.00 7.81 6.90 6.00 7.49 8.75 EAM185 hmr-miR-103 8.79 6.00 8.396.00 8.34 7.93 6.00 7.79 9.02 EAM181 hmr-let-7f 7.95 8.58 8.86 9.12 9.726.00 9.09 8.47 9.80 EAM179 hmr-let-7d 7.02 7.49 8.73 7.65 9.88 8.43 9.029.01 9.57 EAM177 mr-miR-101b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 EAM175 hmr-miR-320 9.89 9.23 8.71 8.40 10.08 7.51 6.66 7.03 8.58EAM168 hmr-let-7e 6.00 6.93 6.00 6.00 6.62 6.00 6.00 6.00 6.00 EAM161hmr-miR-28 6.00 6.00 6.00 6.00 6.08 6.00 6.00 6.00 7.52 EAM160hmr-miR-26b 8.10 8.96 9.69 9.37 9.42 7.41 8.32 7.48 9.69 EAM155hmr-miR-136 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM283mr-miR-211 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM282m-miR-199b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM281mr-miR-217 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM280hmr-miR-30a- 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 3p EAM279hmr-miR-29c 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM278hmr-miR-98 6.00 6.00 6.00 6.25 6.00 6.00 6.00 6.00 6.00 EAM270hmr-miR-30b 8.99 7.63 8.95 8.53 9.45 7.95 7.36 6.00 9.58 EAM159hmr-miR-130a 8.43 8.44 7.06 6.00 8.49 9.20 6.00 6.00 9.15 EAM163hmr-miR-142- 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 7.47 3p EAM171hmr-miR-137 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM306m-miR-201 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM307 m-miR-2026.00 6.00 6.00 6.00 6.00 7.33 6.67 6.00 6.00 EAM308 hmr-miR-206 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM309 m-miR-207 6.00 6.00 6.007.37 6.00 6.00 6.00 6.00 6.00 EAM310 hmr-miR-208 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 EAM247 hmr-miR-212 6.00 6.37 6.00 6.00 6.006.00 6.00 6.00 6.00 EAM251 hmr-miR-216 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 EAM253 hmr-miR-218 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 EAM275 hmr-miR-34a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 EAM246 h-miR-211 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00EAM250 h-miR-215 6.00 6.00 6.92 6.00 6.00 6.00 6.40 7.44 6.00 EAM252h-miR-217 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM224hmr-miR-17-5p 11.52 10.93 10.34 10.89 10.35 11.50 10.47 10.31 10.24EAM225 hmr-miR-18a 7.13 7.50 6.00 6.00 6.00 7.18 6.00 6.00 6.00 EAM226hmr-miR-181a 7.91 9.01 7.64 6.00 8.20 6.00 6.00 6.00 8.26 EAM227hmr-miR-181b 6.95 7.06 6.00 6.00 7.97 6.00 6.00 6.00 6.00 EAM234hmr-miR-199a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM235h-miR-199b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM236hmr-miR-19a 7.76 8.02 7.53 8.50 7.41 7.49 6.00 7.84 7.23 EAM241hmr-miR-203 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM242hmr-miR-204 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM243hmr-miR-205 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.69 EAM245hmr-miR-210 6.00 6.00 6.48 6.00 6.00 6.00 6.00 6.00 6.00 EAM249hmr-miR-214 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM184hmr-miR-100 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM186h-miR-106a 11.18 10.83 10.11 10.62 10.16 11.33 10.18 10.13 10.04 EAM189hmr-miR-10a 6.00 7.49 9.10 6.00 6.43 6.00 6.00 6.00 6.54 EAM191hmr-miR-122a 6.00 6.00 7.20 6.00 6.00 6.00 6.00 6.00 6.00 EAM192hmr-miR-126* 7.58 8.43 8.67 6.00 6.00 6.00 6.00 6.00 8.11 EAM198hmr-miR-130b 6.00 6.01 6.00 6.00 7.44 6.00 6.00 7.98 6.00 EAM202hmr-miR-134 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM209hmr-miR-142-5p 8.13 6.00 6.75 6.77 7.48 8.09 6.00 6.00 9.02 EAM221m-miR-155 7.36 7.54 6.00 6.59 7.89 6.00 6.00 6.00 6.00 EAM223hmr-miR-15b 10.30 9.57 10.03 11.29 10.88 11.16 11.83 11.90 11.05 EAM228hmr-miR-181c 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM222hm-miR-15a 7.27 8.26 6.00 8.36 9.42 10.08 10.72 9.83 8.88 EAM111hm-let-7g 8.71 9.39 9.63 9.43 10.51 10.13 6.00 9.81 10.39 EAM131hmr-miR-92 11.87 11.49 9.87 11.68 11.05 9.45 11.53 11.40 8.71 EAM139hmr-miR-146a 7.16 9.30 8.85 6.00 9.34 10.46 6.82 6.00 10.20 EAM145hmr-let-7c 8.87 10.13 10.11 9.49 9.50 9.31 8.41 8.87 8.35 EAM109hmr-miR-7 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM152 hm-miR-9*6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA215 hmr-let-7i 6.00 6.359.31 7.17 8.40 9.25 6.00 7.09 8.55 EAM153 hmr-let-7a 10.73 11.16 12.0110.47 10.87 11.26 10.78 11.14 10.70 EAM147 hmr-let-7b 7.57 9.14 8.779.57 9.66 6.51 7.43 7.57 8.10 EAM137 hmr-miR-132 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 EAM133 hmr-miR-324-5p 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 EAM103 hmr-miR-124a 6.00 6.00 6.00 6.00 6.00 6.216.00 6.00 6.00 EAM105 hmr-miR-125b 7.21 7.24 7.48 6.00 6.34 6.00 6.006.23 6.00 EAM121 hmr-miR-99a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 EAM115 hmr-miR-16 12.08 12.26 12.61 12.97 12.35 12.37 13.12 12.8512.67 EAM119 hmr-miR-29b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00EAM311 hmr-miR-101 6.00 6.24 6.18 6.00 6.00 6.00 6.00 6.00 6.00 EAM312h-miR-105 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM313hmr-miR-106b 8.64 8.72 9.09 9.65 7.84 9.00 8.32 8.32 8.32 EAM314hmr-miR-126 10.18 11.18 11.85 7.84 9.11 6.00 6.00 6.00 7.96 EAM315hmr-miR-127 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM320hm-miR-189 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA216hmr-miR-200c 6.00 6.00 6.00 6.00 7.88 6.00 6.00 6.00 6.00 EAM323h-miR-224 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.49 EAM324 hmr-miR-258.01 8.81 6.04 7.43 8.29 6.00 6.00 8.55 7.79 EAM386 r-miR-336 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA218 r-miR-343 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 EAM388 r-miR-344 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 EAM338 h-miR-95 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 JLA214 hmr-miR-129 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00EAM340 mr-let-7d* 6.00 7.18 6.00 6.00 6.00 6.00 6.00 8.01 6.00 EAM341m-miR-106a 10.77 10.26 10.07 10.38 9.39 10.73 9.85 9.85 9.54 EAM342hmr-miR-135b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM343mr-miR-151 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM344m-miR-17-3p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM345m-miR-224 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM346 mr-miR-2906.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM347 mr-miR-291-3p 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM348 mr-miR-291-5p 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM349 mr-miR-292-3p 6.00 6.00 7.716.00 6.00 6.00 6.00 6.00 6.00 EAM350 mr-miR-292-5p 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 EAM351 m-miR-293 6.00 6.00 6.00 8.36 6.00 6.456.69 6.00 6.00 EAM352 m-miR-294 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 EAM353 m-miR-295 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00EAM354 m-miR-297 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM355mr-miR-298 6.00 6.00 6.00 6.00 6.00 6.00 10.24 6.00 6.00 EAM356mr-miR-300 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM358hmr-miR-323 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM359hmr-miR-324-3p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM360mr-miR-325 6.00 6.00 7.44 6.00 6.00 6.39 6.00 6.00 6.00 EAM361hmr-miR-326 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM362hmr-miR-328 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM363mr-miR-329 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM365hmr-miR-331 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM366mr-miR-337 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM367hmr-miR-338 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM368hmr-miR-339 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM369hmr-miR-340 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM370mr-miR-341 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM371hmr-miR-342 7.83 6.00 6.00 9.42 10.64 9.88 6.00 9.57 10.38 EAM372m-miR-344 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM373 mr-miR-3456.00 6.00 6.00 6.00 6.00 6.00 7.09 6.00 6.00 EAM374 m-miR-346 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM375 mr-miR-34b 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 JLA217 mr-miR-350 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 EAM377 mr-miR-351 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 EAM378 mr-miR-7b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00EAM382 r-miR-20* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM383r-miR-327 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM384 r-miR-3336.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM385 hmr-miR-335 7.146.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM393 r-miR-7* 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 EAM304 hmr-miR-200a 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 EAM298 hmr-miR-194 6.07 6.00 6.00 6.00 6.006.00 6.00 6.00 6.48 JLA221 hmr-miR-191 8.31 6.00 6.60 8.62 7.95 7.158.30 8.00 8.50 EAM295 hmr-miR-190 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 EAM292 hmr-miR-186 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 JLA219 hmr-miR-185 6.00 7.21 6.00 6.54 7.12 6.00 7.47 9.59 6.23EAM290 hmr-miR-184 6.00 6.21 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM402hm-miR-133b 6.00 6.00 7.29 6.00 6.00 6.00 6.00 6.00 6.00 EAM403h-miR-151 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM404hmr-miR-196b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM418hm-miR-370 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM419 h-miR-3716.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM420 h-miR-372 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM421 h-miR-373 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 EAM422 h-miR-373* 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 EAM423 h-miR-374 6.00 7.19 7.18 6.25 7.10 6.61 6.00 6.006.70 EAM426 m-miR-215 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00EAM427 hm-miR-409-3p 6.54 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM428hm-miR-410 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM429m-miR-376b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM430m-miR-376a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM431 m-miR-4116.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM432 m-miR-380-3p 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM433 hm-miR-412 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 EAM264 hmr-miR-27b 6.00 6.00 8.78 6.806.95 8.02 6.00 7.45 8.57 EAM263 hmr-miR-26a 9.27 9.43 9.90 9.27 9.268.54 8.77 8.20 10.49 EAM262 hmr-miR-24 6.00 6.00 8.39 7.36 6.00 6.006.00 6.00 6.00 EAM261 hmr-miR-23b 7.59 8.64 8.06 7.72 8.59 8.34 6.927.59 8.07 EAM260 hmr-miR-23a 8.42 9.19 8.03 8.11 8.60 8.55 6.00 6.008.15 EAM256 h-miR-220 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00EAM255 hmr-miR-22 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.46 EAM248hmr-miR-213 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM244hmr-miR-21 8.34 8.60 6.73 6.00 8.29 7.93 6.00 6.00 9.48 EAM240hmr-miR-20a 11.40 11.35 9.92 11.02 10.86 12.04 10.43 10.13 10.28 EAM237hmr-miR-19b 8.65 9.13 8.54 9.35 8.39 8.54 6.00 8.44 7.57 EAM233hmr-miR-196a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM214hm-miR-148a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM212hmr-miR-145 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.40 EAM211hmr-miR-144 6.00 6.00 6.00 8.80 6.00 8.40 11.13 10.47 7.05 EAM210hmr-miR-143 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM389r-miR-346 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM390 r-miR-3476.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM391 r-miR-349 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA223 hmr-miR-33 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 EAM277 hmr-miR-96 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 EAM276 hmr-miR-9 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 EAM272 hmr-miR-30d 8.59 6.70 8.78 7.19 8.38 6.00 6.00 6.04 8.35EAM288 mr-miR-10b 6.00 6.00 7.04 6.00 6.00 7.72 6.00 6.98 6.00 EAM293hm-miR-188 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM297hmr-miR-193a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM301h-miR-198 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM232hmr-miR-192 6.00 6.00 6.00 6.00 6.00 6.00 7.14 7.65 6.00 EAM231hmr-miR-187 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM230hmr-miR-183 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM229hm-miR-182 6.00 6.00 6.00 6.39 6.00 6.00 6.00 6.00 6.00 EAM220hmr-miR-154 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM219hmr-miR-153 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM218hmr-miR-152 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.74 EAM217hmr-miR-150 6.00 6.00 8.16 6.79 9.98 6.00 6.00 6.15 10.77 EAM216hm-miR-149 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM215hmr-miR-148b 6.00 6.83 6.00 6.00 6.00 6.00 6.00 6.00 7.49 EAM271hmr-miR-30c 9.13 7.46 8.56 8.72 9.62 7.65 7.67 6.00 9.52 EAM268hmr-miR-29a 6.00 6.00 6.85 6.00 6.20 6.00 6.00 6.00 6.00 EAM305hmr-miR-200b 6.00 6.00 6.00 6.00 7.01 6.00 6.00 6.00 6.00 EAM303hm-miR-199a* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM300h-miR-197 8.29 8.88 7.83 8.40 8.70 6.00 6.00 6.84 7.76 EAM299hmr-miR-195 9.77 9.49 9.17 10.48 9.03 9.81 10.31 9.58 9.72 JLA91hmr-miR-99b 10.42 6.63 8.77 6.00 6.00 6.00 6.00 6.00 6.00 JLA92hmr-miR-433 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA93hmr-miR-431 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA94hmr-miR-365 6.06 7.03 7.03 6.00 6.00 8.39 6.22 6.53 8.13 JLA95hmr-miR-450 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA96hmr-miR-449 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA99hmr-miR-448 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA103hmr-miR-424 6.00 9.39 9.21 6.98 6.00 6.00 6.00 6.00 6.00 JLA105hm-miR-361 6.00 8.25 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA106hm-miR-375 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA107hm-miR-377 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA108hm-miR-378 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA109hm-miR-379 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA110hm-miR-380-5p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA111hm-miR-381 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA112hm-miR-382 8.83 6.00 6.00 6.00 7.08 6.00 6.00 6.00 6.00 JLA115hm-miR-384 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA116hm-miR-425 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA117hm-miR-452 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA118hm-miR-30e-3p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA104mr-miR-129-3p 7.18 6.00 6.00 6.24 6.00 7.62 8.58 7.16 7.12 JLA98mr-miR-429 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA101mr-miR-330 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA102mr-miR-322 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA114 m-miR-3836.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA5 hmr-miR-451 6.00 6.157.06 9.77 7.29 6.77 11.41 12.04 6.79 JLA201 r-miR-421 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 JLA202 m-miR-463 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 JLA203 m-miR-464 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 JLA204 m-miR-465 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00JLA205 m-miR-466 6.00 6.00 6.00 6.00 6.00 7.54 6.48 6.00 6.00 JLA206m-miR-467 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA207 m-miR-4686.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA208 m-miR-469 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA209 m-miR-470 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 JLA210 m-miR-471 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 EAM325 hmr-miR-27a 6.00 6.00 8.84 7.51 7.75 9.09 6.006.80 9.54 EAM326 hmr-miR-296 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 EAM327 hmr-miR-299- 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00EAM328 hmr-miR-301 6.00 6.00 6.00 6.09 6.00 6.00 6.00 6.00 6.00 EAM329hm-miR-302a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM330hmr-miR-30a- 6.05 6.84 8.16 6.64 6.71 6.00 6.00 6.00 6.62 EAM331hmr-miR-30e- 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM332hmr-miR-31 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM333hmr-miR-32 6.00 7.53 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM335 h-miR-34b6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM336 hmr-miR-34c 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM337 hmr-miR-93 9.86 7.32 6.009.38 9.47 8.20 7.82 10.69 8.89 EAM208 hmr-miR-141 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 EAM207 hmr-miR-140 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 JLA222 hmr-miR-139 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 JLA220 hmr-miR-138 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 EAM203 hmr-miR-135a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 EAM200 hmr-miR-133a 6.00 6.00 7.18 6.00 6.00 6.00 6.00 6.00 6.00EAM hmr-miR-128b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAMhmr-miR-128a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM254hmr-miR-219 6.00 6.00 6.00 6.00 6.00 6.00 6.45 6.00 6.00 EAM257hmr-miR-221 6.00 7.88 6.00 6.00 6.00 6.00 8.25 6.00 8.79 EAM258hmr-miR-222 6.90 7.15 7.46 7.68 8.11 6.00 6.00 6.00 8.38 EAM259hmr-miR-223 8.26 6.46 6.31 9.11 8.85 8.89 6.00 6.00 8.82 JLA211m-miR-434-5p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA212m-miR-434-3p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA213m-miR-433-5p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA2hsa-miR-522 6.00 6.00 6.86 6.00 6.00 6.00 6.00 6.00 6.00 JLA3hsa-miR-495 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA200r-miR-297 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA6 hsa-miR-518e6.00 6.00 6.00 6.00 6.00 6.00 6.58 6.67 6.00 JLA7 hsa-miR-519a 6.00 6.807.83 6.00 6.00 6.00 6.68 6.53 6.00 JLA8 hsa-mir-527* 6.00 6.00 6.00 6.006.00 6.00 6.19 6.07 6.00 JLA72 hmr-miR-140* 6.00 6.00 6.01 6.00 8.106.00 6.71 7.22 7.30 JLA10 hsa-miR-521 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 JLA12 hsa-miR-362 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00JLA74 hsa-mir-18* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA14hm-miR-363 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA77hsa-mir-19b-1* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA17hsa-mir- 6.00 6.00 6.69 6.00 6.00 6.00 6.00 6.00 6.00 520c,b,f JLA79hsa-mir-23a* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA20hsa-miR-369-5p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA81hsa-mir-339* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA23hsa-mir-342* 7.31 6.00 6.00 6.00 6.00 6.00 6.00 6.00 8.07 JLA24hsa-mir-19a* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA26hsa-miR-517a,b 9.19 9.68 9.88 6.00 6.00 6.00 6.00 6.00 6.00 JLA27hsa-miR-516-5p 8.01 7.22 8.30 6.00 6.00 6.00 6.00 6.00 6.00 JLA28hsa-miR-518b 6.00 6.00 6.10 6.00 6.00 6.00 6.00 6.00 6.00 JLA29hsa-miR-519d 6.00 8.31 9.35 6.00 6.00 6.00 6.00 6.00 6.00 JLA73hr-mir-151* 8.47 6.00 6.00 6.00 7.04 6.00 6.03 8.07 7.32 JLA31hsa-mir-28* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA33hsa-mir-519a-2* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA34hsa-mir-26b* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA35hsa-miR-526c 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA36hsa-miR-527 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA38hsa-mir-29b-2* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA39hsa-let-7g* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA40hsa-miR-518a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA41hsa-miR-523 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA44hsa-miR-515-3p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA45hsa-mir-146b* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA49hsa-mir-222* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA53hsa-mir-24* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA55hsa-miR-503 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA57hsa-mir-505 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA82hsa-mir-423* 10.59 11.08 10.84 10.71 10.99 9.16 12.28 11.26 10.01 JLA66hsa-miR-432 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA83hsa-mir-425* 6.69 9.11 6.64 8.35 7.69 6.00 6.09 6.00 8.19 JLA84hsa-mir-92-1* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA69hsa-mir-193* 6.00 6.00 6.00 6.00 6.00 6.88 7.72 6.00 6.00 JLA70hsa-miR-515-5p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA71hsa-mir-516-1* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA85hsa-mir-30d* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA125h-miR-20b 10.33 10.27 8.32 9.68 9.66 11.07 9.22 8.63 8.99 JLA198h-miR-191* 6.30 6.00 6.00 7.24 6.00 6.58 6.63 6.11 6.26 JLA199h-miR-154* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM316 h-miR-1476.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM317 h-miR-155 8.97 9.507.69 8.48 9.68 7.96 6.18 6.00 6.00 EAM318 h-miR-17-3p 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 JLA195 h-miR-200a* 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 JLA196 h-miR-302a* 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 JLA197 h-miR-299-3p 6.41 6.00 6.82 6.00 6.78 7.186.47 6.00 6.00 EAM319 h-miR-182* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 EAM405 h-miR-302b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00EAM406 h-miR-302b* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM392r-miR-352 6.00 6.00 6.96 6.00 8.26 7.14 6.72 7.48 7.86 JLA123 h-miR-4236.00 6.00 6.00 6.00 6.00 6.00 6.00 6.39 6.00 JLA124 h-miR-18b 7.00 7.206.00 6.00 6.00 7.50 6.00 6.00 6.00 MEGA1_(—) MEGA1_(—) MEGA1_(—)MEGA2_(—) ProbeID Description 2 3 4 1 MEGA2_2 MEGA2_3 MEGA2_4 MEGA2_5MEGA2_6 EAM190 h-miR-10b 6.00 6.00 6.00 6.00 6.00 6.66 6.00 6.00 7.22EAM187 hmr-miR-107 6.30 6.68 6.79 6.00 6.00 8.32 7.63 6.92 8.79 EAM185hmr-miR-103 6.76 7.19 7.67 6.44 6.00 8.54 8.04 7.13 9.39 EAM181hmr-let-7f 9.53 8.57 10.11 6.73 8.73 9.75 8.60 9.07 9.57 EAM179hmr-let-7d 9.31 8.27 8.89 9.64 9.34 9.91 9.61 9.83 9.79 EAM177mr-miR-101b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM175hmr-miR-320 8.34 8.72 8.73 8.11 8.87 8.50 8.70 7.50 7.51 EAM168hmr-let-7e 6.00 6.00 8.34 6.65 6.00 6.00 6.00 6.00 7.50 EAM161hmr-miR-28 7.96 6.00 8.29 8.44 8.09 8.01 7.47 6.00 8.47 EAM160hmr-miR-26b 9.65 8.59 9.78 8.86 9.24 9.38 9.23 8.61 8.95 EAM155hmr-miR-136 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM283mr-miR-211 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM282m-miR-199b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM281mr-miR-217 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM280hmr-miR-30a-3p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM279hmr-miR-29c 6.56 6.00 6.00 6.00 6.16 8.18 7.23 6.00 6.00 EAM278hmr-miR-98 8.00 7.69 7.32 8.11 6.00 6.00 7.17 9.06 6.50 EAM270hmr-miR-30b 8.74 8.82 9.46 8.10 8.74 9.66 9.54 6.00 9.43 EAM159hmr-miR-130a 7.39 8.91 6.79 8.20 7.67 7.48 6.87 6.00 6.00 EAM163hmr-miR-142-3p 7.43 6.00 7.89 7.56 6.00 7.79 7.27 8.56 6.00 EAM171hmr-miR-137 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM306m-miR-201 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM307 m-miR-2026.00 6.00 6.00 7.21 6.00 6.00 6.00 7.05 6.00 EAM308 hmr-miR-206 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM309 m-miR-207 6.00 6.00 7.576.00 6.00 6.00 6.00 6.00 6.00 EAM310 hmr-miR-208 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 EAM247 hmr-miR-212 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 EAM251 hmr-miR-216 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 EAM253 hmr-miR-218 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 EAM275 hmr-miR-34a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 EAM246 h-miR-211 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00EAM250 h-miR-215 6.00 6.00 6.00 6.00 6.00 6.00 6.00 7.32 6.00 EAM252h-miR-217 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM224hmr-miR-17-5p 10.44 11.27 9.91 10.39 8.79 10.13 10.33 9.48 9.88 EAM225hmr-miR-18a 7.40 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM226hmr-miR-181a 7.87 8.68 7.08 6.00 8.81 6.84 9.72 6.00 6.56 EAM227hmr-miR-181b 6.79 7.49 6.00 6.00 6.00 6.00 7.54 6.00 6.00 EAM234hmr-miR-199a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM235h-miR-199b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM236hmr-miR-19a 7.70 8.90 8.55 6.00 7.14 6.00 7.61 8.19 6.60 EAM241hmr-miR-203 6.00 8.15 6.99 6.00 6.00 6.00 6.00 8.16 6.00 EAM242hmr-miR-204 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM243hmr-miR-205 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM245hmr-miR-210 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM249hmr-miR-214 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.12 EAM184hmr-miR-100 6.00 6.00 6.00 6.00 6.00 6.00 6.00 7.20 6.00 EAM186h-miR-106a 10.31 10.92 9.89 10.11 8.23 10.12 10.01 9.48 9.71 EAM189hmr-miR-10a 7.74 8.59 8.29 6.00 6.00 6.00 6.72 6.00 6.00 EAM191hmr-miR-122a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM192hmr-miR-126* 6.82 7.25 6.18 6.97 6.00 6.00 6.00 6.00 7.21 EAM198hmr-miR-130b 6.27 6.21 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM202hmr-miR-134 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM209hmr-miR-142-5p 7.81 7.04 7.93 7.90 6.86 8.66 8.37 9.90 7.87 EAM221m-miR-155 7.17 8.01 7.16 6.00 6.00 7.48 6.00 6.00 7.03 EAM223hmr-miR-15b 10.50 10.40 9.74 11.50 11.22 10.39 10.79 11.03 11.04 EAM228hmr-miR-181c 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM222hm-miR-15a 9.52 9.67 6.00 9.33 6.00 8.87 10.18 10.57 8.69 EAM111hm-let-7g 10.55 10.12 10.44 8.32 9.39 11.19 10.14 10.65 10.03 EAM131hmr-miR-92 10.50 11.33 9.41 9.74 11.07 9.10 10.74 9.01 10.31 EAM139hmr-miR-146a 9.47 10.48 8.86 6.00 8.51 9.66 8.61 6.00 8.90 EAM145hmr-let-7c 8.69 9.07 9.10 7.53 9.60 7.46 6.68 9.21 7.82 EAM109 hmr-miR-76.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM152 hm-miR-9* 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA215 hmr-let-7i 8.71 8.89 9.07 9.128.59 8.08 9.20 10.60 9.03 EAM153 hmr-let-7a 10.98 10.75 11.12 10.6511.41 10.93 10.44 11.51 11.17 EAM147 hmr-let-7b 8.34 7.17 10.57 6.006.58 6.09 6.78 9.59 6.11 EAM 137 hmr-miR-132 6.00 6.95 6.00 6.00 6.006.00 6.00 6.00 6.00 EAM133 hmr-miR-324-5p 6.00 6.00 6.00 6.00 6.00 6.007.17 6.00 6.00 EAM103 hmr-miR-124a 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 EAM105 hmr-miR-125b 6.00 7.61 6.00 6.00 6.00 6.00 6.00 6.006.00 EAM121 hmr-miR-99a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 7.94 6.00EAM115 hmr-miR-16 12.56 12.12 13.06 12.43 12.37 12.79 12.11 13.02 12.69EAM119 hmr-miR-29b 6.00 6.00 6.91 6.00 6.00 6.00 7.01 6.00 6.00 EAM311hmr-miR-101 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM312h-miR-105 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM313hmr-miR-106b 8.85 9.53 9.17 8.97 8.11 9.38 8.94 7.61 8.82 EAM314hmr-miR-126 9.23 10.02 9.48 8.22 6.00 8.38 8.42 6.00 8.73 EAM315hmr-miR-127 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM320hm-miR-189 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA216hmr-miR-200c 6.00 6.00 6.00 6.96 6.00 7.14 6.52 7.22 6.00 EAM323h-miR-224 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM324 hmr-miR-256.85 8.56 6.00 6.00 7.38 6.00 7.51 6.00 6.00 EAM386 r-miR-336 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA218 r-miR-343 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 EAM388 r-miR-344 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 EAM338 h-miR-95 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 JLA214 hmr-miR-129 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00EAM340 mr-let-7d* 6.00 6.00 6.00 6.99 6.00 6.00 6.00 6.00 6.00 EAM341m-miR-106a 9.43 10.30 9.16 9.99 8.43 9.69 9.84 7.93 9.04 EAM342hmr-miR-135b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM343mr-miR-151 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM344m-miR-17-3p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM345m-miR-224 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM346 mr-miR-2906.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM347 mr-miR-291-3p 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM348 mr-miR-291-5p 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM349 mr-miR-292-3p 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 EAM350 mr-miR-292-5p 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 EAM351 m-miR-293 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 EAM352 m-miR-294 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 EAM353 m-miR-295 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00EAM354 m-miR-297 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM355mr-miR-298 6.00 6.00 6.00 6.00 6.00 7.52 6.00 6.00 6.00 EAM356mr-miR-300 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM358hmr-miR-323 6.00 6.00 6.49 6.00 6.00 6.00 6.00 6.00 6.00 EAM359hmr-miR-324-3p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM360mr-miR-325 6.00 6.63 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM361hmr-miR-326 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM362hmr-miR-328 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM363mr-miR-329 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM365hmr-miR-331 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM366mr-miR-337 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM367hmr-miR-338 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM368hmr-miR-339 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM369hmr-miR-340 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM370mr-miR-341 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM371hmr-miR-342 11.21 8.81 10.24 11.01 11.98 10.79 11.69 11.33 11.20 EAM372m-miR-344 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM373 mr-miR-3456.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM374 m-miR-346 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM37 mr-miR-34b 6.00 6.00 6.00 6.196.00 6.00 6.00 6.00 6.00 JLA217 mr-miR-350 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 EAM37 mr-miR-351 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 EAM37 mr-miR-7b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM38r-miR-20* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM38 r-miR-3276.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM38 r-miR-333 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM38 hmr-miR-335 7.18 7.80 6.00 6.006.00 6.42 6.00 6.00 6.00 EAM39 r-miR-7* 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 EAM30 hmr-miR-200a 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 EAM29 hmr-miR-194 6.00 6.22 6.00 6.00 6.00 6.00 6.00 6.00 6.00JLA221 hmr-miR-191 8.20 7.45 8.85 7.58 8.83 7.67 8.32 8.13 8.89 EAM29hmr-miR-190 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM29hmr-miR-186 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA219hmr-miR-185 6.00 6.00 6.00 6.00 6.00 6.00 7.40 6.00 6.00 EAM29hmr-miR-184 6.00 6.00 6.00 6.00 6.00 6.00 7.33 6.00 6.00 EAM40hm-miR-133b 6.00 6.00 6.00 6.94 6.00 6.00 6.00 6.00 6.00 EAM40 h-miR-1516.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM40 hmr-miR-196b 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM41 hm-miR-370 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 EAM41 h-miR-371 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 EAM42 h-miR-372 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 EAM42 h-miR-373 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00EAM42 h-miR-373* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM42h-miR-374 6.00 7.84 6.58 6.50 6.70 6.78 7.50 6.00 6.82 EAM42 m-miR-2156.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM42 hm-miR-409-3p 6.806.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM42 hm-miR-410 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 EAM42 m-miR-376b 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 EAM43 m-miR-376a 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 EAM43 m-miR-411 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00EAM43 m-miR-380-3p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM43hm-miR-412 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM26hmr-miR-27b 6.46 8.12 7.01 7.72 6.00 6.48 6.42 6.00 6.00 EAM26hmr-miR-26a 10.10 10.36 9.80 10.53 10.61 10.61 10.21 9.69 10.16 EAM26hmr-miR-24 6.06 6.00 6.00 6.00 8.19 6.00 7.34 6.00 7.32 EAM26hmr-miR-23b 8.76 8.71 8.23 9.80 9.82 8.30 9.41 7.07 9.69 EAM26hmr-miR-23a 8.70 9.13 8.70 9.58 9.49 7.88 9.15 7.55 9.76 EAM25 h-miR-2206.00 6.00 6.00 6.00 6.00 6.00 6.00 6.11 6.00 EAM25 hmr-miR-22 6.00 6.006.00 6.00 6.00 6.00 6.82 6.00 6.00 EAM24 hmr-miR-213 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 EAM24 hmr-miR-21 8.75 9.03 10.40 10.10 6.009.43 9.46 8.42 9.73 EAM24 hmr-miR-20a 11.01 11.25 10.42 10.12 8.35 10.589.97 10.81 10.61 EAM23 hmr-miR-19b 7.94 9.23 8.64 6.80 7.05 6.00 8.358.53 7.39 EAM23 hmr-miR-196a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 EAM hm-miR-148a 6.00 6.00 6.00 6.00 6.00 6.05 6.00 6.00 6.00 EAM21hmr-miR-145 6.00 6.16 6.00 7.14 6.00 6.00 6.00 6.00 6.00 EAM21hmr-miR-144 7.20 6.00 6.00 7.46 6.88 6.00 6.17 9.44 7.76 EAM hmr-miR-1436.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM38 r-miR-346 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM39 r-miR-347 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 EAM39 r-miR-349 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 JLA223 hmr-miR-33 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 EAM27 hmr-miR-96 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM27hmr-miR-9 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM27 hmr-miR-30d7.77 7.93 7.87 7.45 7.53 6.00 8.04 7.48 6.00 EAM28 mr-miR-10b 7.30 7.236.00 6.00 6.00 7.97 6.00 6.00 7.89 EAM29 hm-miR-188 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 EAM29 hmr-miR-193a 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 EAM30 h-miR-198 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 EAM23 hmr-miR-192 6.00 6.00 6.00 6.00 6.00 6.00 6.00 8.50 6.00EAM23 hmr-miR-187 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM23hmr-miR-183 6.00 6.00 6.00 6.00 6.00 6.00 6.00 8.16 6.00 EAM22hm-miR-182 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.48 EAM hmr-miR-1546.00 6.00 6.00 6.39 6.00 6.00 6.00 6.00 6.00 EAM hmr-miR-153 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM hmr-miR-152 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 EAM21 hmr-miR-150 11.16 6.00 9.51 11.36 12.1611.59 11.15 9.72 10.24 EAM hm-miR-149 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 EAM hmr-miR-148b 6.00 6.00 6.00 6.00 6.00 7.27 6.00 6.00 6.00EAM hmr-miR-30c 8.38 8.74 9.34 8.39 8.71 9.24 9.92 6.00 9.42 EAM26hmr-miR-29a 8.05 6.00 6.00 6.00 7.29 9.38 8.34 6.29 6.00 EAM30hmr-miR-200b 6.00 6.23 6.00 6.00 6.00 6.51 6.00 6.00 6.00 EAM30hm-miR-199a* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM30h-miR-197 7.57 6.00 6.61 8.15 10.15 6.98 9.26 7.21 8.36 EAM29hmr-miR-195 8.90 8.67 10.18 9.61 9.73 9.28 8.75 10.26 9.42 JLA91hmr-miR-99b 6.00 6.00 9.02 6.00 6.00 6.00 7.63 9.71 6.00 JLA92hmr-miR-433 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA93hmr-miR-431 6.00 6.00 6.00 7.98 6.00 6.00 6.00 6.00 6.00 JLA94hmr-miR-365 6.77 6.53 6.00 9.78 6.00 6.79 6.00 6.00 9.08 JLA95hmr-miR-450 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA96hmr-miR-449 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA99hmr-miR-448 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA103hmr-miR-424 7.35 7.34 6.00 6.00 7.82 6.00 6.20 6.00 7.17 JLA105hm-miR-361 6.00 6.98 7.83 6.00 6.00 6.23 7.28 6.00 6.00 JLA106hm-miR-375 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA107hm-miR-377 6.00 6.78 6.00 6.00 6.00 6.00 6.19 6.00 6.00 JLA108hm-miR-378 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA109hm-miR-379 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA110hm-miR-380-5p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA111hm-miR-381 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA112hm-miR-382 6.00 6.00 6.00 7.52 6.00 6.00 7.61 6.00 6.00 JLA115hm-miR-384 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA116hm-miR-425 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA117hm-miR-452 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA118hm-miR-30e-3p 6.00 6.00 6.00 6.00 6.00 6.36 6.00 6.00 6.00 JLA104mr-miR-129-3p 8.05 6.65 6.00 10.17 6.00 6.00 6.00 9.32 7.47 JLA98mr-miR-429 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA101mr-miR-330 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA102mr-miR-322 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA114 m-miR-3836.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA5 hmr-miR-451 8.40 6.006.13 7.43 9.12 9.14 7.74 7.56 7.28 JLA201 r-miR-421 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 JLA202 m-miR-463 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 JLA203 m-miR-464 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 JLA204 m-miR-465 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00JLA205 m-miR-466 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA206m-miR-467 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA207 m-miR-4686.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA208 m-miR-469 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA209 m-miR-470 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 JLA210 m-miR-471 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 EAM325 hmr-miR-27a 7.10 8.39 6.53 8.76 6.00 6.63 7.026.00 6.84 EAM326 hmr-miR-296 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 EAM327 hmr-miR-299-5p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00EAM328 hmr-miR-301 6.00 6.00 6.00 6.00 6.00 6.09 6.00 6.00 6.00 EAM329hm-miR-302a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM330hmr-miR-30a-5p 6.00 6.00 6.00 6.00 6.00 6.29 6.00 6.00 6.00 EAM331hmr-miR-30e-5p 6.00 7.15 6.00 6.00 6.00 7.02 6.00 6.00 6.00 EAM332hmr-miR-31 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM333hmr-miR-32 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM335 h-miR-34b6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM336 hmr-miR-34c 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM337 hmr-miR-93 8.55 9.94 9.417.91 6.00 9.76 9.69 8.17 8.93 EAM208 hmr-miR-141 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 EAM207 hmr-miR-140 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 JLA222 hmr-miR-139 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 JLA220 hmr-miR-138 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 EAM203 hmr-miR-135a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 EAM200 hmr-miR-133a 6.00 6.00 6.00 6.99 6.00 6.00 6.00 6.00 6.00EAM195 hmr-miR-128b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM194hmr-miR-128a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM254hmr-miR-219 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM257hmr-miR-221 7.37 7.46 6.00 8.97 8.93 6.00 6.00 6.00 6.00 EAM258hmr-miR-222 8.32 7.76 6.95 8.78 6.00 6.00 6.83 6.00 6.00 EAM259hmr-miR-223 8.60 8.36 9.22 9.19 8.58 8.02 8.85 6.64 9.70 JLA211m-miR-434-5p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA212m-miR-434-3p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA213m-miR-433-5p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA2hsa-miR-522 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA3hsa-miR-495 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA200r-miR-297 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA6 hsa-miR-518e6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA7 hsa-miR-519a 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA8 hsa-mir-527* 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 JLA72 hmr-miR-140* 6.03 6.02 6.00 8.06 6.006.93 7.57 6.48 6.93 JLA10 hsa-miR-521 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 JLA12 hsa-miR-362 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00JLA74 hsa-mir-18* 6.00 6.00 6.00 6.39 6.00 6.00 6.00 6.00 6.00 JLA14hm-miR-363 6.00 6.00 7.63 6.00 6.00 6.00 7.63 6.00 6.00 JLA77hsa-mir-19b-1* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA17hsa-mir-520c,b,f 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA79hsa-mir-23a* 6.00 6.00 6.00 6.00 6.00 6.57 6.00 6.00 7.64 JLA20hsa-miR-369-5p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA81hsa-mir-339* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA23hsa-mir-342* 6.00 6.81 6.00 8.42 7.43 6.00 6.00 7.48 6.00 JLA24hsa-mir-19a* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA26hsa-miR-517a,b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA27hsa-miR-516-5p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA28hsa-miR-518b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA29hsa-miR-519d 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA73hr-mir-151* 7.22 6.01 7.57 6.87 8.90 7.45 7.30 6.00 7.78 JLA31hsa-mir-28* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA33hsa-mir-519a-2* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA34hsa-mir-26b* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA35hsa-miR-526c 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA36hsa-miR-527 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA38hsa-mir-29b-2* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA39hsa-let-7g* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA40hsa-miR-518a 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA41hsa-miR-523 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA44hsa-miR-515-3p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA45hsa-mir-146b* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA49hsa-mir-222* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA53hsa-mir-24* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA55hsa-miR-503 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA57hsa-mir-505 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA82hsa-mir-423* 10.16 9.82 9.90 11.38 12.04 10.39 11.13 9.84 11.00 JLA66hsa-miR-432 6.00 7.28 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA83hsa-mir-425* 7.93 7.46 6.00 6.51 6.00 6.89 7.58 6.00 8.04 JLA84hsa-mir-92-1* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA69hsa-mir-193* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA70hsa-miR-515-5p 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA71hsa-mir-516-1* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA85hsa-mir-30d* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA125h-miR-20b 9.71 9.91 8.67 8.72 8.40 8.95 9.35 10.04 9.35 JLA198h-miR-191* 6.00 6.00 6.74 6.36 6.15 6.00 6.00 7.19 6.00 JLA199h-miR-154* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM316 h-miR-1476.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM317 h-miR-155 8.85 9.858.50 6.00 6.00 8.82 7.46 6.00 8.90 EAM318 h-miR-17-3p 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 6.00 JLA195 h-miR-200a* 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 6.00 JLA196 h-miR-302a* 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 JLA197 h-miR-299-3p 6.00 6.00 6.00 6.23 6.00 6.006.00 6.00 7.60 EAM319 h-miR-182* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 EAM405 h-miR-302b 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.19EAM406 h-miR-302b* 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 EAM392r-miR-352 7.72 6.58 7.71 8.32 7.78 8.00 8.07 8.34 8.37 JLA123 h-miR-4236.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 JLA124 h-miR-18b 7.19 6.006.00 6.00 6.00 6.00 6.00 6.00 6.00

Data were normalized, log 2-transformed and thresholded at 6. Readingsfor samples are in columns and readings for miRNAs are in rows. Due topage limitation, every page lists only a subset of samples and miRNAs.The data will also be available online.

What is claimed:
 1. A method of treating thrombocytopenia in a host inneed thereof, the method comprising administering an effective amount ofan agent that increases miR-150 expression in a cell to a host, whereinthe agent comprises a nucleic acid sequence that is at least 90%identical to SEQ. ID. No.
 1. 2. The method of claim 1, wherein the cellis a progenitor cell.
 3. The method of claim 2, wherein the progenitorcell is a hematopoietic progenitor cell.
 4. The method of claim 1,wherein the agent is a vector comprising the nucleic acid sequence thatis at least 90% identical to SEQ. ID. No.
 1. 5. The method of claim 4,wherein the vector is a virus.
 6. A method of treating thrombocytopeniain a host in need thereof, the method comprising: a. obtaining a sampleof hematopoietic progenitor cells from said host; b. contacting thehematopoietic progenitor cells with an agent comprising a nucleic acidsequence that is at least 90% identical to SEQ. ID. No. 1; and c.introducing the cell from step b into the host.
 7. The method of claim6, wherein the agent is a vector comprising the nucleic acid sequencethat is at least 90% identical to SEQ. ID. No. 1.